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Cerebellar ataxias (CA) are a group of movement disorders that cause problems with balance 
and walking. Diagnosis and disease monitoring in CA involve subjective clinical rating scales. 
These methods are not sensitive to subtle longitudinal changes in mobility and there are no 
reliable biomarkers of disease progression in ataxia. Gait analysis techniques can objectively 
quantify gait and have potential to modernise clinical assessment of mobility in CA. 
Methods 
A systematic review and meta-analysis of available literature relating to spatiotemporal gait 
characteristics of CA were completed to define consistent gait abnormalities in CA. A 
validation study of gait analysis equipment was completed. A clinical study of instrumented 
gait tests in CA was undertaken with follow-up tests occurring 12-18 months and 24 months 
post-baseline.  
Results 
Meta-analysis established a consistent spatiotemporal gait pattern in CA. Our portable gait 
analysis system showed a good level of agreement and accuracy of gait event measurements 
compared with a 3D motion capture system in a healthy adult cohort (n=24).  
CA (n=27) cohort displayed by reduced preferred-pace gait speed, increased step width, 
asymmetry, and variability, as well as impaired attenuation of upper body motion and 
reduced postural symmetry and regularity compared with HC (n=27). After a 12-month 
interval (CA n=16), no disease progression occurred. Although step width, gait asymmetry 
and regularity variables showed statistically significant deterioration as clinical measures did 
not reflect a genuine change in function. 
Conclusion 
A thorough characterisation of gait in CA with variables novel to an ataxic cohort has been 
completed. Spatiotemporal gait abnormalities and impaired dynamic stability differentiate 
between people with CA and HC and stratifies by disease severity. As no substantial disease 
progression was detected in the clinical measures or gait measures over a 12-month period, 
these variables require comparison to other disease groups and exploration over a longer 
follow-up interval to confirm their use as biomarkers for disease progression in CA.   
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Chapter 1. INTRODUCTION TO CLINICAL APPLICATIONS OF GAIT ANALYSIS  
1.1. WALKING GAIT 
1.1.1. THE GAIT CYCLE 
Walking gait in humans is cyclic in nature and punctuated by consecutive initial contacts. An 
individual’s body type, dictated by their sex, age and any natural asymmetries, affects their 
unique movement pattern (Rigas, 1984). 
As depicted in Figure 1.1, one gait cycle is equivalent to a single stride and in healthy walking 
can be defined as between two successive heel strikes (initial contact) of the same foot 
(Perry and Burnfield, 1992). The healthy walking gait cycle has two well-defined phases, 
stance phase and swing phase, which correspond to approximately 60% and 40% of the 
stride, respectively. Throughout this cycle, the individual’s weight redistributes continuously. 
In healthy walking gait, following initial contact (heel strike), one foot moves through a flat 
position on the floor (stance phase) during which the opposite foot lifts (final contact) and 
propels forward (swing phase). Then once the opposite foot contacts the floor again, the 
former foot begins to lift off through the foot until the point of final contact, at which point 
the foot enters swing phase. Here, a step is defined as period between the ipsilateral and 
opposite initial contacts, and stride is the period between two initial contacts of the 
ipsilateral initial contacts. Stance phase is the period between ipsilateral initial and final 
contacts where foot is in partial or full contact with the floor, and swing phase is the 
alternate period where the foot is not in contact with the floor. Double support phase and 
single support phases are where both or one foot is in contact with the floor and are sub-
phases of stance. Step width can be defined as the distance between the feet, commonly 
measured between the middle supporting points of each foot.  
1.1.2. GAIT BIOMECHANICS 
The typical walking gait relies on consistent footfalls, arm swing symmetry, as well as 
coordinated fluctuations of trunk, neck and head movements and natural variability for 
appropriate gait adaptation and efficient locomotion. 
One of the primary purposes of the trunk during walking is to aid the stabilisation of the 
head in order to maintain a relatively steady plane of sight (Grossman and Leigh, 1990). 
While, Demer and Viirre (1996) described the effect of walking tasks on visual-vestibular 
|15 
interaction, there is also evidence that the reverse is also true i.e. vision deprivation leads to 
worse postural control (Tomomitsu et al., 2013).  
Therefore, to attenuate oscillations of the lower body through the trunk during walking gait, 
the human body is equipped with passive and active mechanisms. In healthy individuals, the 
spine’s natural S-shaped curvature distributes the mechanical stress of movement. The more 
inferior vertebrae (closer to the ground) carry more of the body weight and intervertebral 
discs add shock absorption to protect the individual bones. During walking, the head and 
neck largely move as a single unit undergoing frontal, vertical and lateral displacement as 
the body’s centre of mass (COM) adjusts with the motion of the pelvis and lower limbs with 
each footfall (Perry and Burnfield, 1992). Counter-rotation of the head and shoulders with 
respect to the pelvis, during double support phases particularly, assists with gaze 
stabilisation. This is the point of the gait cycle where forces are the greatest in the lower 
body (Mulavara et al., 2002). An anterior tilt, lateral pelvic drop and transverse rotation of 
the pelvis occurs in walking across the gait cycle during the forward progression of the body. 
The amount of frontal and vertical plane COM displacement corresponds to walking speed 
(Thorstensson et al., 1984) with a larger displacement rate occurring with increased speed. 
For instance, slow-paced walking is associated with a larger mediolateral COM displacement 
(Orendurff et al., 2004).  
Postural and dynamic instability occurs when these mechanisms break down during standing 
and walking, respectively. The lack of control of the body motion during these movements 
leads to worse balance, and an increased risk of falls. For the purpose of this thesis, 
instability will be defined as uncoordinated or poorly controlled upper body motion with 
postural stability considered during standing and dynamic stability considered during a task 
such as walking.  
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Figure 1.1: The gait cycle 
The gait cycle is punctuated with initial and final contact gait events which in normal individuals 
walking relates to heel strike and toe-off, respectively. One gait cycle is equivalent to a single stride 
and equivalent to two steps with the initial contact event commonly taken as the beginning of the 
gait cycle. Temporal and spatial difference between gait events generates several spatiotemporal 
gait parameters. Swing phase is defined as the period between a final contact and initial contact 
when the ipsilateral foot is off the floor with stance phase occurring between initial contact and final 
contact events when the ipsilateral foot is on the floor. Step width is commonly defined as the 
distance between the middle supporting points of each foot. 
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1.1.3. NEUROPHYSIOLOGY OF GAIT  
As a voluntary movement programme, control of walking gait involves both the nervous 
system and musculoskeletal systems. Walking is initiated and coordinated by a complex 
network of brain areas as well as reflexes which are fed into by various sensory and cognitive 
processes (Takakusaki, 2013)(See Figure 1.2). 
Pattern generating circuits within the spinal cord produce alternating rhythmic activity in 
arm muscles which enables arm swing to be a partially actively controlled (Meyns et al., 
2013). Due to the crossed-extensor reflex, afferent nerve fibres synapsing with interneurons 
on the contralateral side the spinal cord induce extension of the contralateral limb and 
flexion of the ipsilateral limb. These mechanisms together enable inter-limb coordination 
and counter-rotation of the shoulders.  
The lateral and ventromedial pathways of the descending corticospinal tracts continuously 
monitor body position in order to control voluntary movement (i.e. a volitional process) of 
distal musculature, and postural reflexes respectively. The planning of goal-directed 
movements is performed within various areas of the cerebral cortex in coordination with 
subcortical regions. The motor cortex provides innervation signals to muscles in a 
somatotopic map, and the premotor and supplementary motor areas (PMA & SMA) are 
required to plan skilled voluntary movements. The posterior parietal cortex produces a 
visualisation of body position, while the prefrontal cortex decides appropriate actions and 
communicates these to the rest of the neocortex. In addition, the basal ganglia and ventral 
lateral nucleus provide feedback to enable the selection and initiation of movement. 
Throughout this process, the cerebellum coordinates proper execution of movement 
through corrective instructions to the primary motor cortex. Through direct and indirect 
control pathways, automatic and emotional processes come into effect, subject to whether 
the gait is stereotyped or modulated (Hamacher et al., 2015). 
The breakdown of these processes due to lesions, disease and injury can lead to gait 
impairment. Therefore, the study of neurological gait disorders and animal models of these 
can clarify the brain mechanisms controlling gait further. See Section 1.2.4, for further 




Figure 1.2: Neurophysiology of gait 
Gait is controlled by involvement of volitional, automatic, and emotional signal processes. 
Reproduced from Neurophysiology of gait: From the spinal cord to the frontal lobe” Movement 
Disorders, Volume: 28, Issue: 11, Pages: 1483-1491, First published: 16 October 2013, DOI: 
(10.1002/mds.25669). with permission from Wiley.  
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1.1.4. ASSESSMENT OF GAIT 
1.1.4.1. Current Standards of Gait Assessment 
As abnormal gait is a common symptom of movement disorders, observation of gait is a 
standard feature of clinical examinations. The movement of the body within each gait cycle 
can be assessed in many ways, such as, in terms of the location and timings of each footfall, 
trunk or postural sway, as well as the movements of individual muscles and joints.  
Factors such as falls risk, falls history and activity levels are clinically relevant and important 
to consider in determining disease severity and monitoring disease progression. An 
increased risk of falls is associated with gait disorders such as Parkinson’s Disease (Frenklach 
et al., 2009), Multiple Sclerosis (Allali et al., 2016), and Cerebellar ataxia (Schniepp et al., 
2014). In addition, older adults with less confidence in walking and those with movement 
disorders have lower levels of daily physical activity (Hausdorff et al., 2001a). These can be 
measured using retrospective questioning and prospective activity diaries, but such methods 
typically provide subjective and qualitative information. More objective measures of gait 
that are currently available to clinicians include rating scales such as the modified Dynamic 
Gait Index (Shumway-Cook et al., 2013) and gait tests such as the Timed Up and Go 
(Podsiadlo and Richardson, 1991) or timed walking trials. Disease-specific psychometric tests 
are also better able to capture the gait and balance due to their sensitivity to symptoms (e.g. 
Unified Parkinson’s Disease Rating Scale (UPDRS) (Goetz et al., 2007)); Unified Huntington’s’ 
Disease Rating Scale (UHDRS) (Huntington Study Group, 1996); International Cerebellar 
Ataxia Rating Scale (ICARS) (Trouillas et al., 1997); Scale for Assessment and Rating of Ataxia 
(SARA) (Schmitz-Hübsch et al., 2006)). Through descriptive scoring, these semi-quantify the 
severity of patients’ symptoms, and subjectively evaluate gait disturbances in terms of 
walking capabilities, speed and use of supports. Although these scales have acceptable 
clinical utility and are widely used (e.g. SARA, Winser et al., 2015), many items such as the 
retropulsion test remain sensitive to observer variability and are out-performed by objective 
methods like static posturography (Bloem et al., 1998).  
As even the well-trained eye is unable to fully quantify gait characteristics there may be a 
role for instrumented gait analysis in the objective evaluation of gait disorders and to 
provide clinical biomarkers of disease severity and disease progression. Assessment during 
treadmill or over-ground walking can provide valuable information about the way in which 
patients walk and detect subtle changes in gait characteristics. As a feature of a validated 
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rating clinical scale, gait analysis could be incorporated into standard clinical practice, to 
increase the amount of information available to practitioners when managing patient care 
(Culhane et al., 2005). 
1.1.4.2. Gait Analysis Techniques 
The analysis of gait using instrumented techniques, enables various parameters related to 
the symmetry, variability, rotation and overall position of the body, limbs and joints, to be 
captured that otherwise would be too subtle to distinguish (Whittle, 1996). Gait analysis 
techniques make objective quantification of the gait pattern more accurate and readily 
available. A wide range of systems exist from fixed position to portable incorporating 
different technologies such as infrared imaging, pressure monitoring, and inertial 
measurement. As such the variety of systems available enable gait analysis to take place in 
different settings from clinic to real world. Different systems implement different 
approaches to capturing motion: from limb kinetics (measurement of forces associated with 
movement) and limb kinematics (measurement of movement), to muscle dynamics (activity 
and length changes). There are several methods of detection and analysis by which gait can 
be quantitatively examined, including methods for simultaneous measurement of upper and 
lower body movements (Muro-de-la-Herran et al., 2014). This is improving understanding of 
how the symptoms of movement disorders related to the underlying pathology as well as 
facilitating the development of biomarkers for disease progression. 
The gold standard of laboratory gait analysis is three-dimensional video motion capture 
systems, which measure joint angles and limb motion. These are often used in conjunction 
with floor-mounted force plates to assess spatiotemporal characteristics and weight 
distribution, as well as modelling various aspects of movement such as joint loading patterns 
(Kadaba et al., 1989). The analysis relies on the trajectories of reflective markers placed at 
predefined anatomical locations during movement (Cappozzo et al., 2005). These systems 
enable computational modelling of ground reaction forces, joint reaction forces and even 
muscle actions that can be adapted to be highly subject-specific. However, these systems 
require large dedicated laboratory areas and highly skilled staff to complete assessments 
and process data which are often not available in a hospital setting. In addition, laboratory 
gait analysis restrains participant walking to a relatively small measurement volume, making 
it less generalisable to real-world walking gait (Lara et al., 2013). 
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Due to this high cost to time, space, and money, combined with high data analysis burden, 
more feasible methods for use in a clinical setting are pressure-sensitive floor mats and LED 
array gait analysis systems. For physiotherapists and researchers requiring a high throughput 
of participants with a quick output of results, these are the principal methods of analysing 
footfall to measure the spatiotemporal characteristics of gait (Webster et al., 2005). 
For instance, the OptoGait photoelectric system (Microgate Inc. Bolzano, Italy) uses bars 
embedded with a series of LEDs to monitor footfall during over-ground or treadmill walking. 
Using activation thresholds to denote initial contact and final contact location and timing, 
spatiotemporal gait characteristics can be obtained and a patient report provided 
immediately for a clinical appraisal (Lee et al., 2014, Lienhard et al., 2013). 
Wearable inertial sensors are another promising option to those measuring gait. These 
commonly contain accelerometers, gyroscopes and magnetometers and are able to record 
the motion of each sensor at high frequencies for short to long periods. Analysis of temporal 
parameters relies on the exploitation of acceleration and angular velocity signals to establish 
gait events (Taborri et al., 2016). There are various algorithms and approaches described in 
the literature which have proven highly accurate in the segmentation of gait signals in 
healthy cohorts and some disease cohorts such as Parkinson’s Disease but may require 
further adaptation for implementation in assessment of pathological gait (Bruening and 
Ridge, 2014, Pacini Panebianco et al., 2018). 
Calculation of spatial gait parameters from inertial data relies on the computation of forward 
displacement through the integration of acceleration signals (Bertoli et al., 2018, Kluge et al., 
2017). A consensus has not yet been reached about the best method of computing these 
trajectories due to the importance of the location of sensor positioning. Therefore, work is 
underway to improve these algorithms to avoid direct measurement of spatial parameters 
using a second system. Computation of base of support or step width time cannot be 
directly measured with inertial sensors since each device is typically unable to track its 
spatial location relative to any others within the system and gyroscope measurements are 
typically associated with signal drift.  Time of flight (ToF) sensors, meanwhile, measure the 
distance between the sensor and a surface. Therefore implementation of ToF sensors within 
a wearable IMU system, with placement at the ankle, could provide an estimation of step 
width and step count without external equipment (Bertuletti et al., 2019). Another 
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promising approach to solve this problem is to implement sensor-fusion algorithms to 
combine measurements by multiple integrated sensors.  An Extended Kalman filter can be 
used to reduce noise in orientation measurements to provide better estimates of relative 
IMU displacement (Bennett et al., 2013).  
Meanwhile, when worn at positions on the upper body, inertial sensors enable 
quantification of upper body motion and the assessment of gait quality. As imbalance is a 
hallmark of all movement disorders, the assessment of trunk motion during walking is just as 
significant as analysis of the footfall (e.g. Huntington’s Disease (Medina et al., 2013), 
Parkinson’s’ Disease (Bronte-Stewart et al., 2002), and Cerebellar ataxia (Van de Warrenburg 
et al., 2005a)). Inertial sensors can be implemented to gather acceleration and angular 
velocity data in order to reliably detect gait measures (Henriksen et al., 2004). For instance, 
from the inertial signals at different points in the trunk, it is possible to determine the 
intensity and smoothness of motion and whether the forces are adequately controlled 
during walking. The Jerk signal (time derivative of acceleration) is the rate of change in the 
acceleration of movements in each anatomical plane calculated as the first-time derivative 
of acceleration signal (Brodie et al., 2014). This approach indicates the jerkiness of 
movements. Further information about the full gait pattern and the preservation of head 
stability can also be gained from multi-sensor systems using the attenuation coefficient 
(Mazzà et al., 2008, Mazzà et al., 2009). Auto-correlation coefficient analysis involves the 
transformation of acceleration signals to examine the regularity and symmetry of gait within 
periods relating to one step and one stride (first dominant period, AD1 and second dominant 
period, AD2 respectively) (Moe-Nilssen and Helbostad, 2004). 
The wearable nature of inertial sensors and relatively low cost enables the accurate and 
reliable assessment of participants in a variety of settings (Hickey et al., 2017, Storm et al., 
2016). Gait assessments in a clinical or laboratory setting, may not be representative of a 
patient’s natural walking gait due to experimental conditions (Robles-García et al., 2015). 
Therefore at-home physical activity monitoring has the potential to evaluate a patient’s gait 
during their daily lives. A comparison of physical activity monitors available commercially 
concluded that although overall accuracy was good, many of the devices examined 
underestimated step counts and misclassification of activity types was common (Storm et 
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al., 2015). Therefore, further work is required to improve algorithms and ensure that activity 
information is captured reliably. 
While, these methods deliver vast amounts of valuable information demanding analytical 
expertise, progress in understanding and increasing flexibility will enable their application 
into clinical practice and research. 
1.2. FACTORS INFLUENCING GAIT PATTERN 
Everyone has a unique movement pattern, due to their specific body type, sex, and age. How 
features such as gait speed change over time, can reflect important long-term health 
information even in healthy individuals (Fritz and Lusardi, 2009). Therefore, the implication 
of confounding factors is important to consider in any clinical environment and various 
studies have worked to establish those essential to consider when evaluating gait.  
1.2.1. AGEING 
Normal ageing can have a noticeable effect on the way in which individuals walk. For 
example, there is a natural weakening of the hip musculature with age accompanied by the 
onset and worsening of gait instability from the ages of 40-50 (Rigas, 1984, Terrier and 
Reynard, 2015). A natural compensatory response to this is to establish a larger base of 
support, reduce step length and step frequency. Murray et al. (1969), (1970), assessed gait in 
healthy older men and women, and concluded that individuals with increased instability also 
exhibit a larger step width. A study of older adults determined that those with impaired 
balance responses were also prone to falls (Tucker et al., 2010). Groups of younger and older 
people are distinguishable by patterns of head motion smoothness (Brodie et al., 2014). It is 
therefore important to consider the impact of ageing when determining the meaningfulness 
of a change in the gait characteristics of a patient and within the context of a clinical trial or 
observational study, to match cohort demographics for the age when possible. 
1.2.2. SEX DIFFERENCES 
Due to the influence of skeletal and musculature differences between males and females, 
there are several sex-related changes in gait pattern (Murray et al., 1969, Murray et al., 
1970). Examination of the attenuation of accelerations pelvis to head between men and 
women indicates altered postural control of lower body forces (Mazzà et al., 2009). In a 
cohort of healthy individuals around 30 years old, despite walking at the same preferred 
paced walking, men were found to take significantly longer strides with women 
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implementing a higher cadence. Differences in torso rotation were also identified as well as 
changes in arm swing mechanism between the sexes (Bruening et al., 2015).  
These findings indicate the importance of considering sex disparities in recruitment for gait 
studies. In the context of clinical studies, this can add complexity where certain diseases 
more commonly affect one sex over the other.  
1.2.3. ENVIRONMENT 
It is also important to consider the environment in which gait tasks are performed when 
interpreting results. Since gait assessments are usually completed within gait laboratories 
and hospitals these are not necessarily reflective of participants’ gait during daily life. The 
conditions of walking tasks such as the nature of activities completed, the setting and length 
of walking bouts can all lead to adjusted gait patterns in healthy individuals and people with 
movement disorders (Storm et al., 2016, Weiss et al., 2011). 
In addition, patients can adjust their behaviour when being observed during assessments 
which may alter the gait pattern further away from their normal everyday strategies 
(Malchow and Fiedler, 2016, Robles-García et al., 2015, Vickers et al., 2017). It is therefore 
essential to ensure that the clinical or laboratory setting is kept as uniform as possible across 
participants to compensate for the “unnatural” setting.  
The purpose of the walking assessment/study should also inform appropriate gait task 
selection. For instance, in order to study a participant’s best possible function or gait 
capacity, a short distance timed task or 6-minute walk test can be implemented their speed 
or distance travelled. The gait strategy for these tests is arguably different from how they 
may walk when unobserved in their daily life.  
For this reason, there has been a recent recognition in the value of multi-day physical 
activity assessment using specialised wearable IMUs. Physical activity monitors with a long 
battery life and large memory store can be worn continuously over multiple days. This offer 
an opportunity to assess real-world gait patterns and larger-scale activity characteristics. 
However, due to the unsupervised nature of such conditions, validation is required to ensure 
gait event detection algorithms are reliable and accurate enough to have confidence in 
findings. Compared with a clinic setting where the gait tasks are prescribed and more 
controlled, in real-world settings participants are required to adapt their walking pattern to 
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obstacles and events around them. This presents a challenge for people with neurological 
movement disorders for whom disability is common. 
1.2.4. NEUROLOGICAL DISEASE 
Neurological disorders are a large contributor to the number of disability-adjusted life years, 
to economic losses and increased social care needs worldwide (Andlin-Sobocki et al., 2005, 
World Health Organization, 2006). Over the next 40 years, the projected numbers of people 
with movement disorders are expected to increase by 1.6 times the current prevalence 
(Bach et al., 2011). 
Since balance performance is impacted in most movement disorders, investigation of the 
differences between healthy and pathological gait can build an understanding of the disease 
pathology. The evidence surrounding the effectiveness of the existing interventions is largely 
based on the subjective measures as discussed in Section 1.1.4.1. Therefore, the 
implementation of gait analysis has the potential to revolutionise drug and intervention 
development methods by providing novel biomarkers for disease progression. It could also 
aid the identification of individuals in need of additional support (to combat an increased 
falls risk) and those receptive to new therapies. 
However, since movement disorders are caused by a wide range of disease pathologies and 
are often associated with a large overlap in terms of disease features, work is needed to 
ensure that gait measures are disease-specific and sensitive to disease progression. 
1.2.4.1. Cognitive Dysfunction 
There is evidence to suggest that cognitive dysfunction interferes with gait. As previously 
discussed, gait and other types of movement are initiated in the brain, controlled by the 
basal ganglia and coordinated by the cerebellum. The areas conventionally associated with 
movement are also implicated in wider brain functions such as intellect, emotion and 
planning (Manto and Marien, 2015). Individuals with mild cognitive impairment struggle 
with dual-task walking tests and exhibit additional gait impairment in such conditions 
(Montero-Odasso et al., 2012). Since cognitive decline and dementia can be a comorbidity in 
several movement disorders, it is essential that these factors be monitored within a clinical 
study to avoid confounding gait analysis findings. This is especially true for gait tasks where 
participants are required to make conscious adjustments to their walking gait such as 
tandem walking and cued walking.  
|26 
1.2.4.2. Parkinson’s Disease (PD)  
Parkinson’s disease (PD) has received most of the research attention to date, as a target for 
gait analysis application due to its prevalence in the general population. As the second most 
common neurodegenerative disease, research into Parkinsonian gait offers an opportunity 
to develop clinical measures in a highly characterised movement disorder for comparison 
against different and more subtle gait patterns that are associated with other movement 
disorders. PD is caused by a degeneration of the basal ganglia and diagnosed by the 
presence of bradykinesia, muscular rigidity, resting tremor and postural instability (Hughes 
et al., 1992). PD patients (especially those with posture instability dominant subtype (PIGD)) 
often exhibit a distinctive pattern of gait dysfunction characterised by stooped posture, 
asymmetrical arm swing and shortened and quickened stride as well as freezing of gait in 
severe cases (Lees et al., 2009). 
Research has been able to quantify these patterns of spatiotemporal characteristics, 
although mixed clinical subtypes, and differences in medication have been reported to 
impact distinguishability of gait features compared with neurotypical individuals 
(Bovonsunthonchai et al., 2014, Herman et al., 2014). Various studies focused on capturing 
the postural stability in PD using inertial sensors have also revealed that unrelated to tremor 
and the reduced gait velocity in this cohort, individuals with PD are unable to attenuate 
accelerations through the trunk (pelvis to head) sufficiently (Buckley et al., 2015), and have 
increased transverse jerkiness in lower trunk (Mancini et al., 2011) and the head (Brodie et 
al., 2015).  
1.2.4.3. Cerebellar ataxia (CA) 
Ataxia is both a neurological sign and the term for a group of diseases characterised by 
incoordination of bodily movements. Gait ataxia is clinically recognisable as a wide-based 
stance with truncal instability and irregular lurching steps, which causes considerable 
disability in patients (Stolze et al., 2002). 
Cerebellar ataxia (CA) involves damage of cerebellum, but can involve the brainstem through 
space-occupying lesions. It is associated with balance and walking problems due to 
dysfunctional coordination of movements. It is distinct from sensory ataxias that result from 
proprioceptive abnormalities and vestibular disorders.  
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CA has acquired and hereditary aetiologies. The hereditary cerebellar ataxias (HCAs) affect 
more than 10,000 individuals in the UK (Wardle and Robertson, 2007) and are diagnosed 
through careful examination of family history and genetic testing. In these individuals, 
Autosomal Dominant, Autosomal Recessive, Mitochondrial or X-linked genetic mutations are 
inherited (Jayadev and Bird, 2013). Neurodegeneration leads to clinical signs characteristic of 
the area of the Cerebellum affected (Figure 1.3).  
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Figure 1.3: Functional anatomy of cerebellum 
Anatomy of the cerebellum highlighting key zones and lobes with important functions and impact of 
dysfunction noted. Image adapted from Major Regions of the Cerebellum (From Wikimedia 
Commons, the free media repository, licensed under the Creative Commons Attribution 3.0 
Unported license. Attribution: OpenStax College (Anatomy & Physiology, Connexions Web site. 
http://cnx.org/content/col11496/1.6/, Jun 19, 2013.) with details from Clinical Methods: The History, 




Dysfunction of the cerebellum has consistently been correlated with balance related gait 
problems throughout the literature indicating the role of the cerebellum in balance control 
in gait. Movement dysfunctions can map to specific locations of cerebellar dysfunction such 
as deficits in goal-directed movements due to dysfunction of the intermediate zone of the 
cerebellum (Ilg et al., 2007). Studies exploring neurological lesions have elucidated details 
regarding the symptoms of different ataxias. For instance, degeneration of the anterior 
cerebellar cortex and spinocerebellum are associated with a wide staggering gait pattern 
and nystagmus along with vertigo where posterior lobes involved. Meanwhile, 
vestibulocerebellum involvement includes dysarthria, ipsilateral appendicular ataxia as 
symptoms (Brust, 2012). 
There is considerable heterogeneity across the HCAs which leads to highly variable patterns 
of anticipation observed, presentation and progression experienced. Autosomal Dominant 
Cerebellar Ataxias (AD CA) are the most common HCAs with an estimated prevalence of 
between 0.001-0.005% in the general population (0.9-1.3 cases per 100,000 people) but 
subtype prevalence varies worldwide (Ruano et al., 2014). There are more than 40 AD CAs 
including Spinocerebellar Ataxias (SCA) and Episodic Ataxias (EAs). 
It can be difficult to differentiate between ADCAs due to overlapping characteristics such as 
variable age of onset and disease course. In up to two-thirds of SCA cases, for instance, gait 
disturbances are the presenting symptom. However, an isolated or pure cerebellar 
syndrome is uncommon, since many patients also display pyramidal and extrapyramidal 
signs, and cognitive deficits. EAs are characterised by episodes of ataxia and dysarthria 
between seconds and minutes to hours following sudden shock or emotional stress. 
Technological advances in molecular diagnostics have enabled the identification and 
classification of 40 SCAs (Sun et al., 2016), while genetic testing, magnetic resonance 
imaging, motor conduction studies and clinical history are highly informative to diagnosis. 
Unfortunately, phenotypic heterogeneity can lead to diagnostic difficulties in many 
individuals. This information does not impact disease management in a significant way 
beyond diagnosis. For instance, SCAs are progressive trinucleotide (CAGn) repeat diseases 
that result in the formation of nuclear aggregates due to the translation of an abnormal 
polyglutamine tract in the subsequent protein. Although the age of onset shows an inverse 
correlation with the size of CAG repeat expansion, there is no clear correlation between CAG 
|30 
repeat expansion size and disease progression. This indicates that other factors confound 
the prognosis and impact of the disease (Ashizawa et al., 2013).  
There are no established treatments for CA and the rehabilitation and physiotherapy 
interventions widely employed to relieve symptoms and teach compensatory techniques are 
evidenced by only small studies and highly varied results. Therefore, there is a need for 
further investigation of gait in CA to improve understanding of pathologic gait in order to 
contextualise intervention effects (Marsden et al., 2016).  
With the advances in molecular genetics, there is now evidence from the preclinical stage of 
SCAs in an effort to monitor the early disease progression (Maas et al., 2015). For instance, 
Rochester et al. (2014) revealed that a cohort of asymptomatic individuals with a preclinical 
SCA6 mutation, exhibit some gait similarities to a group diagnosed with SCA6 and these 
correlated with disease progression. While step time variability was significantly higher in 
preclinical syndrome than in controls, step velocity and step width, also correlated with total 
ICARS scores suggesting that gait changes are sensitive to progressing ataxia. Similarly, 
Velazquez-Perez et al. (2016) published the first results from a cross-sectional study of 
postural stability during the prodromal phase of SCA2. They described an early increase in 
lateral and anteroposterior sway that correlated to time until disease onset, and that was 
not detectable by standard clinical assessment using the SARA scale. 
Further, vestibular and cerebellar gait disorders can be distinguished on basis of the pace, 
base of support and variability domains of walking gait patterns since patients with these 
diseases often maintain their walking pace to rely less on sensory feedback control 
(Schniepp et al., 2019, Schniepp et al., 2012). Similarly, cerebellar vermis lesion size has been 
shown to correlate with gait stability (Hoogkamer et al., 2015). 
Early studies using instrumented analyses of gait in individuals with cerebellar syndromes 
described the spatiotemporal gait characteristics of CA as reduced cadence, step and length, 
gait velocity, and increased step and stride time and stance and swing phases (Palliyath et 
al., 1998, Stolze et al., 2002). Unfortunately, in these studies, participant numbers were 
small (just 10 and 12 per cohort respectively) and the patient cohorts were of mixed 
aetiology and rarely described by genetic diagnosis. There is, therefore, no clear way of 
retrospectively distinguishing between the different ataxia phenotypes included. 
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Within-person variability of gait is also increased in CA for many spatiotemporal parameters 
and is dependent on walking speed and related to an increased likelihood of falls (Schniepp 
et al., 2014, Wuehr et al., 2013). Trunk instability in individuals with CA has a huge impact on 
their ability to perform complex gait tasks such as sudden stopping and turning as well as 
complete everyday activities (Serrao et al., 2013a, Serrao et al., 2013b). The reduced velocity 
and spatiotemporal variability, observed in those with CA during gait are thought to be the 
principal mechanism of compensating for trunk instability to reduce the likelihood of falls 
(Schniepp et al., 2016, Schniepp et al., 2014).  
Further investigation is needed to identify features that can distinguish otherwise 
asymptomatic population prior to genetic diagnosis but this research demonstrates that 
instrumented techniques have real potential to accurately measure gait deviations in early 
CA, promising biomarkers for disease progression.  
1.2.4.4. Choreic Gait 
Choreiform gait is caused by the hyperkinetic movements that occur in individuals with 
middle to late-stage Huntington’s disease (HD) and is described as slow and wide-based, 
irregular, but unmistakable as a “dancing gait” associated with spontaneous knee flexion and 
leg raising.  
Caused by functional dysregulation of the indirect pathway of the basal ganglia system, HD is 
diagnosed by the presence of chorea, dementia, and psychiatric disturbances (Ross et al., 
2014). The differential diagnosis for HD includes a number of HD-like diseases (Schneider et 
al., 2007), Spinocerebellar ataxia 17 (SCA17) (Schneider et al., 2006) and early-onset 
Alzheimer’s’ Disease as well as some more easily excludable non-inherited conditions such 
as cerebrovascular disease (Drouin-Ouellet et al., 2015). In advanced HD, gait changes 
include bradykinesia, rigidity, and dystonia causing considerable overlap with previously 
discussed gait patterns. Studies have looked to capture gait in HD through instrumented 
analysis. For example, Dalton et al. (2013) implemented a single triaxial accelerometer in 
agreement with a computerised walkway. They were able to distinguish between 
premanifest and manifest HD participants and healthy control participants through 
variability and regularity measures such as step time variability, stride length variability, and 
step and stride length. 
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The impact of disease progression on measurable gait changes continues to be of interest as 
treatments are restricted to symptomatic therapies (Mestre et al., 2009). Therefore, analysis 
of more subtle gait characteristics such as spatiotemporal parameters, the variability of gait 
and features of upper body motion, has potential to distinguish the specific gait changes that 
differentiate HD from other gait disorders. 
1.2.5. MUSCULOSKELETAL DISEASE 
The musculoskeletal system is comprised of the skeleton, joints, muscles, and connective 
tissues and can be affected by a variety of primary or secondary disorders such as metabolic 
disorders, infection, injury and neurological disease.  
Spasticity or muscle stiffness, for instance, is associated with increased tendon reflex activity 
and hypertonia, which is seen in diseases like hereditary spastic paraplegia (HSP), cerebral 
palsy (CP) and multiple sclerosis (MS). Due to increased muscle contraction, the common 
gait characteristic associated with rigidity and foot-dragging. As it can be present in 
individuals with certain forms of CA, it is important to make the distinction between spastic 
and purely ataxic gait (de Bot et al., 2012).  
HSP refers to a group of genetic disorders, which in its “pure” form leads to progressive 
spasticity in the lower limbs and shortened strides (Salinas et al., 2008). Early gait analysis in 
this population identified reduced velocity, stride length, step height and knee-ankle range 
of motion as well as a widened base of support (Braschinsky et al., 2009, Klebe et al., 2004). 
CP is a condition where hypertonia and muscle weakness (termed spastic diplegia) can be 
complicated by seizures and dysphagia. A considerable amount of research has been 
completed into the use of gait analysis in the management of CP (Baumann, 1984). There are 
notable similarities between CP and HSP, such as early childhood disease onset and delayed 
motor milestones. Therefore, gait analysis has a role here to help establish a differential 
diagnosis in cases where patient history is insufficient and genetic testing is not possible. 
Cimolin et al. (2007) and later Piccinini et al. (2011) used gait analysis to distinguish between 
these conditions. These studies reported that compared to typically developing children, the 
pathological groups displayed lower gait velocity, higher step width and reduced step length 
and higher anterior pelvic tilt. The HSP cohort, however, exhibited a more normal ankle 
position, and a distinct motor strategy of the knee than the Spastic Diplegia group, which is 
more flexed during initial contact and hyperextended for longer during mid-stance. 
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Bonnefoy-Mazure et al. (2013) meanwhile explored upper body kinematics and determined 
that HSP compensated for lower limb perturbations through the use of the spine, whilst 
those with Spastic Diplegia used their arms more.  
The gait impairment in CP, however, is not confined to lower limb rigidity and studies 
implementing inertial sensors have observed higher trunk accelerations and asymmetry in all 
three planes of motion (Saether et al., 2014). This results in balance problems and reduced 
gait harmony resulting in impaired gait instability for their age (Iosa et al., 2012).  
Whilst further study is essential, research into HSP and CP demonstrate that gait analysis can 
provide a diagnostic benefit for people affected by spasticity whilst also illustrating the 
impact of specific musculoskeletal pathologies on walking gait. 
1.3. SUMMARY 
Locomotion is a complex movement, controlled by an intricate network of brain areas and 
affected by neurological disorders. The motivation of many research groups is either 
improving understanding of the various contributions to the walking gait or developing a 
clinical biomarker for movement disorders and neurological diseases. This research is 
important, as a consensus needs to be reached regarding the sensitivity and specificity of 
protocols and measures, prior to the incorporation of gait analysis techniques into clinical 
practice and development of novel treatments. 
Neurological diseases and movement disorders can cause considerable disability and form a 
large societal and economic burden which will become greater as the population ages in 
coming years. Compared with healthy people, individuals with movement disorders are less 
stable while walking. This contributes to an inability to adapt their gait to their surroundings 
which can cause considerable disability and increased risk of falls. The ability to complete 
daily activities and independent ambulation are important to the quality of life in people 
with and without movement disorders. Therefore, it is vital to be able to measure these 
factors objectively, reliably, and accurately. 
Gait analysis is now relatively common in sports therapy and physiotherapy and increasingly 
more research is underway into its clinical applications. By assessing gait in healthy people 
and individuals with movement disorders, it is possible to attain additional understanding of 
the neural processes of walking, the influence of upper body motion on overall gait, and the 
implications of neurological disease on walking. This enables the quantification of the 
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precise durations, dimensions and fluctuations of the gait cycle. Furthermore, if 
instrumented assessments of locomotion can distinguish between movement disorders and 
within disease subtypes, there is real clinical potential for the development of a 
complementary index of gait disturbance.  
CA, is a heterogeneous syndrome characterised by incoordination and instability. Individuals 
suspected of CA are now routinely offered genetic testing but in some cases, genetic testing 
is unable to clarify the diagnosis. Rating scales such as the ICARS and SARA, validated for 
assessment of the severity of ataxia, can also have difficulty distinguishing between subtypes 
and monitoring disease progression. There is no disease-modifying therapies in place for CA 
and rehabilitation techniques are not routinely validated in terms of objective gait 
improvement.  
Research into the various contributions to walking gait in pathological populations and the 
development of a clinical biomarker for movement disorders has the potential to 
revolutionise disease monitoring. Therefore, it is important that a consensus is reached 
regarding the gait characteristics of CA. Quantifying the clinically relevant change in gait 
characteristics and establishing reliable protocols will promote the incorporation of gait 
analysis techniques into everyday clinical practice and pharmaceutical trials. 
1.4. AIMS AND OBJECTIVES 
The long-term aim of this project is to uncover a novel gait biomarker for the progression of 
ataxia that is capable of tracking disease progression and is appropriate for incorporation 
into clinical practice. 
In order to achieve this, a number of studies will be completed as part of this project: 
• Completion of a Systematic Review to summarise and meta-analyse the reported gait 
characteristics of cerebellar ataxia (CA). Critical appraisal and quality assessment of 
previously reported results will instruct future work. (Chapter 2) 
• In-house validation of proposed gait analysis equipment against the gold-standard of 
gait analysis (3D motion capture) to ensure the accurate measurement of 
spatiotemporal parameters and confirm the synchronisation of data capture. 
(Chapter 3) 
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• An observational gait analysis study will be completed to assess the gait 
characteristics of CA compared with a healthy age-matched control population. The 
association between upper-body motion and spatiotemporal gait parameters as well 
as the influence of disease severity and walking speed will be explored. (Chapter 4) 
• After period of 12-months, follow up assessments of gait in the study population will 
be completed. A subgroup of participants will also be assessed at 24-month follow-up 
to explore changes over a longer time period. The ability of gait features to detect 
disease progression will also be investigated. (Chapter 5). 
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2.1. INTRODUCTION 
Gait ataxia is clinically recognisable as a wide-based stance with truncal instability and 
irregular lurching steps, which can result in an increased risk of falls (van de Warrenburg et 
al., 2005b). This can be accompanied or predominated by other symptoms depending on the 
ataxia subtype (Stolze et al., 2002). 
Presently, the principal methods of gait assessment in a clinical setting are through the use 
of subjective rating scales such as the Scale for the Rating and Assessment of Ataxia (SARA) 
(Schmitz-Hübsch et al., 2006). Although many of these are validated to detect progression of 
ataxia (Burk et al., 2013, Jacobi et al., 2012), there is evidence to suggest that clinical 
assessment scales might underestimate the severity of gait changes in cerebellar ataxia (CA) 
(Schniepp et al., 2016). 
Instrumented gait analysis techniques quantify subtle gait characteristics that would not be 
detected by clinical examination. There is increasing acceptance of the use of gait analysis 
methods such as 3D motion capture, pressure-sensitive walkway and inertial sensor for the 
assessment of neurological diseases that manifest with gait changes.  
Improved classification of ataxic gait disturbance and definition of biomarkers for disease 
progression will enable quantification of the effect of novel and existing interventions to 
improve disease management in CA while also clarifying the disease mechanisms in specific 
CA subtypes (Bates et al., 2016). 
Early studies using instrumented gait analysis in individuals with cerebellar syndromes 
described the spatiotemporal gait characteristics of CA as reduced cadence, step and length, 
gait velocity, and increased step and stride time and stance and swing phases (Palliyath et 
al., 1998, Stolze et al., 2002). However, other studies provide conflicting results and many 
report inconsistencies within cohorts. There are currently no guidelines to state the clinically 
relevant change in gait characteristics. 
With technological advances making it quicker and easier to implement gait analysis, studies 
exploring neurological gait disorders are becoming more prevalent. It is now possible to seek 
a consensus description of the gait characteristics of CA and differences compared with 
healthy controls. By comparing CA to healthy control cohort in preferred paced walking gait 
tasks, the gait pattern changes that are sensitive to this disease group and reflective of gait 
capacity can be quantified. This will enable an examination of the inconsistencies between 
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published studies and the repeatability of the spatiotemporal gait pattern. It will also allow 
identification of current deficits in research and guide future research by recognising further 
work required in the field.  
2.1.1. AIMS AND OBJECTIVES 
By evaluating and summarising the spatiotemporal gait characteristic measured using 
instrumented gait analysis techniques, this systematic review aims to answer the question: 
Which gait characteristics are able to differentiate between CA and controls?  
This will provide an estimation of the objective gait changes in CA in a larger cohort than 
usually possible in single-centre clinical studies of CA and an indication of the number of 
participants necessary for future case-control clinical studies. 
2.2. METHODS 
Available literature was systematically searched, following a pre-determined protocol 
(PROSPERO 2016: CRD42016042149, Available from 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016042149).  
Using the PICOS framework (Higgins and Green, 2013) the research question was explored in 
order to guide the design of search strategy and selection criteria:  
• Patient population: adults (age 18yrs or older) with CA 
• Intervention: no intervention required 
• Comparison: healthy controls where recruited should be matched for age and sex as 
a minimum 
• Outcome: straight-lined self-paced instrumented walking tests 
• Study type: Studies of all designs were considered, except review articles, if 
published since 1996 and available in English. For interventional studies, only 
baseline gait characteristics included. 
2.2.1. SEARCH STRATEGY 
The search strategy and selection criteria were developed in line with the review questions 
and agreed on by two researchers (AM, EB). Titles and abstracts of articles within a number 
of electronic databases (MEDLINE via OVID, psyc-INFO via OVID, PubMed, IEEE-xplore, 
Cochrane trials library, web of science core collections, and Scopus) were searched 
systematically implementing MESH search terms and keywords where appropriate to 
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combine three search phrases (walking terms (Walk* or gait or Locomotion), measurement 
terms (Measur* OR assess* OR evaluat* OR examin* OR analysis OR analy*e OR 
Biomechanic OR kinematic OR instrumented) and ataxia terms (cerebellar ataxia OR gait 
ataxia)) (Appendix 1). Searches were completed in July 2016, repeated in November 2016, 
and the output restricted to those published since 1996 until the search date. 
Reference lists from eligible articles as well as relevant reviews and systematic reviews were 
hand searched and studies identified subjected to the same selection criteria. This aimed to 
reduce any restrictions of the search strategy in uncovering unpublished and published 
evidence. Records identified were imported into EndNote (Clarivate Analytics), and 
processed to remove duplicate records and any older articles that remained.  
2.2.2. STUDY SCREENING PROCESS 
Article screening was guided by an Inclusion/ Exclusion criteria, pre-defined in line with the 
research question (Appendix 2). Titles and abstracts of articles identified by searches were 
subjected to the selection criteria by two researchers independently. References were 
divided between assessors in the interest of time, while 10% of articles were dual-screened 
to confirm appropriate decision-making and adherence to the selection criteria.  
Those articles that satisfied the screening criteria moved on to full-text appraisal. This was 
completed in parallel by assessors and final selections made through discussion. Where 
articles were suspected or confirmed to report results from identical or overlapping cohorts 
of patients the earliest or most relevant article was selected for inclusion. 
No restriction on study design was established but reviews and articles published in a non-
English language were not considered. The abstracts of non-English articles were translated 
to check if they would be relevant. The cohort or subgroup were required to have a 
diagnosis of CA. Any studies related to single-sex groups were not to be considered in the 
interests of reflecting both sexes equally in the meta-analysis. Studies with a cardiac-related 
focus were also ruled out to ensure that participants did not exhibit any relevant co-
morbidities. It was essential that gait is analysed through instrumented techniques, 
therefore any studies that reported subjectively observed gait parameters were excluded. 
Studies, where only activity level or single muscle activity was reported, were also excluded 
as the core gait characteristics were of interest for meta-analysis. In the interest of 
establishing a uniform gait analysis protocol, it was vital that studies reported 
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preferred/comfortable paced straight-line gait in a “normal” condition so those that only 
investigated gait within “challenged” conditions or during turn phases were not included. A 
control cohort was not critical for inclusion, but where included participant groups should be 
well matched for age and sex as a minimum and display no known morbidities. A publication 
date cut-off was set, with only articles published since the year 1996 considered, intending 
to garner results from newer, relevant studies implementing recent technological advances. 
Participants were not required to undergo any type of intervention as baseline gait 
characteristics were of most interest. References lists from eligible articles were screened to 
identify further references of interest. 
Full-text appraisal was completed in parallel by authors and agreements come to through 
discussion. Where articles were suspected or confirmed to report results from identical or 
overlapping cohorts of patients the earliest or most relevant article was selected for 
inclusion. Literature searches were later repeated to uncover any relevant articles published 
since initial search completion. 
2.2.3. DATA EXTRACTION AND SYNTHESIS 
Study information and gait parameters were extracted from the selected articles and, where 
necessary, authors contacted to request additional results. All available study information 
and reported gait characteristics were collated in Microsoft Excel. Where necessary, data 
were extracted from published images of graphs using WebPlotDigitizer v3.9 (Rohatgi, 2015) 
and where necessary, authors of selected articles were contacted to clarify study details and 
obtain unreported results. This included requesting average and standard deviation of 
cohort gait characteristics where the median and interquartile range was reported and 
coefficient of variation where other variability measures (such as combined standard 
deviation) were reported. Articles, where information was not made available for 
assessment following repeated requests, were excluded from further analysis despite being 
potentially relevant studies. Where multiple subgroups were examined in a single study, 
data were combined to a single result following Cochrane Review guidance (Higgins and 
Green, 2013). 
In articles where despite the cohort being of average adult age, some individual participants 
were younger than 18, authors were asked to provide gait data from the more limited group 
of adult participants.  
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Results were converted to common units of measurement so that all spatial parameters 
were expressed in terms of metres (m) and temporal parameters expressed in terms of 
seconds (s). Speed was expressed as metres per second (m/s), cadence as the number of 
steps in a minute (steps/ min) while phases of the gait cycle were expressed as a percentage 
of the total stride duration (%). Gait variability was reported as either Coefficient of Variation 
((CV) defined as Standard Deviation (SD)/mean (%)) or combined Standard Deviation ((cSD) 
defined as the square root of the mean-variance of the left and right steps (cm))(Galna et al., 
2013). 
2.2.4. STATISTICAL ANALYSIS  
For cohort demographics, descriptive statistics (average, standard deviation (SD) and range) 
were computed using IBM SPSS Statistics for Windows, version 23 (IBM Corp., Armonk, N.Y., 
USA). 
Treating the complete dataset as a cohort, Pearson’s’ non-parametric bivariate correlation 
analysis was also completed to display the associations between parameters. Significant and 
relevant results were deemed as a correlation coefficient greater than 0.6 and lower than -
0.6 and a significant p-value less than 0.05. Correlation analysis was performed for ataxia 
and healthy controls separately. 
2.2.5. META-ANALYSIS 
Meta-analysis was completed in Rstudio (version 3.3.2)(R Core Team, 2017), using the 
“meta” package (Schwarzer, 2007). For parameters where results were available for more 
than 3 studies, the weighted mean difference (MD), 95% Confidence intervals (CI) and the 
standardised Z-score for overall effect were computed. Heterogeneity was tested using I² 
statistic, although a single group random effect model (REM) used throughout to give a 
conservative approach to meta-analysis. 
Forest plots were generated to display the comparison of walking gait characteristics in CA 
and healthy controls from preferred/ comfortable self-paced walking. 
Studies without control cohorts were included in the meta-analysis but not given any 
weighting in the calculation of the pooled estimate. To ensure the uniformity of data 
processing, gait parameters that had been standardised for individual biomechanical 
features (e.g. leg length or height), were excluded from meta-analyses. For gait variability, 
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only coefficient of variation was reported commonly enough for results to be meta-analysed. 
The weighted mean and standard deviation of the most common parameters was also 
calculated implementing the weights as produced in meta-analysis to provide a summary 
output in Rstudio (version 3.3.2)(R Core Team, 2017) using the “weights” package (v1.0 
Pasek, 2020).  
2.2.5.1. Subgroup Meta-analysis 
In the predefined protocol, further analysis of the effect of gait speed, rehabilitation and 
protocols were to be determined following data appraisal. Therefore, a subgroup meta-
analysis was performed in RStudio for two identifiers: Disease group (Mixed CA, SCA, or 
FRDA); and gait analysis technique used (3D motion capture, pressure-sensitive walkway, 
inertial sensor or alternative method).  
For each subgroup, a single group inverse-variance (IV) random effect model to produce the 
weighted mean difference, 95% Confidence intervals (CI) and the standardised Z score for 
overall effect was computed. Heterogeneity was tested using I² statistic (percentage of 
variation across studies that is due to heterogeneity rather than chance). This was not able 
to be applied for any subgroups containing only 1 study. Tests for differences between 
subgroups produced Chi2 statistic and P-value. Forest plots were then generated to display 
weighted mean differences for each subgroup and overall effect. 
2.2.6. QUALITY ASSESSMENT 
Prior to data extraction, studies that were eligible for inclusion underwent a quality 
assessment to detect the risk of bias using an adaptation of the criteria described by Littell et 
al. (2008)(Appendix 3). Researchers judged for each article whether each criterion was met 
(Yes (Y) or No (N), could not be determined (CD), the criterion was not applicable (NA) or 
information was not reported (NR) and gave an overall rating of Good, Fair or Poor. 
Researcher’s independent findings were compared, and ratings were agreed on through 
discussion. This allowed appraisal of the limitations of each study following a uniform 
structure of enquiry but did not aim to exclude articles on the basis of their quality.  
2.2.7. POWER CALCULATION AND SAMPLE SIZE ESTIMATION 
Statistical power estimated following the formula, where Z value taken from random-effects 
model meta-analysis and N given for CA and HC cohorts. 
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Where mean difference between cohorts (CA-HC) taken from meta-analysis results for each 
parameter. The weighted SD was computed implementing the weights as produced by meta-
analysis in Rstudio (version 3.3.2)(R Core Team, 2017) using the “weights” package (v1.0 
Pasek, 2020). SD was adjusted for K, the ratio of participants per cohort (NCA/NHC), an alpha 
level 0.05 (𝑧1−𝑎/2 = 1.96) and statistical power 90% (𝑧1−𝛽 = 1.28). Estimates were 
increased by 10% and rounded up to the next whole number. Where estimation indicates 
that less than 30 participants are required, in order to satisfy the central limit theorem a 
more realistic minimum of 30 participants should be considered more appropriate to ensure 
an approximately normal distribution of values (Kwak & Kim, 2017).  
2.3. RESULTS 
2.3.1. STUDY SELECTION 
In total, 3763 records were identified through searches of 6 databases and numerous 
reference lists. Of the 65 records that were screened as full texts, 21 articles (Caliandro et 
al., 2015, Chini et al., 2016, Conte et al., 2014, Ebersbach et al., 1999, Gouelle et al., 2013, 
Ienaga et al., 2006, Ilg et al., 2010, Ilg et al., 2007, Im et al., 2016, Martino et al., 2014, 
Matsushima et al., 2015, Milne et al., 2014, Mondal et al., 2015, Palliyath et al., 1998, 
Rochester et al., 2014, Schmitz-Hübsch et al., 2016, Schniepp et al., 2014, Seidel and Krebs, 
2002, Serrao et al., 2012, Stephenson et al., 2015, Wuehr et al., 2013) were selected for data 
extraction. Seven other articles were considered for inclusion but deemed to incorporate 
cohorts that overlapped with included articles. Due to issues of data availability, 3 articles 
(Ilg et al., 2010, Im et al., 2016, Mondal et al., 2015) were excluded from the meta-analysis.  
The included articles all reported spatiotemporal gait characteristics of CA, measured using 
instrumented gait analysis techniques during straight-line walking.   
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Full-text articles  
excluded  
(n = 44) 
Population: n = 12 
Intervention: n = 17 
Outcome: n = 5 
Design: n = 3 
Duplicate Cohort: n = 7 
Records remaining after limiting 
date range to 1996-2016 
(n = 3394) 
Records screened 
by title/ abstract 
(n = 1802) 
Articles assessed in full-text  
(n = 58)  
abstract only available  
(n=7) 
Studies included in  
quality assessment  
(n = 21) 
Studies included in  
qualitative synthesis 
(n = 21) 
Studies included in  
meta-analysis 
(n = 18) 
Records excluded due 
to date published 
(n = 369) 
Duplicate records  
removed 
(n =1592) 
Records excluded  
due to irrelevancy 
(n = 1737) 
Records excluded due 
to poor quality or  
high risk of bias 
(n = 0) 
Records excluded from  
meta-analysis due to  
insufficient data  
(n = 3) 
Additional records identified  
through other sources 
(n =21) 
Total records identified 
(n=3763) 
Records identified through 
database searching 
(n = 3742) 
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2.3.2. CRITICAL APPRAISAL 
A summary of the 21 included articles (Caliandro et al., 2015, Chini et al., 2016, Conte et al., 
2014, Ebersbach et al., 1999, Gouelle et al., 2013, Ienaga et al., 2006, Ilg et al., 2010, Ilg et 
al., 2007, Im et al., 2016, Martino et al., 2014, Matsushima et al., 2015, Milne et al., 2014, 
Mondal et al., 2015, Palliyath et al., 1998, Rochester et al., 2014, Schmitz-Hübsch et al., 
2016, Schniepp et al., 2014, Seidel and Krebs, 2002, Serrao et al., 2012, Stephenson et al., 
2015, Wuehr et al., 2013) is displayed in Appendix 4. On average, each study included 19.43 
± 11.33 patients, which combined, reflects gait assessments for 408 patients with 
established CA and 403 healthy controls, with 44.12% and 48.14% females respectively (in 
Table 2.1).  
Although only 16 articles had control cohorts, controls were always matched to the patient 
cohort’s age (47.3±11.23yrs) and often matched for sex. Height and mass were also matched 
when reported and when pooled, no significant difference was found between cohorts in 
any of the morphological features (BMI, mass and height, leg length) in independent t-tests 
(p<0.05). These clinical studies were completed across 10 countries (9 developed and 1 
developing). In 1 paper (Gouelle et al., 2013) gait data from a limited group of adult 
participants were gathered from authors in order to ensure the cohort had an average age 
over 18 years.  
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Table 2.1: Summary of the Cohort Demographics  
  Cases Controls    
n Mean Average  
SD (range) 
k n Mean Average  
SD (range) 
k p Value 
Total no. 
(% Female) 
408 (44.12%) 19.43  11.33  
(8-51) 
21 403 (48.14%) 25.19  29.03 
(6-123) 
16   
Age (yrs) 48.30  11.23  
(20.50-64.30) 
21   48.34  8.55 
(29.60-60.90) 
16 0.991 
Height (cm) 170.87  4.23  
(165.00-176.90) 
10   170.14  2.74 
(167.00-174.00) 
6 0.697 
Mass (kg) 74.90  4.99  
(68.00-81.00) 
8   73.28  3.70 
(69.10-78.00) 
5 0.546 
Leg length (cm) 84.73  6.60  
(78.00-91.20) 
3   85.83  5.35 
(80.00-90.50) 
3 0.834 
BMI (kg/m2) 26.86  3.33  
(23.11-33.90) 
8   25.03  1.54 
(22.60-26.60) 
5 0.277 
Disease duration (months) 41.25  63.26  
(3.70-216.00) 
13         
ICARS (/100) 26.54  8.52  
(16.70-45.10) 
9 
    
SARA (/30) 11.943.19  
(8.60-16.40) 
5 
    
See Appendix 4 for gait analysis results from each study. n = number of participants, k = number of 
articles featured in, results reported as average ± standard deviation (SD) (range). 
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Patient cohorts were very often of mixed aetiology, but most (17) stated the specific 
diagnoses reflected in the group. Gait characteristics of more specific ataxia types were 
explored in 9 studies (Gouelle et al., 2013, Ienaga et al., 2006, Ilg et al., 2010, Milne et al., 
2014, Rochester et al., 2014, Schmitz-Hübsch et al., 2016, Serrao et al., 2012, Stephenson et 
al., 2015, Wuehr et al., 2013) encompassing Chromosome 16q-linked Autosomal Dominant 
Cerebellar Ataxia (16q-ADCA), Spinocerebellar Ataxias (SCA1/2/6/14), cerebellar subtype 
Multiple System Atrophy (MSAc), and Friedreich Ataxia (FRDA). Findings from these studies 
included: a correlation between plantar pressures and Double Limb Support phase (DLS) in 
SCA6 compared with MSAc and 16q-ADCA groups (Ienaga et al., 2006), a greater 
improvement with rehabilitative training in CA than afferent forms of ataxia (Ilg et al., 2010) 
and a longer step length measured in individuals with SCA1/2 than with FRDA (Serrao et al., 
2012). 
Twenty of the records included related to published articles accompanied by one conference 
abstract. This group of articles contains 2 intervention studies that explored the impact of 
rehabilitation and training on ataxic gait and 17 prospective observational studies 
investigating specific gait features of ataxic gait or validating new clinical tools and methods 
of analysis. Follow-up assessments were completed in 4 studies, of which two were training 
studies (Im et al., 2016) which showed significant improvements in motor performance and 
reduced ataxia symptoms in cerebellar ataxia. The third incorporated data as independent 
samples (Gouelle et al., 2013) and the remaining study (Matsushima et al., 2015), performed 
a follow-up assessment at 6 months on a subset of the initial cohort (n=11/51) and identified 
no significant difference in velocity (the only spatiotemporal parameter reported).  
Disease symptoms and balance/gait deficits were rated using clinical rating scales in 17 
studies. Most commonly, International Cooperative Ataxia Rating Scale (ICARS) (Trouillas et 
al., 1997) or Scale for the Assessment and Rating of Ataxia (SARA)(Schmitz-Hübsch et al., 
2006) were implemented, with 8 other rating scales used in the included studies. The ICARS 
and SARA scores reported confirming that patients included here showed gait difficulties but 
were still capable of independent walking (Klockgether et al., 1998, Schmitz-Hübsch et al., 
2006). Use of walking aids was expressly excluded in 14 studies while 11 studies excluded 
individuals with cognitive dysfunction. 
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Falls occurrence was reported in just 3 studies (Chini et al., 2016, Rochester et al., 2014, 
Schniepp et al., 2014) where a higher rate of falls was apparent in CA, with 43.18% (38/88) of 
those patients reported falling with the last 3-12 months. Between these studies, only 
Schniepp et al. (2014) performed an analysis exploring gait metrics associated with fall 
status. They reported that a history of falls is associated with an increased stride length 
variability and stride time variability which correlates with preferred walking speed. 
To track spatiotemporal characteristics of walking, the most commonly implemented gait 
analysis techniques within these studies were 3D Motion Capture, employed in 9 studies, 
and Pressure Sensitive Walkways, used in 8 studies. Other techniques used were: triaxial 
inertial sensors, pressure-sensitive insoles, force plates and pressure-sensitive treadmill. LED 
array and surface EMG was also used in places with one study applying a pulley system 
attached at feet to be monitored by an optical recording device. Within the included studies, 
all participants completed comparable short gait tasks to assess free unassisted, straight-
line, self-determined speed walking in a laboratory setting. Walkway length for different 
studies was between 2.2m and 20m (mean ± SD = 9.1m ± 3.4m) and was principally dictated 
by the equipment type used. Participants walked barefoot in each of the 9 studies where 3D 
motion capture was used. For all other studies, participants wore shoes or this detail was not 
reported. 
Eight studies explored the influence of pace on gait, through trials performed at different 
walking speeds. Different velocity walking trials were executed in 7 studies (Ebersbach et al., 
1999, Im et al., 2016, Martino et al., 2014, Milne et al., 2014, Schmitz-Hübsch et al., 2006, 
Schniepp et al., 2014, Stephenson et al., 2015, Wuehr et al., 2013). Participants within these 
studies completed walking tasks at a range of speeds between very slow and very fast. Upon 
full-text appraisal, fast-paced walking by patients with ataxia was consistently associated 
with increased cadence, step and stride length, and swing phase as well as decreased in the 
stance and DLS phases, compared with preferred- and slow-paced walking. Meanwhile, the 
variability of stride time and stride length, shows a U-shaped curve with the minimal CV 
magnitude observed in preferred paced walking and highest CV magnitude detected in slow-
paced walking (Schniepp et al., 2014, Wuehr et al., 2013). 
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Although 42 gait parameters were identified, only 14 were reported frequently enough to be 
explored further through meta-analysis. A summary of gait metrics reported by each article 
can be seen in Appendix 4 and Figure 2.2 displays the frequency of these gait metrics.  
2.3.3. QUALITY ASSESSMENT 
Upon quality assessment, 10 articles were rated “good” with low risk of bias, 10 rated “fair” 
with some risk of bias (Appendix 5). None were deemed to be of “poor” quality and at too 
high risk of bias for inclusion, but insufficient data were available from one study (Mondal et 
al., 2015) to reach a full rating. Score breakdown can be seen in Figure 2.3.  
2.3.4. STATISTICAL/ DESCRIPTIVE ANALYSIS 
The included articles reported several distinct spatiotemporal gait characteristics measured 
during walking at a self-selected pace. A summary of each study’s average and standard 




Figure 2.2: Frequency of gait metrics reporting 
Frequency of reporting of gait parameters by the articles included in the study with units indicated. 




Figure 2.3: Quality assessment score breakdown  
Break down of ratings for 21 included articles in quality assessment. Abbreviations: “Y” Yes; “N” No; 




The included articles reported several distinct spatiotemporal gait characteristics measured 
during straight-line walking at a self-selected pace.  
Meta-analysis was completed for 14 spatiotemporal gait parameters extracted from 18 
primary studies. Other parameters lacked enough evidence to assess between cohort 
differences. Exclusion of results standardised to leg length or height led to some data being 
excluded from the meta-analysis. A summary of the overall cohort weighted mean values for 
each gait metric can be seen in Table 2.2. 
In the patient dataset (Appendix 7), correlation analysis showed significant positive 
relationships between disease severity and ICARS score (r=0.725, p=0.027), and between 
mass and BMI (r=0.857, p=0.014). The only significant correlations between gait parameters 
were speed with step length (r=0.893, p=0.007) and speed with stride length (r=0.829, 
p=0.042). However, in the control cohort (Appendix 7) the only significant correlation was 
between step length and speed (r=0.964, p=0.000). 
2.3.5.1. Pace 
Walking speed was studied by 14 studies (Caliandro et al., 2015, Ebersbach et al., 1999, 
Gouelle et al., 2013, Ilg et al., 2007, Matsushima et al., 2015, Milne et al., 2014, Palliyath et 
al., 1998, Rochester et al., 2014, Schmitz-Hübsch et al., 2016, Schniepp et al., 2014, Seidel 
and Krebs, 2002, Serrao et al., 2012, Stephenson et al., 2015, Wuehr et al., 2013) and in 
ataxia (n=281) preferred walking speed was significantly reduced compared with healthy 
controls (n=345) (REM, MD=-0.36m/s, 95% CI (-0.43, -0.29), p<0.01, I2=0%) (Figure 2.4a). 
Similarly, in the 10 studies that reported cadence (number of steps per min) (Ebersbach et 
al., 1999, Gouelle et al., 2013, Ienaga et al., 2006, Matsushima et al., 2015, Milne et al., 
2014, Palliyath et al., 1998, Rochester et al., 2014, Schmitz-Hübsch et al., 2016, Schniepp et 
al., 2014, Stephenson et al., 2015) the ataxia cohort (n=208) demonstrated significantly 
reduced cadence than healthy controls (n=267) (REM, MD=-13.28 steps/min, 95% CI (-19.99, 
-6.58), p<0.01, I2=99%) (Figure 2.4b).   
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Table 2.2: Summary overall weight mean gait metrics 
 Cases Controls  
 n 
Mean  
Average ± SD 
k n 
Mean  




Pace        
Speed (m/s) 281 0.91± 0.16 14 345 1.27 ± 0.15 12 <0.01 
Cadence (steps/min) 208 98.68 ± 10.85 10 267 111.97 ± 6.71 8 <0.01 
Spatial  
      
 
Step Length (m) 139 0.54 ± 0.09 7 251 0.68 ± 0.06 7 <0.01 
Stride Length (m) 94 1.17 ± 0.01 5 142 1.37 ± 0.04 3 0.01 
Base Width (m)  192 0.17 ± 0.04 10 241 0.11 ± 0.03 8 <0.01 
Temporal  
     
 
Step Time (s) 42 0.63 ± 0.01 3 158 0.51 ± 0.02 3 0.01 
Stride Time (s) 120 1.21 ± 0.06 7 177 1.03 ± 0.04 6 <0.01 
Gait Cycle  
     
 
Swing Phase (% cycle) 54 33.92 ± 3.44 4 146 39.25 ± 0.14 3 <0.01 
Stance Phase (% cycle) 57 65.99 ± 2.78 4 161 60.55 ± 0.22 4 <0.01 
Double Limb Support Phase (% cycle) 126 22.50 ± 6.77 7 170 16.76 ± 7.26 5 <0.01 
Variability  
     
 
Step Length Variability (%CV) 78 8.96 ± 1.94 5 184 3.07 ± 0.71 5 <0.01 
Stride Length Variability (%CV) 80 6.82 ± 1.70 4 142 1.95 ± 0.24 3 <0.01 
Stride Time Variability (%CV) 116 5.54 ± 1.05 6 187 2.24 ± 0.36 5 <0.01 
Speed Variability (%CV) 40 7.68 ± 4.31 3 148 3.46 ± 0.49 3 0.20 
Weighted scores obtained from the random-effect model meta-analysis. Abbreviations: “n” 
number of patients, “k” number of studies, “SD” standard deviation  
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Figure 2.4: Pace parameter meta-analysis results 




Step length, was studied by 7 studies (Caliandro et al., 2015, Gouelle et al., 2013, Ilg et al., 
2007, Matsushima et al., 2015, Rochester et al., 2014, Serrao et al., 2012, Stephenson et al., 
2015) and was significantly reduced in ataxia cohort (n=139) compared to healthy controls 
(n=251) (-0.14m (-0.20, -0.08), p<0.01, I2=0%) Figure 2.5a). Stride length was also 
significantly reduced in ataxia (n=94) compared to healthy controls (n=142) (REM, MD=-
0.20m, 95% CI (-0.36, -0.04), p=0.01, I2=0%) as reported by 5 studies (Gouelle et al., 2013, 
Milne et al., 2014, Schniepp et al., 2014, Stephenson et al., 2015, Wuehr et al., 2013) (Figure 
2.5b). Walking base width was studied by 10 studies (Caliandro et al., 2015, Gouelle et al., 
2013, Ienaga et al., 2006, Ilg et al., 2007, Milne et al., 2014, Rochester et al., 2014, Schmitz-
Hübsch et al., 2016, Schniepp et al., 2014, Seidel and Krebs, 2002, Serrao et al., 2012, Wuehr 
et al., 2013) and people with ataxia (n=192) demonstrated significantly increased walking 
base width compared with healthy controls (n=241) (REM, MD=-0.06m, 95% CI (0.02, 0.10), 
p<0.01, I2=0%) (Figure 2.5c). 
2.3.5.3. Temporal 
As reported by 3 studies (Gouelle et al., 2013, Palliyath et al., 1998, Rochester et al., 2014), 
step time is significantly increased in ataxia (n=42), compared with healthy controls (n=158) 
(REM, MD=0.11s, 95% CI (0.03, 0.20), p=0.01, I2=0%) (Figure 2.6a). Stride time was examined  
by 7 studies (Gouelle et al., 2013, Ilg et al., 2007, Palliyath et al., 1998, Schmitz-Hübsch et al., 
2016, Schniepp et al., 2014, Serrao et al., 2012, Wuehr et al., 2013) and overall, the ataxia 
cohort (n=120) demonstrated significantly increased stride time than healthy controls 




Figure 2.5: Spatial parameter meta-analysis results 
Mean difference in a) step length (cm), b) stride length (cm) and c) base width (cm) during self-




Figure 2.6: Temporal parameter meta-analysis results 
Mean difference in a) step time (s) and b) stride time (s) during self-selected pace walking. 
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2.3.5.4. Gait Cycle 
The swing phase of the gait cycle was explored by 4 studies (Caliandro et al., 2015, Gouelle 
et al., 2013, Milne et al., 2014, Stephenson et al., 2015). People with ataxia (n=54) exhibited 
a significantly reduced swing phase proportion than healthy controls (n=146) (REM, MD=-
5.33%, 95% CI (-9.18, -1.43), p<0.01, I2=97%) (Figure 2.7a). Stance phase accounted for a 
significantly increased portion of the gait cycle in the ataxia cohort (n=57) than in healthy 
controls (n=161) (REM, MD=5.44%, 95% CI (2.12, 8.76), p<0.01, I2=97%) as reported by 4 
studies (Caliandro et al., 2015, Gouelle et al., 2013, Serrao et al., 2012, Stephenson et al., 
2015) (Figure 2.7b). Double limb support phase was studied by 7 studies (Caliandro et al., 
2015, Gouelle et al., 2013, Milne et al., 2014, Schmitz-Hübsch et al., 2016, Schniepp et al., 
2014, Serrao et al., 2012, Stephenson et al., 2015) and the ataxia cohort (n=126) 
demonstrated significantly increased double limb support phase proportion than controls 
(n=170) (REM, MD=5.74%, 95% CI (3.81, 7.68), p<0.01, I2=93%) (Figure 2.7c). 
2.3.5.5. Variability 
As shown in Figure 2.8a, the variability of step length was investigated by 5 studies 
(Ebersbach et al., 1999, Gouelle et al., 2013, Ienaga et al., 2006, Palliyath et al., 1998, Serrao 
et al., 2012). The ataxia cohort (n=78) demonstrated significantly increased step length 
variability compared to controls (n=184) (REM, MD=5.88 %CV, 95% CI (3.42, 8.34), p<0.01, 
I2=97%). Variability of stride length was also significantly increased in people with ataxia 
(n=80) compared to healthy controls (n=142) (REM, MD=4.87 %CV, 95% CI (2.29, 7.45), 
p<0.01, I2=95%) (Gouelle et al., 2013, Palliyath et al., 1998, Schmitz-Hübsch et al., 2016, 
Schniepp et al., 2014) (Figure 2.8b). Variability of stride time was considered by 6 studies 
(Ebersbach et al., 1999, Gouelle et al., 2013, Palliyath et al., 1998, Schmitz-Hübsch et al., 
2016, Schniepp et al., 2014, Serrao et al., 2012), confirming a significant increase in ataxia 
(n=116) compared with healthy controls (n=187) (REM, MD=3.17 %CV, 95% CI (1.97. 4.37), 




Figure 2.7: Gait cycle parameter meta-analysis results 
Mean difference in a) swing phase (%), b) stance phase (%) and c) Double Limb Support (DLS) phase 
(%) during self-selected paced walking.  
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Figure 2.8: Variability parameter meta-analysis results 
Mean difference in a) step length variability (% CV), b) stride length variability (% CV), c) stride time 
variability (% CV) and d) speed variability (% CV) during self-selected paced walking. 
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2.3.5.6. Subgroup Analysis 
Subgroup meta-analysis was completed to explore the effect of disease type and equipment 
implemented. Due to the number of confounding variables within the dataset these results 
are considered with caution. 
Equipment influence 
All but one of the gait metrics (stride length) were analysed for differences incurred by the 
type of equipment implemented, 3D motion capture, pressure-sensitive walkway, inertial 
sensor or other (Appendix 8). Of those investigated, 4 metrics (swing %, stance %, step 
length variability and speed variability) showed significant (p<0.05) subgroup differences 
(Table 2.3). However, for three of these subgroup analyses (swing %, stance %, and speed 
variability), the studies had consistent cohort diagnosis and equipment used making it 
problematic to extract the influence of either on the combined result. 
Mean difference in swing % meanwhile was significantly lower compared with healthy 
controls was observed in Mixed CA via 3D motion capture than FRDA via pressure-sensitive 
walkway (REM, MD =-8.82, 95% CI (-10.36, -7.28) vs MD =-3.62, 95% CI (-6.50, -0.74) 
respectively, p<0.01). Also, the reverse is true with stance % significantly higher than healthy 
controls in Mixed CA measured via 3D motion capture than in FRDA measured via pressure-
sensitive walkway (REM, MD =7.41, 95% CI (6.52, 8.30) vs MD =3.45, 95% CI (-0.04, 6.93) 
respectively, p=0.03). Speed variability was significantly lower compared with healthy 
controls in Mixed CA measured via 3D motion capture than in FRDA patients measured with 
a pressure-sensitive walkway (REM, MD =-8.82, 95% CI (-10.36, -7.28) vs MD =-3.62, 95% CI 
(-6.50, -0.74) respectively, p<0.01). 
For the remaining significantly different result (step length variability), it appears that the 
pressure-sensitive walkway detected a larger step length variability than that measured by 
3D Motion capture (REM, MD =9.10, 95% CI (7.68, 10.52) vs MD =5.01, 95% CI (3.48, 6.54) 
respectively, p<0.01). However, since two of the subgroups contained only 1 study, 
heterogeneity analysis was not completed, and the validity of this result cannot be 
confirmed.   
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Speed Equipment 3D-MC vs other vs PSW 
vs Inertial sensor 
1.07 3 0.79 5 vs 1 vs 7 vs 1  12 
Cadence Equipment Other vs PSW vs 3D-MC 
vs Inertial sensor 
5.48 3 0.14 1 vs 6 vs 2 vs 1 8 
Spatial 
       
Step Length Equipment 3D-MC vs PSW vs Inertial 
sensor 
1.01 2 0.6 3 vs 3 vs 1 7 
Base Width Equipment 3D-MC vs PSW 0.08 1 0.78 4 vs 6 8 
Temporal 
       
Step Time Equipment PSW vs 3D-MC 0.13 1 0.72 2 vs 1 3 
Stride Time Equipment PSW vs 3D-MC 0.36 1 0.55 4 vs 3 6 
Gait Cycle 
       
Swing % Cycle Diagnosis & 
equipment 
Mixed CA & 3DMC vs 
FRDA & PSW 
9.75 1 <0.01 1 vs 3 3 
Stance % Cycle Diagnosis & 
equipment 
Mixed CA & 3DMC vs 
FRDA & PSW 
4.66 1 0.03 2 vs 2 4 
DLS % Cycle Equipment PSW vs 3D-MC 0.61 1 0.43 5 vs 2 5 
Variability 
       
Step Length Variability Equipment Other vs PSW vs 3D-MC 23.68 2 <0.01 1 vs 1 vs 3 5 
Stride Length Variability Equipment PSW vs 3D-MC 0.31 1 0.58 3 vs 1 3 
Stride Time Variability Equipment Other vs PSW vs 3D-MC 2.12 2 0.35 1 vs 2 vs 2 5 
Speed Variability Diagnosis & 
equipment 
FRDA & PSW vs mixed CA 
& 3DMC 
102.68 1 <0.01 1 vs 2 3 
Where Diagnosis and Equipment are combined in analysis, the grouped articles were consistent in 
ataxia diagnosis and technique used meaning that alternative grouping was unnecessary. The 
reduced number of articles given weight in the meta-analysis reflects the exclusion of results where a 
control cohort was not present. Abbreviations: CA = cerebellar ataxia, FRDA = Friedreich's Ataxia, SCA 




Of the 8 studies assessing specific ataxias key subgroups, pure cerebellar and those including 
afferent ataxias were the main diagnoses available for comparison. In a subgroup analysis by 
disease diagnosis, significant differences are seen in swing %, stance %, DLS%, Step length 
variability, stride length variability, stride time variability and speed variability (Appendix 8). 
The influence of disease diagnosis on gait could be assessed separately from the equipment 
used for four metrics (Table 2.4): 
• DLS% - compared with healthy controls, the weighted mean difference is significantly 
different in FRDA and Mixed CA vs SCA (REM, MD =6.35, 95% CI (0.27, 12.42) vs MD 
=6.85, 95% CI (4.55, 9.15) vs 2.36 95% CI (0.40, 4.32) respectively, p<0.01). 
• Step length variability – when compared with healthy controls FRDA significantly 
higher MD than Mixed CA (REM, MD =9.10, 95% CI (7.68, 10.52) vs MD =4.92, 95% CI 
(3.93, 5.92) respectively, p<0.01) 
• Stride length variability – when compared with healthy controls, FRDA exhibit a 
significantly larger MD than Mixed CA and SCA (REM, MD =7.00, 95% CI (5.71, 8.29) 
vs MD =4.10, 95% CI (2.73, 5.47) vs MD =3.37, 95% CI (2.17, 4.57) respectively, 
p<0.01) 
• Stride time variability – when compared with healthy controls FRDA significantly 
higher MD than Mixed CA and SCA (REM, MD =5.00, 95% CI (3.82, 6.18) vs MD =2.60, 
95% CI (1.45, 3.76) vs MD =3.05, 95% CI (1.88, 4.21) respectively, p<0.01) 
However, within each of these, a small number of studies within subgroups were present 
which leads to doubt on the validity of this analysis.  
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Speed Diagnosis Mixed CA vs FRDA vs SCA 0.51 2 0.77 8 vs 3 vs 3 12 
Cadence Diagnosis Mixed CA vs FRDA vs SCA 5.32 2 0.07 5 vs 3 vs 2 8 
Spatial 
       
Step Length Diagnosis Mixed CA vs FRDA vs SCA6 0.41 2 0.81 4 vs 2 vs 1 7 
Stride Length Diagnosis FRDA vs mixed CA 0.06 1 0.8 3 vs 2 3 
Base Width Diagnosis Mixed CA vs FRDA vs SCA 0.1 2 0.95 5 vs 2 vs 3 8 
Temporal 
       
Step Time Diagnosis FRDA vs mixed CA 0.04 1 0.85 1 vs 2 3 
Stride Time Diagnosis FRDA vs mixed CA vs SCA 1.43 2 0.49 1 vs 4 vs 2 6 
Gait Cycle 
       
Swing % Cycle Diagnosis & 
equipment 
Mixed CA & 3DMC vs FRDA 
& PSW 
9.75 1 <0.01 1 vs 3 3 
Stance % Cycle Diagnosis & 
equipment 
Mixed CA & 3DMC vs FRDA 
& PSW 
4.66 1 0.03 2 vs 2 4 
DLS % Cycle Diagnosis Mixed CA vs FRDA vs SCA 8.92 2 0.01 3 vs 3 vs 1 5 
Variability 
       
Step Length Variability Diagnosis Mixed CA vs FRDA 22.33 1 <0.01 4 vs 1 5 
Stride Length Variability Diagnosis FRDA vs mixed CA vs SCA 17.62 2 <0.01 1 vs 2 vs 1 3 
Stride Time Variability Diagnosis Mixed CA vs FRDA vs SCA 9.13 2 0.01 4 vs 1 vs 1 5 
Speed Variability Diagnosis & 
equipment 
FRDA & PSW vs mixed CA 
& 3DMC 
102.68 1 <0.01 1 vs 2 3 
Where Diagnosis and Equipment are combined in analysis, the grouped articles were consistent in 
ataxia diagnosis and technique used meaning that alternative grouping was unnecessary. The 
reduced number of articles given weight in the meta-analysis reflects the exclusion of results where a 
control cohort was not present. Abbreviations: CA = cerebellar ataxia, FRDA = Friedreich's Ataxia, SCA 
= Spinocerebellar Ataxia, 3D-MC = 3-Dimensional Motion Capture, PWS = Pressure Sensitive 
Walkway.  
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2.3.6. POWER CALCULATION AND SAMPLE SIZE ESTIMATE 
On the basis of these results, the sample size calculation has been completed (Table 2.5). 
This indicates that for the majority of spatiotemporal gait parameters investigated here, 13 
or less participants per group is required to achieve statistical power in a two-sided test. This 
estimate excludes DLS time and speed variability which require 43 and 42 participants 
respectively. However, central limit theorem indicates that studies should include at least 30 
participants therefore, the design of studies investigating these gait variables in CA 
compared with HC to avoid underestimating the required number of participants, a larger 
cohort size should be considered (Kwak & Kim, 2017).  
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Table 2.5: Sample size calculation for future studies 
 Mean Diff. Z Effect Size Sample size required 
Pace     
Speed -0.36 m/s -9.6 -0.5 6* 
Cadence -13.3 steps/min -3.9 -0.3 14* 
Spatial     
Step Length -14 cm -4.3 -0.3 14* 
Stride Length -20 cm -2.5 -0.2 5* 
Base Width 6 cm 2.7 0.2 10* 
Temporal     
Step Time 110 ms 2.5 0.3 2* 
Stride Time 180 ms 3.8 0.3 3* 
Gait Cycle     
Swing % Cycle -5.3 % -2.7 -0.3 14* 
Stance % Cycle 5.4 % 3.2 0.3 9* 
DLS % Cycle 5.7 % 5.8 0.5 47 
Variability     
Step Length Variability 5.9 % 4.7 0.4 4* 
Stride Length Variability 4.9 % 3.7 0.4 3* 
Stride Time Variability 3.2 % 5.2 0.4 3* 
Speed Variability 4.2 % 1.3 0.1 46 
Results of sample size calculation. Mean diff. (CA-HC) and Z value taken from random-effects model 
meta-analysis. Where sample size required indicated as less than 30 (*), a larger cohort than 
reported should be considered more appropriate.  
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2.4. DISCUSSION 
This systematic review objectively evaluated the existing evidence base for the 
spatiotemporal gait characteristics of adult CA. The 21 included studies reflect quantitative 
gait assessments for 408 CA patients and 403 healthy controls. This forms a larger cohort 
than typically available in an individual descriptive study. Each individual study confirmed 
that cohort demographics (age, sex, height, leg length and Body Mass Index (BMI)) were 
equivalent and no significant differences between cases and control characteristics are 
present in the meta-analysis. 
2.4.1. HEADLINE RESULTS 
Following our searches and subsequent scrutiny of the literature from the last 20 years, 
twenty-six studies were identified that considered spatiotemporal gait characteristics in 
individuals with CA, as measured by instrumented analysis techniques during preferred 
paced steady-state walking.  
There is strong evidence that during preferred paced walking, CA patients display the 
following gait differences against healthy controls: 
• reduced walking speed and cadence 
• reduced step length, stride length, and swing phase 
• increased base width, stride time, step time, stance phase and double limb support 
phase 
• increased variability of step length, stride length, and stride time. 
These adjustments were significantly different (p<0.01) and consistently associated with a z-
score greater than the 95% critical z-score (1.96). The gait parameters that were greatest 
affected in CA (in terms of z-score) were speed, double limb support phase duration (%cycle) 
and stride time variability followed by step length variability and step length. Although this 
suggests that these may be most useful in clinical practice, further research is necessary to 
consider a number of contributing factors.  
2.4.2. HETEROGENEITY OF RESULTS 
Significant amounts of between-study heterogeneity were observed in some meta-analyses 
of gait metrics while for other gait metrics analysed, large confidence intervals were found 
within individual studies. Unfortunately, due to limitations of the dataset, it is not possible to 
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formally explore the influence of distinct confounding influences such as ataxia diagnosis 
type separately from equipment used, the interactions between upper body and 
spatiotemporal gait parameters, or the effect of changing velocity or disease progression on 
gait characteristics. 
One important consideration is the influence of technical restrictions of equipment on study 
design, walking protocol and parameter definitions. This impacts the length of the walkway, 
whether participants complete the walking task barefoot and the ability of participants to 
reach steady-state walking pace which together can affect walking characteristics (Franklin 
et al., 2015, Sustakoski et al., 2015). Also, it should be noted that, despite studies validating 
equipment and techniques, differences in analytical approach may affect the results 
attained.  
The reduced walking speed reported by all studies in CA had large overlapping confidence 
intervals. The decreased cadence in patients exhibited smaller confidence intervals, 
heterogeneity between studies was significant. The studies reporting an increased step time 
and stride time in CA showed large overlapping confidence intervals in meta-analysis with 
low overall heterogeneity. Also, step length and stride length were both reduced in CA but 
large overlapping confidence intervals in meta-analysis leads to low heterogeneity. The 
increased step width in CA was associated with large overlapping confidence intervals with 
low heterogeneity in meta-analysis. Furthermore, the changes to gait cycle proportions 
(reduced Swing%, and increased stance%, and DLS% phase) were associated with significant 
heterogeneity despite small confidence intervals within each study. And, the increased 
variability of step length, stride length, stride time and speed were all accompanied by a 
large amount of heterogeneity overall. 
The heterogeneity revealed in these analyses implies that results may have limited 
compatibility despite the systematic review design intending to reduce this. For instance, the 
parameters taken forward to meta-analysis were those most commonly reported in these 
articles. This was intended to provide the best opportunity for evaluation in the largest 
number of participants. Only studies with adult ataxia were included to reduce the impact of 
age on the gait. Moreover, the pooled estimate for ataxic and healthy populations was 
calculated only where results were reported in more than 3 studies and only data collected 
during preferred speed straight-line self-paced walking and at baseline assessment were 
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considered for meta-analysis. This was intended to restrict protocol design and avoid the 
effect of an intervention or changes to speed. 
Subgroup analysis, therefore, offers a chance to explore these changes further and whether 
ataxia diagnosis and equipment used were able to account for this heterogeneity. These gait 
metrics with large between-study heterogeneity, had apparent subgroup differences 
especially related to the specific disease diagnosis although equipment type may also 
influence findings. 
For instance, the equipment used had significant implications in four gait metrics with 
pressure-sensitive walkways perceiving a higher mean difference swing %, lower stance % 
mean difference and greater mean difference variability of speed and step length than 3D 
motion capture. Also, despite walkway length being equipment dependent, in correlation 
analysis, walkway length did not correlate with any of the gait metrics. There was insufficient 
data available to perform further formal analysis on aspects such as the number of steps/ 
passes so there may remain differences in gait analysis and protocols contributing to 
heterogeneity.  
In reality, these comparisons are more likely to be confounded by disease diagnosis and 
cohort differences as there were a small number of studies within each meta-analysis. From 
a clinical standpoint, differences between ataxia subtypes are an important factor and the 
values for healthy controls were similar across the systems. In subgroup analysis to examine 
the influence of disease diagnosis on the gait measures directly, as well as the above 
associations, 4 gait metrics showed a significant subgroup difference. The weighted mean 
difference was significantly lower for SCA than FRDA and mixed CA in DLS%, significantly 
higher for step length variability, stride length variability and stride time variability in FRDA 
than mixed CA and SCA. Since values for healthy controls were consistent across the meta-
analyses for each metric and most studies were related with large confidence intervals, 
there may be a diagnosis-specific gait pattern. Better classification of mixed CA cohorts may 
have enabled a reduced heterogeneity of these results.  
Of the 8 studies assessing specific ataxias key subgroups, pure cerebellar and those including 
afferent ataxias were the main diagnoses available for comparison. FRDA for instance, has a 
younger age at onset than other forms of ataxia included in studies with a mixed CA cohort 
(Harding, 1981). However, in correlation analysis, neither age nor disease duration 
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significantly correlated to any of the changes in gait metrics in the CA cohort. Therefore, it is 
unclear whether results related to disease diagnosis or cohort specific patient demographics.  
In both the Ataxia and Control cohorts, there were significant correlations between walking 
speed and step length, and in the Ataxia cohort walking speed also correlated with stride 
length. This demonstrates the importance of walking speed on the spatial features of gait. 
Unfortunately, there was not enough consistent data available in the literature to produce a 
formal analysis of gait changes in different speed walking using data. However for those that 
did report different speed walking gait patterns, a these findings is outlined in section 2.4.3. 
2.4.3. IMPLICATIONS FOR PRACTICE  
Our findings indicate a clear pattern of walking gait pattern modifications in ataxia and how 
it compares against healthy controls. The changes observed may reflect a compensation for 
incoordination and trunk instability (Bunn et al., 2013), intending to reduce the falls risk 
common to these patients. Reduced velocity of self-selected walking and increased sagittal 
gait variability (Schniepp et al., 2014), as well as widened gait (Chini et al., 2016), correlate 
with the increased risk of falls detected by clinical measures. It is thought that increased gait 
variability directly reflects imbalance during walking in CA and is related to the presence of 
cerebellar damage (Serrao et al., 2017b, Serrao et al., 2012). Also an increased step width, 
and decreased step length occur, to compensate for reduced balance performance by 
enlarging base of support, reducing forward progression (McAndrew Young and Dingwell, 
2012, Serrao et al., 2012). This provides better control of the changing centre of gravity 
during walking. However, since the reduced preferred walking speed will inherently lead to 
gait alterations due to the interplay of gait pattern characteristics, these changes may not be 
specific to CA pathophysiology. 
Although upper body metrics were reported in a minority of studies, there is evidence to 
indicate that exaggerations in trunk flexion-extension and an increased trunk rotation are 
present in CA to increase stability (Conte et al., 2014). In this way, gait velocity and 
spatiotemporal parameters are preserved and maintain an energy-efficient gait. In CA, 
patients display increased trunk instability in all 3 directions but the anterior-posterior 
direction particularly (Chini et al., 2016, Matsushima et al., 2015, van de Warrenburg et al., 
2005b). While the overall instability correlates negatively with ICARS score, and positively 
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with disease stage, this anterior-posterior instability may contribute to fall direction 
(Fonteyn et al., 2010). 
Of course, by design, these results are limited to assessment of self-selected paced walking 
in ataxia compared with a healthy control cohort and does not account for different paced 
walking, use of walking aids, cued walking tasks, longitudinal changes or differences with 
non-ataxic disease cohorts. Therefore, they reflect functional gait capacity in cerebellar 
ataxia and may not be applicable to real-world walking gait performance which may present 
a greater challenge to people with ataxia.  
A number of articles report that in cerebellar ataxia, walking at preferred speed minimises 
the gait abnormalities and recommend analysis of gait at a wide range of speeds (Wuehr et 
al., 2013). However, since subjective rating scales incorporating preferred self-selected 
paced walking remain the main method of clinical gait assessment, our findings clarify ataxic 
gait characteristics as they would appear in a typical assessment. As the preferred self-
selected speed gait pattern captured in clinical/ lab setting reflects what patients choose to 
do this has relevance to comfortable real-life walking. However, since real-world walking 
requires adaptation to speed and gait pattern, quantifying the gait pattern of different 
walking speeds in clinical/lab settings uses the more challenging gait task to establish an 
individual’s functional capacity. In ataxia patients, with increasing speed walking, gait is 
characterised by increased cadence, step and stride length, and swing% phase as well as 
decreases in the stance% and DLS% phases (Milne et al., 2014). A nonlinear correlation is 
reported in stride time variability and stride length variability, with the highest CV in slow-
paced walking, and preferred paced walking associated with the minimal CV magnitude 
(Schniepp et al., 2014, Wuehr et al., 2013). Many of these speed-dependent gait changes are 
also observed in healthy adults (Hebenstreit et al., 2015, Thomas et al., 2017), and are more 
pronounced with age (Menz et al., 2004). However, in controls, gait variability is less closely 
associated with speed changes to allow flexibility and adaptability of walking strategy 
(Beauchet et al., 2017). In Multiple Sclerosis (Comber et al., 2017), fast-paced walking is 
reported to be more sensitive to gait changes, therefore, this complexity makes it unclear 
whether fast or slow walking is more clinically sensitive in CA. It appears that different 
compensation strategies are at play in fast and slow-paced walking. For instance, while more 
strongly significant differences have been reported in swing, stance and DLS phase between 
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patients and controls in fast walking, than in preferred paced walking (Stephenson et al., 
2015), the increased variability of slow-paced walking is correlated with falls risk (Schniepp 
et al., 2014). Further, spatiotemporal parameters of gait measured in slow-paced conditions 
correlate with a fewer number of clinical markers than in fast and preferred paced walking 
(Milne et al., 2014). 
There is also evidence to suggest that gait has the potential to distinguish between 
neurological gait disorders, differentiate forms of CA and be sensitive to disease progression 
although these questions were not formally analysed in this study. For instance, Parkinson’s 
Disease (PD) and Huntington’s disease (HD), two diseases of the basal ganglia, are also 
characterised by decreased stride/step length with a reduced walking velocity (Scafetta et 
al., 2009) but have a number of differences from CA and each other. In PD, cadence remains 
normal, and a linear relationship between stride length and velocity is maintained, 
comparable to healthy controls (Ebersbach et al., 1999, Ilg et al., 2007, Stolze et al., 2002). 
Gait variability is increased compared with healthy controls but remains lower than in CA 
(Moon et al., 2016) although changes to step width are unclear, (either decreased or 
unaffected). However, in manifest HD, increased step width and even more increased gait 
variability are apparent while stride time is not significantly different from PD (Dalton et al., 
2013, Hausdorff et al., 1997, Moon et al., 2016, Stolze et al., 2002). Furthermore, although a 
significant increase in width of walking base was found in the meta-analysis reported here, it 
has previously been suggested that stride width may not be a disease-specific gait 
characteristic but a compensation for the instability that occurs in many gait disorders 
(Seidel and Krebs, 2002). While it is likely that through objective gait analysis, movement 
disorders of the basal ganglia can be distinguished from those of cerebellar origin, it is not 
possible to appraise specific changes across different pathologies from the present dataset 
(Scafetta et al., 2009). 
Clarification of the objective differences between forms of ataxia has the potential to 
improve understanding of the underlying disease. While a number of studies explored the 
differences between specific forms of CA there is insufficient evidence to categorically define 
the interaction between disease type and gait changes. However, there appears to be 
different gait features present between ataxia subtypes which may relate to the underlying 
disease differences, such as patterns of cerebellar degeneration, the presence of pyramidal 
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signs and disease duration. This may contribute by affecting components of gait, or the 
patient’s ability to apply compensations. Further work is required to clarify these 
interactions and their influence on falls status and link to clinical markers (Fonteyn et al., 
2010, Milne et al., 2014). 
The studies included here that explored longitudinal gait changes were not sufficiently able 
to provide a conclusive description of gait disturbances with disease progression. However, 
follow-up articles to two studies included here have recently been published (Serrao et al., 
2017a, Zesiewicz et al., 2017). In Friedreich Ataxia (FRDA) and mixed CAs, at 2 year and 4-
year follow-up assessments respectively, with time a reduced gait speed, an increase in gait 
variability, cadence and stride length, and step length as well as reduced swing and 
increased DLS phases were apparent. In comparison with baseline characteristics, these 
changes reflect an increase in gait instability with disease progression. These studies also 
observed that gait variability was able to predict loss of independent gait, and disease 
severity (measured by Friedreich's Ataxia Rating Scale (FARS) or SARA) was significantly 
different at follow-up from baseline. FARS scores changes correlated well with objective gait 
characteristics, while SARA scores did not. Due to the complex nature of these findings, 
further assessment of the objective gait characteristics within a longitudinal study is 
required to clarify the impact of disease progression on different CA subtypes.  
These corroborate with the earliest descriptions of ataxic gait and reflect overall walking 
disability (Stolze et al., 2002). Step and stride length were also shorter in ataxic individuals 
than healthy controls. Serrao et al. (2012) for example, studied the gait pattern of individuals 
with SCA 1 or 2 and Friedreich’s Ataxia (FRDA) as well as healthy controls. All spatiotemporal 
characteristics evaluated were significantly different in ataxia patients versus healthy 
individuals. In addition, a significantly shortened step length was observed in those with 
FRDA than SCA1/2.  
Increased duration of DLS phase, stance time, step time, stride time and swing phases were 
observed in patients when compared with controls. Mari et al. (2014) explored the muscle 
activations underlying spatiotemporal parameters (STPs) in SCA1/2 or sporadic adult-onset 
ataxia of unknown aetiology (SAOA). They hypothesised that joint rigidity in ataxia patients 
provides compensation for balance deficits, which is reflected in the cycle phase 
distributions. Increased co-contraction of the antagonist muscles at both the knee and ankle 
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joints control the forward motion in the same leg and reduce the influence of the motion of 
the opposite leg.  
A wider base of support is commonly present in individuals with CA than in healthy controls 
(Palliyath et al., 1998). This was reflected in the pooled estimates for the base of support and 
step width from the studies included. Unfortunately, due to technical limitations, studies are 
often unable to measure step width despite its importance in this population. Dynamic 
instability is thought to be reflected in this widened gait and to correlate with a history of 
falls (Chini et al., 2016).  
Meanwhile, patients also exhibited increased variability in step length, step width, stride 
length and stride time. Conte et al. (2014) for example, measured trunk oscillations and their 
relationship with spatiotemporal parameters using an optoelectronic infrared camera 
system. Movements in the frontal and sagittal planes were found to correlate with the 
variability of swing phase. This indicates that exaggerations in trunk flexion-extension may 
be associated with controlling foot placements and preserving the spatiotemporal 
parameters of gait to increase stability.  
Furthermore, the 2 studies exploring the effect of rehabilitation and physical training as an 
intervention showed significant improvements in motor performance and reduced ataxia 
symptoms. Therefore, this shows promise for objective quantification of training and 
therapy effects in CA. 
The sample size estimate calculated from the results of this meta-analysis indicate that 
between n=2 and n=47 individuals (n = 13 ± 15 mean ± SD) is a necessary recruitment target 
to establish differences in gait characteristics between CA and HC in case controls studies 
reporting these variables. Although for many variables this is lower than the participant 
numbers recruited to the studies, for DLS phase and speed variability the estimate are 
greater than recruited. Since there were statistically significant differences between cohorts, 
and heterogeneity within cohorts, this estimate may be inflated as the clinically relevant 
difference may be larger than these results indicate. These estimates should be considered 
in the planning of future studies and effect size should always be established when reporting 
findings from studies of this nature. 
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2.4.4. STRENGTHS AND LIMITATIONS 
In assessment of the methodological quality, all included studies were of a sufficiently high 
quality to be considered suitable, although some limitations were apparent, and a few 
concerns remain. Findings should be interpreted in the context of its strengths and 
weaknesses. 
Many studies considered confounding variables, and all completed concurrent cohort 
assessments in an appropriate trial protocol. For instance, walkway lengths were relatively 
consistent between studies and mostly considered long enough to analyse a sufficient 
number of steps collected from steady-state gait. Gait metrics were mostly well-defined and 
findings, research questions and inclusion/ exclusion criteria were clearly reported. Study 
populations were usually well-defined, and cohorts were representative and evenly matched 
for age, BMI and sex to restrict their influence on gait parameters. Patients with non-
clinically “pure” ataxia were commonly excluded to avoid the involvement of other 
neurological systems. 
There are several limitations of the included studies that should be taken into account. 
Primarily, heterogeneity analysis revealed disparity between studies in meta-analyses for 
cadence, swing (%cycle), stance (%cycle), double limb support phase (%cycle), step length 
variability, stride length variability, stride time variability and speed variability, but large 
within-study variability in the remaining variables (speed, base width, stride length, step 
length, step time, stride time). 
The comparative rarity of CA in the general population can lead to recruitment difficulties in 
observational clinical studies and in fact many of these studies recruited less than fifteen 
participants per cohort (19.43 (±11.33) patients and 25.19 (±29.03) healthy controls in each 
study). It is essential that studies report an effect size justification and attempt to reach 
statistical power where possible in order to reliably determine precise differences between 
cohorts. 
Meanwhile, some intervention studies did not assess healthy individuals as control 
participants, as might be expected. In addition, a number of the studies reported results for 
specific parameters of interest and did not consider all possible parameters of gait despite 
possible associations. 
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Many of the patient cohorts were either not fully characterised in terms of diagnosis or 
several ataxia subtypes were grouped despite potential differences in the ataxia syndrome 
(Burk et al., 2003). Disease severity was inconsistently characterised with a variety of rating 
scales employed. Most of the patients studied completed the walking task unaided, 
reflecting the relatively low disease severity in the cohort. This is a common problem in gait 
analysis studies as more severely affected patients are unable to take part without 
additional support. 
In addition, some articles did not report the full results of gait parameters analysed, opting 
to present a combined measure, or secondary analysis, for example, the results of 
correlation analyses or the variability of gait parameters. However, several authors made 
additional data available for this systematic review. Gait metrics were mostly well-defined 
and findings, research questions and inclusion/ exclusion criteria were clearly reported.  
Due to the heterogeneous nature of clinical studies, these were not deemed to be fatal flaws 
but informed restrictions on data included in the meta-analysis. To overcome protocol 
differences and the influence of changing gait strategies with speed, only spatiotemporal 
gait characteristics measured using instrumented gait analysis techniques during preferred-
paced straight-line walking in a laboratory setting at baseline assessment were considered 
and standardised data excluded from the meta-analysis. 
Meanwhile, it should be considered that in walking gait, many characteristics are inherently 
interdependent. Therefore, while considered separately here, step/ stride periods, and 
swing/ stance/DLS phases inevitably contribute to each other (Hebenstreit et al., 2015, Lord 
et al., 2013). Also, although results were excluded from meta-analysis where for contributing 
factors such as gait velocity and biomechanical features were controlled through 
standardisation, it is important to bear in mind that these do influence gait characteristics in 
the individual. 
2.5. CONCLUSION 
This systematic review provides a consensus description of clarifies the spatiotemporal gait 
characteristics associated with ataxic gait disturbance in a large cohort of people with CA 
compared with a healthy control cohort. Since CA is a rare disease, individual observational 
studies typically have difficulty recruiting a large cohort so this provides a more thorough 
estimate of the features that distinguish CA from HC. 
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Taken together it appears that in CA, an gait variability increases and to compensate for this, 
walkers increase the width of the base of support, take smaller steps and increase the 
duration of foot contact to floor. Reducing swing phase portion of the gait cycle, they 
progress forward at a slower pace. The significant differences in spatiotemporal parameters 
uncovered by our meta-analysis reflect the considerable gait disability seen in these patients 
compared with healthy controls. People with CA exhibit a reduced balance performance, and 
increased risk of falls therefore these gait changes may reflect protective compensation 
mechanisms to improve trunk stability. These measures may also have potential as markers 
of disease progression due to their sensitivity to disease severity in CA.  
Advances in technology, have enabled gait analysis techniques to be more widely employed 
and genetic testing is also more readily available (Nemeth et al., 2013, Wren et al., 2011). To 
accompany this, an increase in the quality of research and reporting in the future is needed 
to aid clinical decision making. Key criticisms such as studies lacking control cohorts, small 
participant numbers and specific genetic diagnoses should be addressed in future research. 
High-quality research and reporting are needed to explore specific genetic diagnoses and 
identify biomarkers for disease progression in order to develop well-evidenced clinical 
guidelines and interventions for CA. 
It is not possible from this data to formally analyse the gait associated with different forms 
of CA, risk of falls or disease progression or to identify which changes to the gait pattern 
occur as a result of specific gait stabilization mechanisms. However, a consensus description 
based on an objective evaluation of the existing evidence base for the gait characteristics of 
adult CA has been provided as well as a discussion of the inconsistencies between published 
studies which can guide further research. 
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Chapter 3. VALIDATION OF THE MICROGATE OPTOGAIT PHOTOELECTRIC 
SYSTEM & ADPM OPAL TRIAXIAL INERTIAL SENSORS IN PREPARATION FOR 
CLINIC-BASED GAIT ANALYSIS 
3.1. INTRODUCTION 
Clinical assessment of gait relies on subjective measures such as disease-specific clinical 
rating scales, or costly laboratory-based motion capture systems (Baker et al., 2016). 
However, affordable portable systems have recently been developed. These enable a cost-
effective method of assessing the gait pattern during overground walking. This gives an 
opportunity for gait analysis to objectively quantify gait in a clinical setting. 
3.1.1. OPTOGAIT INSTRUMENTED PHOTOELECTRIC WALKWAY 
The OptoGait instrumented photoelectric walkway (Microgate S.r.l., Italy) is one such 
system. The OptoGait consists of a series of bars with embedded Light Emitting Diodes 
(LEDs) which transmit between the bars. As a participant walks through the assessment area, 
the spatial location and timing of each footfall is detected by monitoring the activation of an 
LED series. Different LED filters are applied to dictate the number of LED required to be 
activated to indicate a gait event. Through its software’s internal algorithms, a variety of 
spatiotemporal parameters such as the length, durations and proportions of participants’ 
gait cycle are computed in real-time. The validity of the system to derive spatiotemporal gait 
parameters has been explored in previous studies.  
Lienhard et al. (2013), evaluated walking characteristics in 15 patients (9 men, 6 women) 
who had undergone unilateral total knee arthroplasty 2–14 months previously but were able 
to walk without walking aids, and 15 healthy age-matched controls, comparing the OptoGait 
to the GAITrite mat (CIR System Inc., Clifton, NJ, USA). This study, reported high discriminant 
validity for the OptoGait, detecting the same cohort level differences as the criterion 
instrument. Concurrent validity was also high with Intraclass Coefficients (0.933-0.999, 
p<0.001), and low %limits of agreement (%LoA) and standard error of the estimate (SEE). 
However, a heteroscedastic pattern was reported for stance time, swing time, cadence and 
walking speed, and the OptoGait consistently measured longer stride time, stance time, 
shorter swing time and reduced cadence, walking speed and step length. 
More recently, Gomez Bernal et al. (2016) tested intrasession and intersession reliability of 
the OptoGait in a larger cohort of 126 healthy participants. Across all gait parameters 
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captured by the OptoGait, only acceleration, progressive step time (total time spent in each 
step) and progressive distance (total distance walked/run by a patient) showed less than 
good to excellent intra-session agreement (ICC<0.6). Intrasession variability was greater than 
10% for acceleration, progressive step time, distance, heel contact phase, foot flat phase and 
take-off phase. Intersession reliability was good with no significant differences observed for 
the spatiotemporal gait parameters between sessions 2 weeks apart. Excellent session 
reliability (ICC >0.7) was observed for all gait parameters except acceleration which 
displayed low session agreement (ICC<0.2) and high variability (140.24%CV). All other 
variables demonstrated good intersession variability (<10%CV) except the progressive 
distance, heel contact phase and foot flat phase (11.75%, 38.63% and 13.31% respectively). 
For both sessions, low intra-session SEM values were also reported in this study for all 
variables except progressive distance (session 1: 0.0072-2.7288%; session 2: 0.0071-
3.4961%). This pattern was also apparent for intersession standard error of the mean (SEM) 
values (0.0044-1.8281% excluding progressive distance). 
These results indicate that a systematic difference is often present between instruments. 
Therefore, further validation is required prior to clinical implementation to explore the 
limitations of the OptoGait system and the source of the apparent inaccuracies. These 
articles went on to suggest that some systematic difference was potentially due to the 
height of the LEDs from the ground. Authors reasoned that the low threshold for gait event 
detection led to anticipation of heel-strike and delay in detection of toe-off. This results in 
the underestimation of swing time and overestimation of stance time compared with the 
criterion instrument. 
To compensate for the height of the LEDs in an effort to reduce this effect, the 
manufacturers recommend the OptoGait system be configured so that a triggering threshold 
of 3 or more LEDs be required to detect a footfall. Therefore, only when 4 consecutive LEDs 
are interrupted/uninterrupted is a initial contact/final contact gait event perceived, 
respectively. Recently, a study has investigated the validity of using this LED threshold to 
filter data (Healy et al., 2019). The authors concluded that in a cohort of 18 healthy 
participants that a threshold of 3 LEDs (vs 0, 1 or 2 LEDs) was an acceptable adjustment to 
ensure accurate detection of gait events compared with the Vicon Motion Capture system 
and force plates. For the majority of variables, all four settings exhibited high concurrent 
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validity with the motion capture system (ICCs ranging 0.690-0.999, p<0.001). Significant 
differences between systems were observed for stance phase, swing phase, and gait speed 
in the 0 LED and 1 LED setting, with the OptoGait differing by a maximum of 0.04s greater 
and lower for stance and swing phase, respectively. Gait speed was a maximum of 0.007m/s 
slower compared to motion capture. For the 2 LED and 3 LED settings, ICCs ranged 0.831-
0.999 and 0.717-1.000 respectively (within good to excellent ranges) while %LOA were 
within ±2% for most gait parameters. Even with the adjustment, %LOA for stance and swing 
phase were slightly greater at ±5%.  
These previous studies have also criticised the one-dimensional measurement possible with 
the default configuration. However, the system can be configured in a two-dimensional 
configuration with a “boosted” transmission bar available to enable an extended walkway 
capable of measuring step width and tracking mediolateral step trajectory. To date, only a 
single study has reported results using this feature of the OptoGait system but did so 
without thorough validation (Gorecka et al., 2018). 
When configured in the two-dimensional formation, the OptoGait uses the bar 
perpendicular to the walkway to determine the centre point of each footfall. The shortest 
mediolateral distance between these points is defined as the step width. There are 
difficulties associated with validating the measurement of step width since different 
protocols employ different definitions of the measure is not established. To the best of our 
knowledge, this measure has not been validated thoroughly in previous studies. 
3.1.2. TRIAXIAL INERTIAL MEASUREMENT UNITS (IMUS) 
Triaxial inertial measurement units (IMUs) provide an alternative method of objectively 
measuring an individual’s gait pattern. These wireless, wearable sensors, provide a high 
frequency, synchronised measurement of motion using accelerometers, gyroscopes and 
magnetometers. Dependent on IMU placement, spatiotemporal gait parameters can be 
assessed (Esser et al., 2011), as well as postural changes by monitoring upper body motion. 
This offers an opportunity to monitor gait within more flexible gait tasks including clinic-
based and real-world walking rather than being restricted to a lab-based environment. 
Various algorithms have been developed to detect gait events from inertial data captured by 
sensors placed at the ankles or feet without floor-based equipment. A recent article 
explored 17 gait segmentation algorithms from the literature for the analysis of 35 healthy 
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participants straight-line self-selected speed walking using triaxial IMU, motion capture and 
force platforms (Pacini Panebianco et al., 2018). The authors concluded that shank- and foot-
based algorithms performed better for gait event detection than trunk-based algorithms. A 
systematic bias was reported (higher for trunk than foot) which resulted in a delay of initial 
contact (IC) events and anticipation of toe-off (TO) events and a further underestimation of 
stance time. Compared with acceleration-based algorithms, angular velocity-based 
algorithms were deemed to perform less accurately at detecting toe-off and computing 
stance time but were more repeatable for IC and TO gait event detection and stance time. 
However, most algorithms performed comparably for quantification of step time although 
the differences in stance time and gait event detection (particularly final contact) indicate 
the importance of IMU positioning and computational approach.  
3.1.3. AIMS AND OBJECTIVES 
Taken together, the OptoGait photoelectric bars and ADPM Opal sensors  triaxial inertial 
sensors potentially provides a portable gait system that is capable of measuring both the 
spatiotemporal and upper body motion characteristics during over-ground walking within a 
clinic environment.  
Prior to use of the OptoGait/ADPM Opal sensors in a clinical setting, a group of healthy 
control participants from the University of Sheffield were recruited to take part in a 
validation study. The Vicon 3D motion capture system will be used as the reference 
device/gold standard.  
This experiment will enable the optimisation of our data analysis and confirm the accuracy 
of the three system’s and algorithm’s footfall detection in a controlled laboratory setting. 
The impact of the algorithm on gait parameter calculations were examined.  
The influence of gait speed on the accuracy of the gait analysis systems were investigated to 
aid interpretation of findings in future pathological cohorts.  
3.2. METHODS 
3.2.1. STUDY INFORMATION 
This study is incorporated by the generic research project “Innovative techniques for human 
movement analysis” for the purposes of validating tools and analysis using healthy controls. 
The study was conducted, according to the Declaration of Helsinki, and received ethical 
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approval by the University Ethics Committee (reference number 015433, approved 
11/07/2017). All testing took place at the Gait Analysis Laboratory, Department of 
Mechanical Engineering, Sheffield. Participants were given at least 24 hours to read through 
the information sheet and ask questions before informed consent was obtained from all 
participants. 
3.2.2. PARTICIPANTS 
In accordance with the approved protocol at the time of ethics application, healthy able-
bodied adults with no known morbidities were recruited from with the staff and students of 
the University of Sheffield by word of mouth or by email.  
3.2.3. PROTOCOL  
Participants were advised to dress comfortably and wear flat-soled everyday shoes during 
testing. This reduced any impact of participants’ attire on walking gait and enables the 
equipment to detect footfalls without difficulty while ensuring results would be relevant to 
our proposed procedure for the clinical gait analysis study (Chapter 4). Height, mass and leg 
length were also measured for purposes of data standardisation. Following the completion 
of the proforma, reflective markers adhered to participant’s lower limbs and three ADPM 
Opal inertial sensors were also attached at the ankles and lower back was attached to the 
participant as described in Section 3.2.4. 
Then, each participant was asked to complete 10 short preferred paced gait tasks along a 
walkway of approximately 8m in length within the volume of the Vicon Motion Capture 
system and the assessment area of the OptoGait 5m system with the 1m “Boosted” 
transmission bar add-on. Data collection sessions lasted 45mins-1hour per participant 
excluding configuration of the systems which was completed before their arrival.  
3.2.4. EQUIPMENT 
The Vicon 3D motion capture system was the primary tool implemented to validate the 
OptoGait/ ADPM Opal sensors system. All equipment was set up following the 
manufacturer’s guidance as detailed in Figure 3.1. The software was run concurrently upon 
the same desktop computer to assist synchronisation. 
The Vicon 3D Motion Capture Camera system (Vicon Motion Systems Ltd), incorporates 10 
MX T-series infrared cameras (MXT160, firmware 502) sampling at 100Hz with focal length 
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approx. 17.4mm, and 2 video cameras. Dynamic calibration to 1500 valid wand frames was 
completed resulting in average image error between 0.15-0.21mm and world error between 
0.10-0.24mm and static calibration to set the global coordinate system for the capture 
volume. Motion capture was limited to the lower limbs as a full-motion analysis was not 
required to appraise footfall. Nine 14mm reflective markers were placed on the lower limbs 
through manual palpation of specific bone prominences and secured using double-sided 
adhesive tape (Table 3.1, Figure 3.2). These positions comprised the calcaneus, and 2nd 
metatarsal head on each foot as well as the lower right shank to allow orientation of the 
skeleton at a later date. Markers were also placed in two sets of additional locations at 
lateral malleolus and 5th metatarsal head or inferior to the lateral malleolus and anterior to 
the lateral malleolus as reference markers. The latter set was initially used then updated to 
the former to provide a more stable reference frame. The experiment was run through Vicon 
Nexus 2.7 (Vicon Motion Systems Ltd) using a customised protocol incorporating marker 
templates, skeleton calibration and synchronisation capabilities via the Vicon MX Giganet 
unit. Force plates were not incorporated in the protocol in order to capture multiple steps 
within a trial and allow participants to walk without “aiming” for the platform.  
The OptoGait (Microgate S.r.l., Italy), consists of a series of bars (100cm x 8cm) with 96 Light 
Emitting Diodes (LEDs) embedded at intervals of 1.041cm and height 3mm from floor which 
transmit between the bars at 1000Hz. The 5m system with the 1m “Boosted” transmission 
bar add-on was configured in a two-dimensional layout to provide an assessment area of 4m 
x 1m (Figure 3.3). An activation threshold of 3 LEDs was set according to the manufacturer’s 
recommendations to compensate for the height of the LEDs from the floor. Due to this 
filtering threshold, when more than 2 LEDs are covered, an initial contact gait event is 
indicated and following a stance period, a final contact gait event occurs when the foot is 
raised from the floor until only 2 LEDs are covered. Recordings were captured by the 
OptoGait software at 1000Hz and synchronised to the Vicon, using a custom synchronization 
configuration file (.gpo in Appendix 10) synchronisation output cable via MX giganet. The 
OptoGait (version 1.12.1, 2018) was configured to require an external start trigger signal to 
begin recording and time out after 20 seconds of recording. 
Three ADPM Opal triaxial inertial sensors (APDM Inc.) were attached on the Left and Right 
Ankles at the lower shank and at the lower back in line with the 5th Lumbar vertebrae using 
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Velcro and elastic straps. Through the Motion Studio software (APDM Inc.) movement was 
sampled at 128Hz and recordings were synchronised with the Vicon via a custom sync 
output cable (6pin digital I/O connector to RCA phono) at the MX giganet, implementing the 
“duration.gpo” synchronization configuration file (available from Vicon). Motion Studio was 
configured to require an external start and stop trigger signal to begin and end recordings. 
Following data extraction, signals were processed through custom-written algorithms 
(performed in MATLAB) to filter, resample data to 100Hz, detect the gait events and 
segment data on a stride-to-stride basis. For further details see Section 3.2.5.  
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Figure 3.1: Depiction of motion capture laboratory. 
Depiction of motion capture system comprising 10 3D infrared cameras (black camera icons), 2 digital 
cameras (grey camera icons) as well as the OptoGait photoelectric system in a 2D orientation. This 
provides 7m capture space and walkway. 
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Table 3.1: Marker information 
Marker label Position description 
RHeel/LHeel  (Right and Left) On the calcaneus at the same height above the plantar surface of the foot 
as the toe marker 
RToe/LToe (Right and Left) Over the second metatarsal head, on the mid-foot side of the equinus 
break between fore-foot and mid-foot  
LShank Left Midshank (For Orientation) 
Additional reference markers  
Set 1 (P7-18,P20-24) Set 2 (P1-6,P19) 
Ank1 inferior to the lateral malleolus LMET05 5th Metatarsal 
Ank2 anterior to the lateral malleolus LLMAL  On the lateral malleolus along an 
imaginary line that passes through 
the transmalleolar axis 
Marker position descriptions with the two alternative reference marker sets and the participants 
they were implemented for.  
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Figure 3.2: Sensor & marker location 
a) Inertial sensors were positioned at ankles on the anterior aspect of the distal tibia and at the lower 
back in line approximately with 5th Lumbar vertebrae. b & c) reflective markers were positioned on 
shoes in locations as defined in Table 3.1 at calcaneus, and 2nd metatarsal head with two sets of 




Figure 3.3: OptoGait LED settings 
a) The OptoGait bars are embedded with LEDs at 1cm intervals approximately 3mm above the 
ground. b) Heel strike gait events are classified by interruption of 3 LEDs or more c) Toe-off gait 
events classified as the removal of interruption of 3LEDs. 
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3.2.5. DATA PROCESSING AND ANALYSIS 
Initial and final gait events and a number of spatiotemporal gait parameters were extracted 
following the methods described below. For the 3 systems within the experiment, initial and 
final contact gait events, and temporal gait parameters (stride time, step time, stance time 
and swing time) were extracted, expressed in seconds. Spatial parameters (step length, 
stride length and step width) were extracted from the Vicon and OptoGait, expressed in cm 
In order to ensure uniform comparisons between systems, data were resampled to a 
resolutions common to all systems: frequency 100Hz, spatial resolution 1cm or 1mm. 
Resampling used a linear interpolation to down-sample data sequences. Values for all gait 
events and temporal gait parameters were synchronised to 100Hz, meanwhile, step and 
stride length values were sampled to 1cm resolution and step width values sampled to 1mm 
resolution. 
3.2.5.1. Vicon Motion Capture System 
Trajectory data from Vicon Motion Capture was analysed using MATLAB (Mathworks Inc., 
Natick, MA, USA) through custom computational programmes created in collaboration with 
Dr Lorenza Angelini.  
A 2nd order lowpass digital bidirectional Butterworth filter with a cut-off frequency of 20Hz 
was applied to motion capture trajectories. The smoothed trajectory data from right and left 
heel and toe markers was automatically searched to identify peaks related to final contact 
and initial contact gait events where velocity deviates/ approaches 0 m/s respectively. 
From the timing of gait events, stride time, step time, stance time and swing time were then 
computed. From the spatial location of these gait events step length and stride length were 
computed. Step width was computed as the distance between the mid-point of each foot 
(on toe-heel axis) at midstance (midpoint between initial contact and final contact where 
velocity is 0 m/s). All gait parameters were exported to be compared to results from other 
systems. 
3.2.5.2. ADPM Opal Triaxial Inertial Sensors 
Motion inertial data from the ADPM Opal triaxial inertial sensors were analysed using 
MATLAB (Mathworks Inc., Natick, MA, USA) through custom computational programmes 
created in collaboration with Dr Fabio Storm, Dr Christopher Buckley and Dr Lorenza 
Angelini.  
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Gait data were segmented at turn events to indicate straight-line segments of walking using 
x-axis gyroscope signals from upper body sensors. Direction change was indicated by 
changes in smoothed orientation signals (locally weighted quadratic polynomial regression 
function). 
Gait events were determined following the method used by Salarian et al. (2004). This 
algorithm is widely used and well established. This was selected as reports indicated to have 
a high repeatability for IC and FC gait event detection and high accuracy for IC despite a less 
accurate detection compared with acceleration-based algorithm (Pacini Panebianco et al., 
2018). Using gyroscope data from the left and right ankle sensors, a subject-specific 
threshold and range were used to indicate the signal peaks corresponding to left and right 
mid-swing phases during the central steady walking segment of each pass. The timing of 
each heel strike (initial contact) and toe-off (final contact) gait events were then identified 
from the shank sensor angular velocity. Since each midswing period of the gait cycle is 
associated with a large positive peak in the shank angular velocity with the highest value 
occurring at the timing of the midswing. Initial control was detected as the nearest local 
minimum after the midswing point. A low-pass FIR filter was applied to angular velocity 
signals with a cutoff frequency of 30Hz and pass-band attenuation of less than 0.5 dB to 
smooth the spurious peaks in the signal (Salarian et al., 2004). These settings were reported 
in the literature and have been validated in a cohort of people with Parkinson’s disease .The 
signal was searched preceding the midswing point, to identify the local minimum 
corresponding to the final contact events (Figure 3.4)(Aminian et al., 2002).  
From the timing of these gait events, stride time, step time, stance time and swing time 
were then computed and all were exported to be compared to results from other systems  
3.2.5.3. Microgait OptoGait photoelectric walkway 
The Optogait system’s software automatically detects the temporal and spatial location 
using intersecting LED transmissions. Appropriate identification of footfalls was verified 
visually, and trial results exported and imported into Matlab for further processing.  
All trial data were scrutinised using semi-automated computational scripts to identify 
footfalls where both initial contact and final contact were considered to begin within the 
system. Such invalid data were removed to ensure accurate detection of initial and final 
contact events for calculation of gait parameters. For the purposes of validation, initial  
|101 
 
Figure 3.4: ADPM Opal sensors gait event plot  
Example angular velocity signals from right ankle (red), left ankle (blue) and lumbar (black) IMUs, 
with all gait events and included gait data (first to last IC) marked. *: midswing (“M”), x: initial contact 
(“IC”), O: final contact (“FC”). 
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contact (heel strike) split time from the external trigger time, step time, stride time, swing 
time and stance time were extracted as well as step length, stride length and step width. 
Final contact time was computed as initial contact plus stance time for each step. 
3.2.6. SYSTEM COMPARISON 
Custom written MATLAB scripts were implemented to combine data from the three systems. 
For each trial, the first step common to the three systems was identified manually (Table 
3.2). Data were aligned to ensure correct computation of between-system differences.  
3.2.7. STATISTICAL ANALYSIS 
The analysis was limited to the gait events occurring within the OptoGait assessment area 
and Vicon motion capture volume in order to cross-validate step detection. 
Data were not normalised in order to retain the unadjusted results. Differences and absolute 
differences and averages of gait event timing and temporal gait parameters detected by the 
3 systems were computed on a step by step basis between Vicon-OptoGait, Vicon-Opal and 
OptoGait-Opal systems. As spatial gait events were only computed by the Vicon and 
OptoGait differences (Equation 3.1) and absolute differences (Equation 3.2) between the 2 
systems (Vicon-OptoGait) were computed on a step by step basis. 
Equation 3.1: System Difference = system 2 - system 1 
Equation 3.2: System Absolute Difference = [system 1 - system 2] 
For each valid trial, mean difference and average values were calculated to avoid pseudo-
replication of data. Gait speed was computed for each stride, from the Vicon system and a 
mean value computed for each trial. 
Equation 3.3: Speed (m/s) = stride length (m) / stride time (s) 
Shapiro-Wilks Normality test was used to examine the distribution of values. The following 
statistical tests were used to check the validity of the gait event detection by the two 
systems: 
• Intraclass correlation coefficient analysis with a two-way random, single 
measures model for absolute agreement and R2 (coefficient of determination) 
through linear regression analysis to indicate consistency of measurements. 
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• Calculation of standard error of estimate (SEE) and paired T-Test were used to 
assess relative agreement. 
• Pearson’s Correlation to examine the influence of speed on system accuracy on a 
trial by trial basis  
P-values of less than 0.05 were considered significant. Correlation coefficients greater than 
0.6 were considered to indicate good to an excellent inter-rater agreement in line with 
Cicchetti (1994). 
Correlation and Bland Altman plots were generated to display the relationships between 
values measured by the 3 systems and the differences between these (Bland and Altman, 
1986). For both the differences and absolute differences 95% Limits of Agreement (LoA, 
Equation 3.3) were calculated to indicate the level of systematic bias and precision of the 
measurements and the %LoA (Equation 3.4) for difference between measurement systems 
was used as an indication of the maximum expected bias for future studies. 
Equation 3.4: LoA = mean diff ± SDdiff x 1.96 
Equation 3.5: %LoA = LoAdiff / mean x 100 
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Table 3.2: Step matching strategy 
Step Reference L/R Vicon OptoGait Opal 
1 L 1 
 
1 
2 R 2 1 2 
3 L 3 2 3 
4 R 4 3 4 
5 L 5 4 5 
6 R 6 5 6 
7 L 7 6 7 
8 R 8 
 
8 
Example approach to matching data on a step by step basis. Only gait events that were concurrently 
measured by all three systems were included (bold). On a trial by trial basis, gait events were 





3.3.1. PARTICIPANT CHARACTERISTICS 
During four assessment sessions, 24 healthy controls (16 females) were recruited. The group 
had an average age of 27±8 years [range 21-54 yrs], an average BMI of 22.8±2.5 kg/m2 [19.4-
27.3 kg/m2], reflecting an average height 172.5±9.2 cm [158 - 197.5cm], and mass 67.9±9.2 
kg [52-82 kg]. Participants had an average leg length (to ankle) of 89.7±7.3cm [77-100cm]. 
Most participants reported no exclusionary medical history although one participant 
reported a history of Ulcerative Colitis and one reported a previous Right-Anterior Cruciate 
Ligament reconstruction which was not active at the time of assessment. 
3.3.2. VALIDITY OF DATA 
Each participant was asked to complete at least 10 trials with additional repeats requested 
where issues were evident during data collection. In some circumstances, data (n=10) were 
later found to be unusable, however valid data were captured for 230 trials from 24 
participants. For the 10 trials excluded, 5 trials were data recorded from 1 participant, add 2 
trials were recorded from a 2nd participant with the other 3 trials excluded from 3 individual 
participants. Reasons for exclusion were: data file was corruption (n=1), incorrect gait event 
detection by the one of the system/ algorithms (Vicon n=2 , OptoGait n=5), or problems with 
synchronisation of the systems occurred for at least one of the systems (Opal n=1, OptoGait 
n=2).  For one trial, the OptoGait mislabelled the steps as left/right so step width was not 
calculated and this was removed from this analysis. 
3.3.3. GAIT EVENTS 
From data 230 valid walking trials, a total of 972 initial contact and 1012 final contact gait 
events were detected from the three gait analysis systems. This equates to an average of 4.2 
initial contacts and 4.4 final contact events per participant. Table 3.3 and Table 3.4 display 
the median and interquartile range (IQR) of Initial Contact (Heel Strike) and Final Contact 
(Toe-Off) gait events timing detected by the three gait analysis systems as well as the system 
differences and absolute differences with significant differences indicated. The correlations 
of Heel Strike and Toe-off gait events detected between the three systems are also 
displayed. Figure 3.5 and Figure 3.6 display the correlations of three system measurements, 
and Bland-Altman plots for differences and absolute differences between systems for both 
gait events.  
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Table 3.3: Gait Event Results - Initial Contact 
COMPARISON Vicon-OptoGait Vicon-Opals OptoGait-Opals 
ICC(2, 1) (95% CI) 1.000 (0.996, 1.000)** 1.000 (1.000, 1.000)** 1.000 (0.999, 1.000)** 
R2 1.000 1.000 1.000 
Absolute System Difference 
(Mean [+95% LoA]) 
0.02s [0.05s] 0.02s [0.05s] 0.03s [0.07s] 
System Difference 
(Mean [±95% LoA]) 
0.02s [-0.01s, 0.05s] 0.01s [-0.05s, 0.06s] -0.02s [-0.07s, 0.04s] 
SEE 0.017s 0.027s 0.028s 
p <0.001 <0.001 <0.001 
Abbreviations: ICC: intraclass coefficient, CI: confidence interval, LoA: Limits of Agreement, IQR: 
interquartile range, n: number of participants, Opals: ADPM Opal sensors, ** p<0.01 *p<0.05  
 
Figure 3.5: Gait Events graphs – Initial contact 
Correlation of initial contact gait event (s) measurements by different systems Vicon:OptoGait, 
OptoGait:Opal, Vicon:Opal. Correlation plots display reference line (black) and correlation line 
between systems (red). Bland Altman plots display the mean of system measurements against the 
difference/ absolute difference between systems measurements with mean difference (red) and 95% 
Limits of Agreements indicated (blue). Abbreviation: s, seconds  
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Table 3.4: Gait Event Results - Final Contact 
COMPARISON Vicon-OptoGait Vicon-Opals OptoGait-Opals 
ICC(2, 1) (95% CI) 0.999 (0.924, 1.000)** 1.000 (0.998, 1.000)** 1.000 (0.999, 1.000)** 
R2 1.000 1.000 1.000 
Absolute System Difference 
(Mean [+95% LoA]) 
0.04s [0.07s] 0.03 [0.07] 0.03s [0.06s] 
System Difference 
(Mean [±95% LoA]) 
-0.04s [-0.07s, -0.01s] -0.02 [-0.07, 0.03] 0.02s [-0.03s, 0.06s] 
SEE 0.017s 0.024s 0.024s 
p <0.001 <0.001 <0.001 
Abbreviations: ICC: intraclass coefficient, CI: confidence interval, SEE: Standard Error Estimate, LoA: 
Limits of Agreement, IQR: interquartile range, n: number of participants, Opals: ADPM Opal sensors, 
** p<0.01 *p<0.05 
 
 
Figure 3.6: Gait Events graphs – Final Contact 
Correlation of final contact gait event (s) measurements by different systems Vicon:OptoGait, 
OptoGait:Opal, Vicon:Opal. Correlation plots display reference line (black) and correlation line 
between systems (red). Bland Altman plots display the mean of system measurements against the 
difference/ absolute difference between systems measurements with mean difference (red) and 95% 
Limits of Agreements indicated (blue). Abbreviation: s, seconds  
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3.3.4. GAIT PARAMETERS 
From successive gait events in 230 valid walking trials, temporal gait parameters were 
computed by all 3 systems. A total of 742 step times, 511 stride times, 860 stance times and 
662 swing times were calculated and contributed to results for the cohort. Spatial gait 
parameters computed by the Vicon and OptoGait provided 776 step lengths, 546 stride 
lengths and 676 step widths. Table 3.5 to Table 3.9 display the cohort’s mean±SD for gait 
parameters from the gait analysis systems with significant differences indicated. The 
correlations of gait parameters captured by the three systems are also displayed. 
Figure 3.7 to Figure 3.11 display the correlation of three system measurements, and Bland-
Altman plots for differences and absolute differences between systems.  
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Table 3.5: Gait Parameter Results - Step time  
Vicon OptoGait Opals 
Mean±SD 0.55s±0.05s 0.55s±0.05s 0.55s±0.05s 
COMPARISON Vicon-OptoGait Vicon-Opals OptoGait-Opals 
ICC(2, 1) (95% CI) 0.989 (0.986, 0.992)** 0.981 (0.975, 0.985)** 0.987 (0.983, 0.990)** 
R2 0.979 0.963 0.974 
Absolute System Difference 
(Mean [+95% LoA]) 
0.01s [0.03s] 0.01s [0.04s] 0.01s [0.03s] 
System Difference 
(Mean [±95% LoA]) 
-0.001s [-0.01s, 0.01s]  -0.001s [-0.02s, 0.02s] -0.001s [-0.02s, 0.01s] 
SEE 0.007s 0.009s 0.007s 
p 0.112 0.021 0.174 
Abbreviations: ICC: intraclass coefficient, CI: confidence interval, SEE: Standard Error Estimate, LoA: 
Limits of Agreement, IQR: interquartile range, n: number of participants, Opals: ADPM Opal sensors, 
** p<0.01 *p<0.05 
 
Figure 3.7: Gait parameter graphs - Step time 
Comparison of step time (s) measurements by different systems Vicon:OptoGait, OptoGait:Opal, 
Vicon:Opal. Correlation plots display reference line (black) and correlation line between systems 
(red). Bland Altman plots display the mean of system measurements against the difference/ absolute 
difference between systems measurements with mean difference (red) and 95% Limits of 
Agreements indicated (blue). Abbreviation: s, seconds  
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Table 3.6: Gait parameter results - Stride time  
Vicon OptoGait Opals 
Mean±SD 1.09s±1.14s 1.09s±1.14s 1.09s±1.14s 
COMPARISON Vicon-OptoGait Vicon-Opals OptoGait-Opals 
ICC(2, 1) (95% CI) 0.998 (0.997, 0.998)** 0.995 (0.993, 0.996)** 0.995 (0.994, 0.996)** 
R2 0.996 0.989 0.990 
Absolute System Difference 
(Mean [+95% LoA]) 
0.01s [0.02] 0.01s [0.03] 0.01s [0.03] 
System Difference 
(Mean [±95% LoA]) 
0.00s [-0.02, 0.02] 0.00s [-0.03, 0.03] 0.00s [-0.03, 0.03] 
SEE 0.009s 0.014s 0.013s 
p 0.179 0.413 0.972 
Abbreviations: ICC: intraclass coefficient, CI: confidence interval, SEE: Standard Error Estimate, LoA: 
Limits of Agreement, IQR: interquartile range, n: number of participants, Opals: ADPM Opal sensors, 
** p<0.01 *p<0.05 
 
Figure 3.8: Gait parameter graphs - Stride Time 
Comparison of Stride Time (s) measurements by different systems Vicon:OptoGait, OptoGait:Opal, 
Vicon:Opal. Correlation plots display reference line (black) and correlation line between systems 
(red). Bland Altman plots display the mean of system measurements against the difference/ absolute 
difference between systems measurements with mean difference (red) and 95% Limits of 
Agreements indicated (blue). Abbreviation: s, seconds  
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Table 3.7: Gait parameter graphs - Stance time  
Vicon OptoGait Opals 
Mean±SD) 0.68±0.07 0.62±0.06 0.66±0.07 
COMPARISON Vicon-OptoGait Vicon-Opals OptoGait-Opals 
ICC(2, 1) (95% CI) 0.651 (-0.076, 0.883)** 0.857 (0.466, 0.939)** 0.800 (0.164, 0.924)** 
R2 0.851 0.907 0.886 
Absolute System Difference 
(Mean [+95% LoA]) 
0.06 [0.11] 0.03 [0.06] 0.04 [0.08] 
System Difference 
(Mean [±95% LoA]) 
-0.06 [-0.12, 0.00] -0.02 [-0.07, 0.02] 0.04 [-0.01, 0.08] 
SEE 0.024 0.020 0.023 
p <0.001 <0.001 <0.001 
Abbreviations: ICC: intraclass coefficient, CI: confidence interval, SEE: Standard Error Estimate, LoA: 
Limits of Agreement, IQR: interquartile range, n: number of participants, Opals: ADPM Opal sensors, 
** p<0.01 *p<0.05 
 
Figure 3.9: Gait parameter graphs - Stance Time 
Comparison of Stance Time (s) measurements by different systems Vicon:OptoGait, OptoGait:Opal, 
Vicon:Opal. Correlation plots display reference line (black) and correlation line between systems 
(red). Bland Altman plots display the mean of system measurements against the difference/ absolute 
difference between systems measurements with mean difference (red) and 95% Limits of 
Agreements indicated (blue). Abbreviation: s, seconds  
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Table 3.8: Gait parameter graphs - Swing time  
Vicon OptoGait Opals 
Mean±SD 0.42±0.03 0.48±0.04 0.44±0.03 
COMPARISON Vicon-OptoGait Vicon-Opals OptoGait-Opals 
ICC(2, 1) (95% CI) 0.266 (-0.074, 0.605)** 0.466 (-0.071, 0.737)** 0.582 (0.100, 0.784)** 
R2 0.482 0.632 0.609 
Absolute System Difference 
(Mean [+95% LoA]) 
0.06 [0.11] 0.03 [0.06] 0.04 [0.08] 
System Difference 
(Mean [±95% LoA]) 
0.06 [0.01, 0.11] 0.02 [-0.02, 0.06] -0.04 [-0.08, 0.01] 
SEE 0.027 0.021 0.021 
p <0.001 <0.001 <0.001 
Abbreviations: ICC: intraclass coefficient, CI: confidence interval, SEE: Standard Error Estimate, LoA: 
Limits of Agreement, IQR: interquartile range, n: number of participants, Opals: ADPM Opal sensors, 
** p<0.01 *p<0.05 
 
Figure 3.10: Gait parameter graphs - Swing Time 
Comparison of Swing Time (s) measurements by different systems Vicon:OptoGait, OptoGait:Opal, 
Vicon:Opal. Correlation plots display reference line (black) and correlation line between systems 
(red). Bland Altman plots display the mean of system measurements against the difference/ absolute 
difference between systems measurements with mean difference (red) and 95% Limits of 
Agreements indicated (blue). Abbreviation: s, seconds  
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Table 3.9: Gait parameter graphs – Step Length, stride length, step width 
Step Length  
Vicon Mean (SD) 73 (7) 
OptoGait Mean (SD) 73 (7) 
COMPARISON 
 
ICC(2, 1) (95% CI) 0.986 (0.984, 0.988)** 
R2 0.995 
Absolute System Difference (Mean [+95% LoA]) 1 [2] 
System Difference (Mean [±95% LoA]) 0 [-1, 1] 
SEE 0.483 
p 0.519   
Stride Length 
 
Vicon Mean (SD) 146 (16) 
OptoGait Mean (SD) 146 (16) 
COMPARISON 
 
ICC(2, 1) (95% CI) 0.996 (0.995, 0.997)** 
R2 0.998 
Absolute System Difference (Mean [+95% LoA]) 1 [2] 
System Difference (Mean [±95% LoA]) 0 [-1, 2]  
SEE 0.718 




Vicon Mean (SD) 9.3 (2.4) 
OptoGait Mean (SD) 12.5 (3.1) 
COMPARISON 
 
ICC(2, 1) (95% CI) 0.668 (-0.072, 0.882)** 
R2 0.621 
Absolute System Difference (Mean [+95% LoA]) 3.3 [6.9] 
System Difference (Mean [±95% LoA]) 3.2 [-0.5, 7.0] 
SEE 1.924 
p <0.001 
Abbreviations: ICC: intraclass coefficient, CI: confidence interval, SEE: Standard Error Estimate, LoA: 




Figure 3.11: Gait parameter graphs - Step Length, stride length, step width 
Comparison of measurements of Step Length, Stride Length and Step Width by Vicon and OptoGait. 
Correlation plots display reference line (black) and correlation line between systems (red). Bland 
Altman plots display the mean of system measurements against the difference/ absolute difference 
between systems measurements with mean difference (red) and 95% Limits of Agreements indicated 
(blue). Abbreviation: cm, centimetre  
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3.3.5. CORRELATION WITH SPEED 
On a trial by trial basis where valid data were available, the correlation of differences in gait 
event and gait parameters with gait speed from the Vicon (Table 3.10) was examined. 
Average gait speed was 1.34±0.2m/s (range: 0.98-1.79m/s).  
Of the 230 valid trials, 1 trial was excluded from correlation analysis for step width due to 
procedural issues with the OptoGait bar. Meanwhile, for one other trial, too few gait events 
were captured concurrently by the 3 systems to denote a stride so was excluded for stride 
time and stride length correlations.  
None of the comparisons resulted in a strong significant correlation between gait speed and 
measurement differences (|r|<0.5) indicating gait speed did not impact the agreement of 
the gait event and gait parameter measurements.  
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Table 3.10: Correlation between gait speed and system differences  
 n Vicon:OptoGait Vicon:Opal OptoGait:Opal 













Initial Contact 229 -0.324 <0.001 0.016 0.812 -0.042 0.523 
Final Contact 229 0.127 0.055 0.228 <0.001 0.032 0.634 
Step Time 229 -0.249 <0.001 -0.024 0.721 0.019 0.770 
Stride Time 229 -0.273 <0.001 0.051 0.440 0.069 0.299 
Stance Time 229 -0.417 <0.001 -0.231 <0.001 -0.145 0.028 
Swing Time 229 -0.452 <0.001 -0.211 0.001 -0.212 0.001 
Step Length 229 -0.153 0.021         
Stride Length 229 -0.293 0.000         








Initial Contact 229 -0.345 <0.001 -0.221 <0.001 -0.009 0.891 
Final Contact 229 0.027 0.680 -0.152 0.021 -0.177 0.007 
Step Time 229 0.007 0.912 0.061 0.358 0.062 0.353 
Stride Time 229 0.039 0.559 0.087 0.190 0.065 0.326 
Stance Time 229 0.441 <0.001 0.373 <0.001 -0.191 0.004 
Swing Time 229 -0.463 <0.001 -0.347 <0.001 0.226 <0.001 
Step Length 229 -0.289 <0.001     
Stride Length 229 -0.307 <0.001     
Step Width 228 -0.037 0.578     
Results of Pearson’s correlation analysis between gait speed and system absolute differences/ 
differences on a trial by trial basis. Abbreviations: n number of trials, r correlation coefficient, p p-
value indicating correlation significance  
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3.4. DISCUSSION 
The present study explored the accuracy and precision of the OptoGait photoelectric system 
and ADPM Opal triaxial inertial sensors compared with the Vicon motion capture system as 
the gold standard criterion instrument in a cohort of 24 healthy adult participants (16 
females). Valid data were captured and analysed for all participants and, a large number of 
trials and steps were captured from each participant available for statistical analysis. 
Exclusion of unusable trial data was necessary for 10 trials where data file was corrupted, 
incorrect gait event detection by the one of the systems, or problems with synchronisation 
of the systems occurred for at least one of the systems. Since issues commonly occurred in 
the same participants, there may have been a recurring issue with the configuration that 
was corrected for other trials.   
3.4.1. GAIT EVENTS 
The mean difference between Vicon and OptoGait system measurements for initial contact 
and final contact gait events were 0.02s (±0.03s 95%LoA, p<0.001) and -0.04s (±0.03s 
95%LoA, p<0.001) respectively indicating that the OptoGait produced a small but statistically 
significant delay in detection of initial contact and anticipation of the final contact event. 
Gait event values displayed strong significant correlations between systems (IC: 1.000 
(0.996, 1.000), p=0.001; FC: 0.999 (0.924, 1.000), p<0.001, (ICC(2,1)(95%CI)). 
When compared with the Vicon, gait events values from ADPM Opal IMUs were significantly 
different: 0.01s (±0.05s 95%LoA, p=0.004) and -0.02s (±0.05s 95%LoA, p<0.001) for initial 
contact and final contact respectively. Similar to Vicon:OptoGait results, strong significant 
correlations were present between the Vicon and ADPM Opal sensors gait event values (IC: 
1.000 (1.000, 1.000), p<0.001; FC: 1.000 (0.998, 1.000), p<0.001 (ICC(2,1) 95%CI))).  
In comparison of gait event values measured by the OptoGait and ADPM Opal sensors, a 
significant difference of -0.02s (±0.06s 95%LoA, p<0.001) and 0.02s (±0.05s 95%LoA, 
p<0.001) were observed for initial contact and final contact respectively. This indicates that 
the ADPM Opal sensors initial contact detection is anticipated and final contact delayed 
compared with the OptoGait and that the ADPM Opal sensors provides an intermediate gait 
event value to the Vicon and OptoGait. However strong ICCs were exhibited between 
systems (IC: 1.000 (0.999, 1.000); FC: 1.000 (0.999, 1.000) (ICC(2,1) 95%CI, p<0.01)).  
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Taken together it seems that although a small statistically significant systematic bias is 
present, the concurrent validity appears to be excellent as indicated by strong significant ICC 
values. Since the data from the three systems was resampled to 100Hz, the 95%LoA 
reported can be considered excellent.  
The selection of LED filter greatly impacts the detection of gait event by the OptoGait and is 
related to the gait task performed. For instance while, to study walking by healthy adults 
with the OptoGait, the use of 2in/2out and 3in/3out filter settings are valid (Healy et al., 
2019). Therefore, the use of a 3in/3out filter in the present study results in a pattern of 
initial contact delay and final contact anticipation following results reported in the literature 
for both OptoGait and ADPM Opal sensors validation compared with motion capture.  
Final contact gait event detection also appears inherently associated with a higher system 
difference than initial contact gait event detection. Previous studies have identified similar 
issues with final contact gait event detection from the IMUs. Since the algorithms 
implemented here rely on the identification of gait events from angular velocity signals 
measured by gyroscopes at the lower shank, this strategy is fundamentally different from 
gait event detection when using marker trajectories in motion capture techniques. 
Therefore, differences are common when comparing shank worn IMU data to motion 
capture analysis. Since the position of inertial sensors on the front rather than the lateral 
side of the shank, some impact on the accuracy of the gait event detection algorithms is 
present. Panebianco et al. (2018) also reported significant differences between foot-based 
algorithms and shank- or trunk-based algorithms for initial contact however, foot- and 
shank-based algorithms displayed comparable accuracy and repeatability. Meanwhile, 
significant differences were identified between all sensor positions for final contact 
detection with foot-based algorithms performing with higher accuracy and repeatability 
than shank-based algorithms. The authors also described a delay in initial contact detection 
and anticipation of final contact detection as corroborated here.  
3.4.2. GAIT PARAMETERS 
3.4.2.1. Temporal Gait Parameters 
The calculation of step time was not significantly different between the Vicon:Optogait and 
OptoGait:Opals gait analysis systems (-0.01s-0.01s, ±2.4%, 95%LoA, p=0.112; -0.02s-
0.02s,±2.6%, 95%LoA, p=0.174). Although results indicate a statistically significant difference 
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in step time measured by Vicon:Opals (-0.02s-0.01s, ±3.2%, 95%LoA, p=0.021), this 
difference was within acceptable ranges. Strong significant correlations are present across 
the three instrument comparisons (ICC(2,1)>0.90, p<0.001; R2>0.9). For stride time, no 
statistically significant system differences were present within the comparisons between the 
3 instruments (-0.02s-0.02s, ±1.6%, 95%LoA, p=0.179; -0.03s-0.03s, ±2.5%, 95%LoA, p=0.413; 
-0.03s-0.03s, ±2.4%, 95%LoA, p=0.972) and strong significant correlations can be observed 
(ICC(2,1)>0.90, p<0.001; R2>0.9). Therefore, step time and stride time display an acceptable 
accuracy and reliability between instruments, with a difference less than ±3.2% (Table 3.11).  
The meta-analysis of gait measures in healthy control and CA cohorts in Chapter 2 indicates 
that a mean difference of 110ms and 180ms is present for step time and stride time 
between the cohorts. Therefore, this level of agreement will be sensitive enough to detect a 
difference in similar groups in future studies. 
Significant differences in measurement of stance time, and swing phase by the OptoGait 
were detected which follows previously reported findings and the behaviour of gait event 
detection measurements (Lee et al., 2014, Lienhard et al., 2013). Measurements of stance 
time from the three systems show a lower consistency but fair level of agreement 
(ICC(2,1)>0.60, p<0.001; R2>0.8) and larger differences between systems (Vicon:OptoGait -
0.12-0.00, ±8.7%, 95%LoA, p<0.001; Vicon:Opal -0.07-0.02, ±6.6%, 95%LoA, p<0.001; 
OptoGait:Opal -0.01-0.08, ±7.0%, 95%LoA, p<0.001), indicating a systematic bias in the 
measurement. As stance time is inherently linked with any differences in the initial and final 
contact gait events detection, it follows that OptoGait to Opals displaying the a positive error 
in stance time values while Vicon:OptoGait and Vicon:Opal comparison indicate a negative 
average differences. In addition, as gait events obtained from ADPM Opal sensors are 
intermediate to those obtained from the Vicon and OptoGait, the stance time values are also 
intermediate to the other two systems. For swing time measurement by the systems, 
correlations are less precise indicating less reliable measurement (ICC(2,1): 0.266-0.629, 
p<0.001; R2: 0.48-0.63) and 95%LoA are within similar ranges (Vicon:OptoGait 0.01s-0.11s, 
±12.0%; Vicon:Opal -0.02s-0.06s ±9.6%; OptoGait:Opal -0.08s-0.01s, ±10.1%). Therefore, 
stance and swing time display larger differences, a systematic bias and weaker consistency 
of measurements between systems. Again, the ADPM Opal sensors values for swing time are 
intermediate measurements by the other two systems (Figure 3.12). Therefore, stance time 
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and swing time display poorer precision accuracy and reliability between instruments, with a 
expected difference approximately ±9.0% (Table 3.11).  
These results are comparable to results from previous literature. Similar to findings by 
Panebianco et al. (2018), for the APDM Opal IMU compared with the Vicon Motion Capture 
system, the initial contact delay and final contact anticipation, results in very little difference 
in step time and stride time. However, since the computation of stance and swing time 
accumulates the small differences in initial and final contact gait event. Similarly, for the 
OptoGait comparison to the Vicon 3D motion capture system, while step and stride time 
intervals consistent and show good level of accuracy, stance and swing time are associated 
with lower precision and agreement (Healy et al., 2019). 
Taken together, as the gait event detection by the OptoGait is intermediate to Vicon and 
ADPM Opal sensors, an under-/ overestimation of stance and swing time measurements 
respectively are apparent by both the ADPM Opal IMU system and OptoGait photoelectric 
system compared with Vicon measurements (Figure 3.12). Since the between-system 
differences 95%LoA for the OptoGait and Opals are between 2.4-10.1% for these temporal 
measures while some systematic bias is present the accuracy is within acceptable levels.   
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Figure 3.12: Depiction of system differences 
Depiction of the difference between gait event detection by the three systems and the impact on 
temporal gait parameter calculation. Since initial contact detection by the OptoGait are slightly 
delayed and final contact detection is slightly anticipated, compared with the Vicon and ADPM Opal 
sensors systems, stance/swing proportions are impacted. Measurements of step and stride duration 
are unaffected.  
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Table 3.11: Summary of 95% limit of agreement (%) for possible system differences 
Gait Parameter Threshold (Vicon-OptoGait, Vicon-Opal, OptoGait-Opal) 
Step Time 2.4%; 3.2%; 2.6% 
Stride Time 1.6%; 2.5%; 2.4% 
Stance Time 8.7%; 6.6%, 7.0% 
Swing Time 12.0%; 9.6%; 10.1% 
Step Length 1.4% 
Stride Length 1.0% 
Step Width 34.6% 
Summary of 95% limit of agreement (expressed as +LoA%) as indication of possible differences 
between gait parameters measurements. 
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3.4.2.2. Spatial Gait Parameters 
For the spatial gait parameters, only comparisons between OptoGait and Vicon were 
completed, in order to focus on the systems capable of direct spatial measurements. The 
measurement of step length and stride length were both associated with small non-
significant differences between systems (0cm (-1cm, 1cm), ±1.4% p=0.519; 0cm (-1cm, 2cm) 
±1.0% 95%LoA, p=0.233) and excellent correlations (ICC(2,1)>0.90, p<0.001, R2>0.9). Since 
the spatial resolution of the OptoGait system is 1.041cm this level of agreement can be 
considered excellent (Cicchetti 1994). A previous study also indicated that step length and 
stride length measurements by the OptoGait using the same LED in/out filter settings 
correlate strongly with measurement by a 3D motion capture system (ICC(2,1), step length: 
0.987 (0.962-0.995, 95%CI); stride length: 0.998 (0.995-0.999 95%CI)) with %LOA of ±2% 
(Healy et al., 2019). Therefore, the measurements here are within previously reported values 
and are sensitive enough to measure the mean difference of 14cm and 20cm necessary to 
differentiate between HC and CA.  
Measurement of step width was associated with a poor agreement between systems 
(ICC(2,1)=0.459, p<0.001) and a significant differences between systems (3.2cm (-0.5cm-
7.0cm), ±34.6% 95%LoA, p<0.001), although the overestimation is a relatively consistent 
compared with the Vicon (R2>0.6). This larger system difference is likely due to the 
fundamentally different definitions of step width between the two systems. For the Vicon, 
step width was defined as the mediolateral distance between midfoot positions (toe to heel) 
at midswing (initial contact to final contact), the OptoGait by default, defined step width, as 
the distance between midfoot positions as identified by LED activations. Although the 
OptoGait detects LED activations across a 2D area, it is unable to detect the angle of foot 
position which is especially important when considering step width measurement. The study 
protocol was designed prioritise the maximum length of the walkway for capture of a natural 
walking gait. Therefore, although force plates (a gold-standard measurement system for 
spatial measures of gait event) would provide a more precise measurement of the real 
footfall location, these were not implemented in the present study. To overcome this, a 
lateral reflective marker common to all participant’s may have allowed for a more realistic 
position estimate of the midfoot point. With this in mind, the study approach may not be 
appropriate to adequately assess the OptoGait method of step width measurement. Further 
research is required to explore this impact further and this threshold should be considered 
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when interpreting future results of clinical studies. Meta-analysis of gait characteristics 
measured in  CA and HC indicate that the cohorts are differentiated by a difference in step 
width of 6 cm. As this is within the limits of agreement for the OptoGait system, 
measurements of step width should be interpreted with caution. 
3.4.2.3. Correlation with speed 
Correlation analysis indicates that some significant but weak correlations exist between the 
system differences for gait events and gait parameters and participant gait speed from 
OptoGait and Vicon. However, no strong significant correlations were present between 
system differences and participant gait speed on a trial by trial basis, therefore, the between 
system agreement for the OptoGait and Vicon is not correlated with the participant’s gait 
speed. 
Since correlations between gait speed and system accuracy were weak in this study, it is 
likely that slower gait speed does not confound gait assessment by the OptoGait or ADPM 
Opal sensors. Gait speed is inherently interdependent with cadence and stride length as well 
as stance/swing phase (Kirtley et al., 1985). People with gait impairments typically walk 
slower than healthy individuals, and gait speed can indicate functional ability (Perry et al., 
1995) and falls risk (Maki, 1997). Therefore, it is important to explore the impact of gait 
speed on system accuracy when contemplating an appropriate system to use and to ensure 
that differences are not exacerbated in slow paced walking. The influence of speed on 
measurement accuracy is important when considering the use of the OptoGait and Opal 
systems within a non-laboratory setting where the 3D motion capture system is unavailable 
within experiments involving pathological cohorts. Therefore, the measurement agreement 
assessments of gait in patients with movement disorders will be minimally affected by 
pathological speed change. 
However, all participants within the current study were healthy participants and trial gait 
speeds within the present dataset ranged from 0.98m/s-1.79m/s. Many patients with gait 
impairments walk considerably slower than the healthy participants within this study 
(Pearson et al., 2004). As these were not within the range of functional dependence or 
requiring intervention (Fritz and Lusardi, 2009), more research is required in a disease cohort 
to explore this further. 
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3.5. STRENGTHS AND LIMITATIONS 
This study incorporated a healthy control cohort in order to reduce possible impact of 
comorbidities on the measurements. Therefore, further validation of the systems in cohorts 
of people with movement disorders is necessary to establish the validity of the systems for 
measurement of pathological gait pattern. In the literature in people with neurological 
disorders (Moon et al., 2016), and cerebellar ataxia specifically (Schniepp et al., 2014) 
variability and asymmetry of the gait measures is commonly effected. However, the validity 
of these measures was not assessed in this study in the interest of focussing on the average 
value for the measure. Healy et al (2019) indicated that with the LED filter settings used in 
this study (3in, 3out), there was no difference in the %LOA for left and right measurements. 
Therefore, as asymmetry is measured based on average of left and right measurements 
(Godfrey et al., 2015) it can be inferred that the validity of asymmetry would not be 
impacted differently from the overall gait measure. 
The measures that displayed the poorest accuracy and precision to the gold standard 
measurement was step width. As discussed, a systematic bias and large limit of agreement 
present, likely reflect the different estimation methods employed so future studies should 
be wary of this measurement until further validation is completed. Researchers should 
consider whether incorporation of an offset is necessary to correct the systematic bias 
detected here. 
Some data was excluded from analysis due to issues with the detection of the gait events by 
the OptoGait which is possibly related to differences in footwear and gait speed. Issues with 
synchronisation of the systems may pose an issue if data is to be segmented by gait events 
detected by another system. The requirement to exclude data from analysis may pose an 
issue in future implementation of the Optogait system. Since repeating trials is not always 
possible in people with pathological gait, who may be prone to fatigue, it is important to 
capture data as reliably as possible. To ensure repeatability of trials, issues should be 
monitored and minimised wherever possible through proper configuration. However, testing 
was quick to complete, lasting between 45mins to 1 hour for each participant, which 
indicating a low burden to participants.   
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3.6. CONCLUSION 
In summary, the OptoGait and ADPM Opal sensors show good to excellent agreement with 
the Vicon Motion Capture system and excellent accuracy for initial contact and final contact 
gait events, as well as step time, stride time, step length and stride length. A slight delay in 
recognition of initial contact gait event and anticipation of final contact gait event by the 
OptoGait instrumented walkway, and to a lesser extent the ADPM Opal IMU system, was 
detected. These disagreements compound to impact the reliability of stance and swing time 
measurements. Step Width was consistently measured larger by the OptoGait than the 
Vicon likely due to the differing parameters definitions therefore this should be considered 
in future studies incorporating this system.  
Taken together, thresholds for acceptable measurements can be inferred from %LoA in 
preparation for interpretation of clinical gait assessments (Table 3.11). These will be 
considered as a reference in the following chapters of this thesis. Measures where values 
vary greater than %LoA>5% will be interpreted with caution.  
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Chapter 4. ANALYSIS OF GAIT IN HEREDITARY CEREBELLAR ATAXIA  
4.1. INTRODUCTION 
Cerebellar ataxia (CA) is a neurodegenerative disease where dysfunction of the cerebellum 
leads to problems with balance performance. It causes considerable disability and is 
associated with an increased risk of falls (Fonteyn et al., 2010). Speed of disease progression 
is indicative of survival (Diallo et al., 2019). 
At present, no disease-modifying therapies are available, however, gait analysis has the 
potential to provide an objective tool to determine disease severity and monitor disease 
progression as part of clinical practice and clinical trials. Prior to this implementation, full 
characterisation of gait impairment and the quality of postural control in ataxia is essential 
(Buckley et al., 2019). 
The spatiotemporal gait characteristics of CA have been explored previously (Chapter 2, 
Buckley et al., 2018). CA manifests as a reproducible gait pattern: reduced preferred cadence 
and walking pace, increased gait variability, as well as increased width of the base of 
support, shorter steps and lower swing phase proportion and higher stance phase 
proportion compared with healthy controls.  
The postural support is an important consideration when quantifying gait impairment in CA 
since patients are at an increased risk of falls and long-term disability. Previous studies of 
balance in patients with CA have focused on posturography (standing balance) (Bunn et al., 
2013, Diener et al., 1984, Ilg et al., 2018). From these studies, it is apparent that CA is 
characterised by larger postural responses than observed in healthy controls (Horak and 
Diener, 1994, Mummel et al., 1998), which progresses in line with the natural history of the 
disease (Nanetti et al., 2017, Zesiewicz et al., 2017) and is impacted disproportionately by 
dual-task conditions (Jacobi et al., 2015). These studies have also shown that measures of 
postural control have the potential to contribute to the differential diagnosis of hereditary 
ataxia subtypes (Schwabova et al., 2012). Posturography studies indicate that during stance, 
ataxia is associated with increased forward trunk flexion and reduced knee flexion (Küng et 
al., 2009). Other studies have reported ineffective anticipatory postural adjustments in 
ataxic individuals from the assessment of upper limb motion (Bruttini et al., 2015) and gait 
initiation (Timmann and Horak, 2001). 
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Meanwhile, motion capture studies have observed large trunk displacements, and 
exaggerated ankle instability in ataxic cohorts as well as impaired head and trunk range of 
motion and displacement (Conte et al., 2014). More recently insufficient coordination 
between the upper and lower body segments was identified in terms of angular position and 
angular velocity (Caliandro et al., 2017).  
Inertial sensors offer a more flexible approach to movement analysis in comparison to 
motion capture. A number of variables have been developed to capture various aspects of 
posture quality during gait. These have mostly been used in the monitoring of Parkinson’s 
Disease and ageing (Siragy and Nantel, 2018) and are not commonly used to examine Ataxic 
cohorts. Therefore, there is still an opportunity to expand the characterisation of ataxic gait. 
Ataxic gait has previously been expressed as a reduced smoothness both in terms of Jerk 
signal (Baldinotti et al., 2010, Fazio et al., 2013), and harmonic ratio (Ilg et al., 2019) as well 
as magnitude of accelerations which correlates with disease severity (Shirai et al., 2015). 
Meanwhile, step regularity (autocorrelation coefficient) and degree of body sway (ratio of 
direction root mean square to root mean square vector magnitude) are also impacted 
(Matsushima et al., 2015). In addition, impaired angular displacement and velocity of trunk 
motion have been identified in CA during walking (Van de Warrenburg et al., 2005a). Many 
of these variables, the jerk signal especially, are inherently confounded by the movement 
speed (Hogan and Sternad, 2009). The jerk ratio was proposed as a dimensionless parameter 
that is able to assess stability during walking while avoiding speed as a confounding factor 
(Brodie et al., 2014).  
Although, many gait studies have only implemented a single waist-worn sensor, postural 
coordination includes upper trunk and forehead. Therefore, to measure gait quality entirely, 
the Coefficient of Attenuation can be implemented to assess attenuation of acceleration 
between levels of the trunk. In people with CA, the reduced intersegmental coordination 
results in a highly variable walking pattern which requires postural adjustment on a step to 
step basis (Ilg et al., 2018). This means they are unable to compensate for the inherent 
instability of walking and falls are common especially during slow-paced walking (Schniepp 
et al., 2016). Since a reduction in walking speed is a common compensation for individuals 
experiencing reduced balance performance, it is important to fully understand the 
pathophysiological mechanisms behind this. 
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Therefore, the examination of the impact of changing gait speed, disease severity, as well as 
the upper body motion, is warranted. Also, simultaneously studying postural control and 
spatiotemporal parameters will allow the full characterisation of the ataxic gait pattern. This 
will establish the limits of the sensitivity of gait measurement as a biomarker for disease 
severity, gait disability and risk of falls in CA. Identification of biomarkers specific to disease 
severity and sensitive to disease progression is necessary to develop well-evidenced clinical 
guidelines and interventions for CA. 
4.1.1. AIMS AND OBJECTIVES 
This study aimed to objectively quantify the CA gait pattern and differentiate CA from 
healthy individuals. Spatiotemporal gait parameters and upper-body motion characteristics 
will be measured concurrently. This will enable:  
• Characterisation of CA gait in preferred-paced walking, while examining the influence 
of gait speed.  
• Comparison against clinical measures of disease severity (Scale for Assessment and 
Rating of Ataxia (SARA) and balance performance (Berg Balance Scale, BBS). 
4.2. METHODS 
4.2.1. STUDY INFORMATION 
This observational case-control study is incorporated by STH19282 and SCH2048 “Gait 
Analysis in Cerebellar Ataxia and Hereditary Spastic Paraparesis”, which is sponsored by the 
Sheffield Children’s Hospital. This project aims to detect subtle gait characteristics of ataxia. 
This study was conducted, according to the Declaration of Helsinki, and received ethical 
approval by the North West - Liverpool East Research Ethics Committee (REC: 16/NW/0343). 
Local approvals were obtained from the Sheffield Children’s Hospital as study sponsor and 
the Sheffield Teaching Hospitals Trust as the site of data collection. All testing took place at 
the Clinical Research Facility at the Northern General Hospital, Sheffield. All participants 
signed an informed consent form. Data collection took place between October 2016 and 
August 2018. 
4.2.2. PARTICIPANTS 
Participants with a diagnosis of CA were recruited, as well as healthy individuals as control 
participants. Individuals were identified through the Sheffield Clinical Genetics Service in the 
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context of the following criteria. This was intended to confirm CA diagnosis and participants’ 
ability to consent as well as the ability to complete the walking tasks unaided although some 
participants used walking aids in daily life.  
Inclusion: 
• Confirmed diagnosis of cerebellar ataxia 
• Capable of giving consent 
Exclusion: 
• Under 18 years old 
• Unable to walk for 10m unaided 
• Other comorbidities that affect walking e.g. knee replacement 
Participant Information Sheets were distributed to those identified, detailing the study and 
inviting them to take part (Appendix 11). Volunteers were also sought through Ataxia UK and 
its local patient support group via posters (Appendix 12).  
A cohort of healthy controls was recruited amongst participant’s family members and 
university staff. Following recruitment and data collection in a large cohort of healthy 
controls, a number of healthy participants were selected based on the patient cohort’s 
average age. 
4.2.3. PROTOCOL & CLINICAL ASSESSMENT 
Prior to each assessment visit, written informed consent was established (Appendix 13). 
Then guided by a structured medical interview, participants underwent examination 
including medical history and neurological examination (Appendix 14) with findings captured 
via a standard clinical report form. 
Participants were advised to dress comfortably and wear their own flat-soled everyday 
shoes during testing. This reduced any impact of participant’s attire on walking gait and 
enables the equipment to detect footfalls without difficulty whilst preserving their 
comfortable walking pattern and in the interests of safety. 
Height and mass measurements were taken to establish Body Mass Index (BMI) as well as 
the measurement of exterior leg length (greater trochanter of the hip to the floor) for the 
purposes of data standardisation. 
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A clinical assessment of the participants cognition, balance and ataxia symptoms/severity 
were assessed using the Montreal Cognitive Assessment (MoCA, Nasreddine et al., 2005), 
the Berg Balance Scale (BBS, Berg et al., 1995) and the Scale for Assessment of Ataxia (SARA, 
Schmitz-Hübsch et al., 2006), respectively. The MoCA provides a measure of cognitive 
function, with a score of less than 24 out of 30 considered abnormal. Meanwhile, the BBS 
and SARA are validated methods of assessing falls risk and ataxia severity. The BBS provides 
a score out of 56, with less than 41 referring to medium to high risk of falls and change of 8 
points indicating a genuine change in function. Meanwhile, the SARA rates symptoms out of 
40 with a change of 8 overtime referring to a clinically relevant change. A score of 8 or lower 
has previously been defined as a cut off for independent gait status (Kim et al., 2011). The 
SARAgait&posture (SARAG&P) subscore was calculated as the sum of gait, stance and sitting 
subscores (Lawerman et al., 2017) 
Later, participants performed a short gait task, walking back and forth at least six times along 
a walkway of approximately 10m in length (total distance walked 60m). This allowed a 
suitable number of steps to be recorded without causing fatigue. For trials where a low 
number of steps are captured, for instance, due to a participant’s increased stride length and 
cadence, additional passes were completed. 
Each participant’s gait was assessed using the OptoGait photoelectric 5m gait analysis 
system with Boosted transmission bar (Microgate Corporation, Bolzano, Italy) while wearing 
five ADPM Opal triaxial inertial sensors (APDMInc, Portland, OR, USA) (see section 4.2.4 for 
further information on equipment used).  
Participants were asked to complete walking trial at a self-selected speed with instructions 
to “look straight ahead until turning on the spot at the end of the walkway and returning”. 
The use of different speeds enabled assessment of the influence of perceived gait speed on 
gait parameters. A short period of quiet standing was recorded at the start and end of each 
trial in order to discriminate starting and ending gait events during data analysis.  
In the interests of safety, participants were permitted to look at the floor to recognise the 
end of the system and requested not to step out of the system. Participants were instructed 
to allow sufficient space to turn comfortably at the end of each pass and advised that the 
test can be paused at any time should they need to rest for a short time and stopped if 
necessary. Participants were allowed a break between trials although in many cases this was 
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unnecessary. Examiners were on hand at all times at either end of the walkway so did not 
guard the participants as they walked the trial. Data collection sessions lasted 1-1.5hours per 
participant excluding configuration of the systems which was completed before their arrival.  
4.2.4. EQUIPMENT 
Gait analysis was performed on participants using two gait analysis systems: the OptoGait 
LED array system (Microgate Corporation, Bolzano, Italy) and the ADPM Opal system of 
triaxial inertial sensors (APDMInc, Portland, OR, USA) as previously validated (see Chapter 3).  
All data gathered for the purposes of the study was backed up to an encrypted external hard 
drive and stored in a locked cupboard within the Sheffield Institute for Translational 
Neuroscience, the University of Sheffield alongside completed study report forms. Signed 
consent forms were stored within the site file and lists of recruited participants maintained 
regularly.  
The OptoGait 5m system was configured in a two-dimensional formation (as depicted in 
Figure 4.1a) to provide a 10m x 2m capacity of the system with approximately 4m of two-
dimensional assessment space. To compensate for the height of LEDs from the ground, the 
system was configured to register a heel-strike event when at least 3 LEDs are activated 
during the participant’s footfall following manufacturers recommendations. The threshold of 
3 LEDs was also used to register a final contact event. OptoGait’s built-in software captures 
and records data to measure several spatiotemporal gait parameters, including step width, 
with a spatial resolution of 1.041cm and sampling frequency of 1000Hz.  
Meanwhile, each participant’s motion during walking was also assessed with an inertial 
measurement unit (IMU) system (ADPM Opal sensors via Motion Studio software, APDM 
Inc., Portland, OR, USA). These contain an accelerometer, a gyrometer and a magnetometer, 
sampling movement at 128Hz in three directions (x-axis pointing downward, y-axis pointing 
laterally and z-axis pointing forward) (Figure 4.1b). Sensors were attached to the patient via 
velcro straps and adhesive tape at five positions: the forehead, top of the back in line with 
the 7th Cervical vertebra (C7) to represent the level of the shoulders, bottom of the back in 
line with the 5th lumbar vertebra (L5) to represent the level of the pelvis and on the ventral 
side of the left and right ankles (Figure 4.1c). These positions were selected to represent the 
3 segments of the trunk. Correct orientation of the devices was confirmed prior to the start 
of trials. 
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In order to synchronise data capture between the two systems, a custom-made cable was 
acquired to connect the IMU and photoelectric systems and external “trigger” signal 
configured to initiate and terminate recordings. Further details of this can be found in 
Appendix 15.  
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Figure 4.1: Gait analysis equipment outline 
a) ADPM Opal triaxial inertial sensor with Velcro strap attachment b) position of IMU sensor 
attachments at both lower shanks, forehead, upper trunk (7th cervical vertebrae), lower back (5th 
lumbar vertebrae) c) the OptoGait system contains LEDs at regular intervals which transmit across 
the walkway d) the walkway was assembled in a two-dimensional configuration with bars either side 
and at either end. 
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4.2.5. DATA ANALYSIS 
4.2.5.1. Spatiotemporal Gait Parameters 
The OptoGait photoelectric systems software automatically detects the temporal and spatial 
location using intersecting LED transmissions. Appropriate identification of footfalls was 
verified visually and trial results exported to Microsoft Excel. Only footfalls where both initial 
contact and final contact were considered to begin within the system were included to 
ensure accurate detection of initial and final contact events for calculation of gait 
parameters.  
Gait parameters of interest here include measurement of speed (m/s), cadence (steps/ min), 
step time (s), stride time (s), step length (cm), stride length (cm), step width (cm), walking 
base (cm), stance phase (% cycle), swing phase (% cycle), single support phase (% cycle), 
double limb support phase (% cycle). The OptoGait system is also able to compute the 
duration and proportion of finer cycle phases such as pre-swing, loading response, contact, 
flat, propulsive, and flight. For further explanation of gait parameters, see Figure 1.1. 
In order to verify accuracy of the gait event detection with results of our validation study 
(Chapter 3), initial contact (heel strike) time (s) from the external trigger time as well as step 
time (s), stride time (s) and stance time (s) were extracted and final contact time (s) 
computed as initial contact plus stance time. 
For each walking trial captured, descriptive statistics (average and standard deviation (SD) of 
Left, Right and All steps) were computed for each gait parameter using MATLAB (Mathworks 
Inc., Natick, MA, USA) through custom computational programmes in preparation for cohort 
level-analysis. The within-person variability of these parameters was considered through the 
calculation of the coefficient of variation (CV, expressed as a percentage) (Equation 4.1) 
where SD and mean are calculated for each gait measure for left and right combined. 
Coefficient of variation is a commonly used measure of overall within-person gait variability 
and previously reported in ataxic cohorts (Ebersbach et al., 1999, Gouelle et al., 2013, Ienaga 
et al., 2006, Palliyath et al., 1998, Schmitz-Hübsch et al., 2016, Schniepp et al., 2014, Serrao 
et al., 2012)).Meanwhile, computing left-right asymmetry (Equation 4.2) from absolute 
Equation 4.1: Coefficient of Variation (%) = SD mean⁄ × 100 
Equation 4.2: 𝐴𝑠𝑦𝑚𝑚𝑒𝑡𝑟𝑦 = [𝑚𝑒𝑎𝑛 𝐿𝑒𝑓𝑡 − 𝑚𝑒𝑎𝑛𝑅𝑖𝑔ℎ𝑡] 
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difference of mean gait measures recorded for left and right feet enables an appreciation of 
step to step differences (Godfrey et al., 2015). 
4.2.5.2. Upper body Motion Gait Parameters 
Motion inertial data were analysed using MATLAB (Mathworks Inc., Natick, MA, USA) in the 
same way as Chapter 3. Trial data were segmented into single straight-line sections of passes 
by assessing the location of turn phases using the peak in the mediolateral angular velocity 
from the lumbar sensor (Figure 4.2). Direction change was also indicated by changes in 
smoothed orientation signals (locally weighted quadratic polynomial regression function). 
Gait events were identified using the method defined by Salarian et al., (2004) (as Chapter 3, 
see Figure 3.4). From the timing of these gait events, a temporal parameters were computed 
(stride time, step time, stance time) for comparison again the OptoGait system. 
A number of variables were calculated on a stride-stride basis from upper body sensors. The 
acceleration signals from the pelvis, shoulder and forehead were transformed to a 
horizontal-vertical orthogonal coordinate system as described by Moe-Nilssen et al (1998). 
This assumes that the device is positioned securely so that the measured anteroposterior 
(AP) acceleration vector is in the sagittal plane relative to a walking participant throughout 
the gait cycle but corrects for the forward inclination of the trunk during walking to ensure 
the accuracy of later analysis. Computational analysis of transformed signals was then 
completed to included: Root Mean Square (RMS) of accelerations (at each of the three 
levels) (Helbostad and Moe-Nilssen, 2003), Coefficient of Attenuation (between the three 
levels) (Mazza et al., 2008), followed by Harmonic Ratio (Latt et al., 2008), RMS Jerk and Jerk 
Ratio (also at the three levels, (Brodie et al., 2014, Fazio et al., 2013)). Auto-correlation 
coefficient analysis for step and stride durations were computed for each pass within the 
walking trial (Moe-Nilssen and Helbostad, 2004). Meanwhile, root mean square ratio (RMSR) 
normalises directional acceleration by vector magnitude to control for walking speed (Sekine 
et al., 2013). Details of the analysis of motion at the head, trunk and pelvis levels can be 
found in Table 4.1. Descriptive analysis of upper-body gait parameters was then completed 
per participant in MATLAB prior to export in preparation for cohort statistical analysis. 
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Figure 4.2: Depiction of segmentation strategy for inertial gait signals. 
a) Absolute value of angular velocity signal from lumbar and ankle sensors to identify turn events b) segments of walking trial related to walking and turning 
c) identification of turns based on the change in smoothed orientation signal. 
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Table 4.1: Upper Body motion parameters analysis calculations 
Measure (with reference)  Description  Computation performed  
RMS Accelerations  
(Helbostad et al 2003)  
Measure of the magnitude of 
accelerations  
Root of mean square of Accelerations 
for each stride in AP, ML, V at the 
head, shoulder, Pelvis  
RMS Jerk  
(Fazio et al 2013)  
RMS of the first time derivate of 
each component of the 
acceleration signal  
Root of mean square of differentiation 
of acceleration signals in AP, ML, V at 
the head, shoulder, pelvis.  
Harmonic ratio  
(Latt et al 2008)  
Measure of step to step 
asymmetry of acceleration 
components within a stride  
Discrete Fourier transform for each of 
the acceleration components 
measured at head, shoulder, pelvis. 
The fundamental frequency was set 
equal to the stride frequency.  
For the AP and V components: 
 
For the ML component: 
 
Coefficient of Attenuation  
(Mazza et al 2008)  
Measure of degree of attenuation 
of accelerations in AP, ML, V 
achieved by the upper body 
between pelvis & head, pelvis & 
shoulder, and shoulder & head. 
 
Jerk Ratio  
(Brodie et al 2014)  
Normally distributed and 
dimensionless measure of 
stability  
Log ratio of RMS Jerk AP/V, ML/V at 
head, shoulder, pelvis  
Root mean square ratio  
(Sekine et al 2013)  
Normalised for vector magnitude 
to control for walking speed  
Ratio of root mean square acceleration 
in each direction (RMSx) to the root 
mean square vector magnitude (RMST) 
in AP, ML, V at head, shoulder, pelvis  
Autocorrelation coefficients (Moe-Nilssen and Helbostad 2004)  
Step regularity index (AD1 
coefficient)  
Measure of the regularity across 
consecutive steps  
Peak value at the first dominant period 
in AP, ML, V at head, shoulder, pelvis  
Stride regularity index (AD2 
coefficient)  
Measure of the regularity across 
consecutive strides  
Peak value at the second dominant 
period in AP, ML, V at head, shoulder, 
pelvis  
Auto-Symmetry  Ratio of step/stride regularity  Symmetry = 𝐴𝐷1/𝐴𝐷2  




Σamp .  of  even  harmonics
Σamp .  of  odd  harmonics
 
HR = 
Σamp .  Of  odd  harmonics
Σamp .  Of  even  harmonics
 
𝐶𝑃𝐻 = (1 −
𝑅𝑀𝑆𝐻
𝑅𝑀𝑆𝑃
) × 100 
𝐶𝑃𝑆 = (1 −
𝑅𝑀𝑆𝑆
𝑅𝑀𝑆𝑃
) × 100 
𝐶𝑆𝐻 = (1 −
𝑅𝑀𝑆𝐻
𝑅𝑀𝑆𝑆
) × 100 
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4.2.6. STATISTICAL ANALYSIS 
Power analysis was completed based on the results from our systematic review of 
spatiotemporal gait characteristics (Chapter 2, (Cohen, 1988, Wolf and Wolf, 1986)). This 
calculation indicates that for many spatiotemporal gait measures an between 2-47 patients 
are required to achieve statistical power for the majority of spatiotemporal parameters 
between CA and HC (Chapter 4). The variable requiring the largest number of participants 
per group were speed variability and DLS phase percentage requiring 46 and 47  individuals  
respectively (Table 2.5). As this has been calculated based on results of a meta-analysis, this 
estimate may over-inflate the difference between cohorts and should only be used as a 
guide. Since upper body variables of motion have not been consistently measured in CA 
previously, it is not possible to calculate the appropriate sample size. 
Participant results for each system were assembled into a single data table and imported 
into SPSS Statistics (version 23, IBM) for cohort level statistical analysis. Descriptive analysis 
(average and standard deviation) was completed for demographic characteristics. 
In order to check the validity of the gait event detection by the two systems, a number of 
statistical tests were used including Paired samples t-test, intraclass correlation coefficient 
for random effects consistency (ICC(2,1)), standard effects estimates (SEE). 
Descriptive analysis was also completed for spatiotemporal gait characteristics and upper 
body motion gait measures to compare ataxic and healthy control cohorts during the 
preferred speed trial. Normality of the datasets was tested using Shapiro Wilks tests, then 
between-group differences assessed through independent t-tests (parametric) and Wilcoxon 
signed-rank tests (non-parametric) following Levene’s tests for equality of variance. A 
significant result was indicated by p-value <0.05. No adjustment for multiple comparison was 
made but effect sizes calculated to examine the statistical power for the test.  
Z score (Equation 4.3) and effect size calculated (Equation 4.4) where thresholds of 0.1, 0.3, 
and 0.5 were recommended by Field (2018) for small, medium, and large effect sizes, 
respectively. 










Pearson’s Correlation/ Spearman’s Rho Correlation analyses were completed for all variables 
to observe those that correlate with the SARA and BBS scores and gait speed. 
To examine the influence of disease severity, participants were separated into subgroups 
related to the SARA scores (≤8 vs >8). For normally distributed data, one-way ANOVA tests 
and Welch’s tests of equality of means followed by post hoc Tukey/ Games Howell tests for 
multiple comparisons. Where non-normally distributed data were indicated by Shapiro-Wilks 
tests, Kruskal-Wallis tests were completed followed by Mann Whitney U tests for each 
subgroup comparison. Univariate regression analyses, adjusted for age, sex and gait speed, 
as covariates, were used to determine subgroup differences in gait variables.  
To aid selection of parameters that may be sensitive to longitudinal change in preparation 
for Chapter 5 (longitudinal assessment), those measures that were significantly different 
between CA vs HC, able to discriminate HC to mild ataxia and mild ataxia to moderate ataxia 
in both hypotheses tests and adjusted regression analyses were considered. This approach 
intended to reduce to the number of measures selected, avoiding those that are 
considerably interrelated with speed and interchangeable with other variables (i.e. swing/ 
single support phase). Z scores for the selected variables for the CA cohort were displayed in 
radar plots to indicate the between group differences in hypotheses tests and adjusted 
regression analyses where HC cohort specified as Z=0.  
Partial correlation analysis was completed to examine the association between 
spatiotemporal and upper body variables independent of gait speed. 
4.3. RESULTS 
4.3.1. PARTICIPANT CHARACTERISTICS 
27 CA patients were recruited to the present study. The participants in the ataxic cohort 
reported high blood pressure, depression, vertigo, and benign prostatic hyperplasia but we 
were not made aware of any disqualifying medical history or medications (Table 4.2). From a 
group of healthy participants, 27 individuals were selected to provide an age-matched 
control cohort (Table 4.3). Table 4.4 contains the summarised demographics of the patient 
and control cohorts. No significant differences were discovered between the cohorts in age, 
height, mass or leg length. The patient cohort performed significantly worse on the SARA 
and BBS reflecting their reduced functional status and disease severity. A significant 
difference was also observed in the MoCA but all scores from the ataxic cohort were 
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considered to be within the normal range. Disease severity subgroups (≤/>8 SARA) were 
comparable on all demographic characteristics but there was a significant difference in SARA 
scores (p<0.01), SARAG&P (p<0.001) and BBS Scores (p<0.01) (Table 4.5). The moderate ataxia 
group differed significantly from Healthy control and Mild Ataxia cohorts in the MoCA.  
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P01 F 52 161 54 78 R 0 SCA6 6 N 14.5 6 29 53 N 
P02 M 58 150 70 82 R 14 SPG7 10 N 15 4 24 43 Y 
P03 M 54 174 70 77 R 5 SPG7 21 N 14 4 26 43 Y 
P04 M 51 162 82 78 L 0 •   N 10 3  27 41 Y 
P05 M 58 182 82 74 R 0 SPG7   Y 13 5 27 36 Y 
P06 M 53 187 81 90 R 6 SPG7 3 N 6 1 25 56 N 
P07 F 55 160 56 74 R 5 SCA6 21 Y 2 1 30 56 N 
P08 M 52 180 90 83 R 2 AD FHx 42 Y 13 5 26 31 Y 
P09 M 49 181 91 82 R 0 SPG7 10 Y 15 7 27 39 Y 
P10 M 52 175 91 73 R 23 SPG7 16 N 8.5 4 30 39 Y 
P11 F 61 171 60 80 R 3 SCA6 4 Y 2.5 1 29 56 N 
P12 F 45 170 73 79 R 10 SCA6 6 N 4.5 2 26 54   
P13 M 65 186 105 87 L 30 SCA6 10 N 10 5 25 42 N 
P14 F 57 161 41 84 R 0 SCA6 6 N 18 5 27 29 N 
P15 M 63 188 97 74 R 10 SPG7 2 N 11 6 26 36 Y 
P16 F 66 171 62 92 R 5 SPG7 0 N 4.5 2 24 44 N 
P17 M 65 181 63 75 L 5  • 10 N 10.5 4 28 51 N 
P18 M 37 175 73 73 R 0  •   N 11 3 25 41 N 
P19 F 26 161 56 67 R 5 CACNA1A 
missense 
  Y 8 3 30 47 N 
P20 M 53 175 73 83 R 0 SPG7 7 Y 8.5 5 26 39 Y 
P21 F 19 161 62 67 R 5 SCA6 0.5 N 11.5 4 28 47 N 
P22 F 63 131 68 79 L 5 SCA6 1.5 N 11.5 4 26 52 N 
P34 M 50 181 86 102 L 0  • 4 N 13.5 4 28 40 N 
P35 M 62 178 82 96 R 5  • 20 N 11.5 3 27 40 N 
P36 M 67 170 113 80 L 28 SCA6   N 2 1 29 55 N 
P37 F 56 168 86 75 R   SCA6 6 Y 9 5 29 35   
P38 M 71 167 81 83 R 5 SCA6 6 N 8.5 3 28 52 N 
Abbreviations: M-Male, F-Female, •- no genetic diagnosis available at time of testing. SCA6 – 
spinocerebellar ataxia 6, SPG7 – spastic paraplegia 7, AD FHX – autosomal dominant family history, Y-
Yes, N-No, UMN-upper motor neuron signs, SARA- Scale for Assessment and Rating of Ataxia, BBS – 
Berg Balance Scale, MoCA-Montreal Cognition Assessment. 
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C02 F 49 162 80 74 R 8 30 56 
C03 F 59 167 74 78 R 14 28 56 
C04 F 62 175 65 79 R 30 30 56 
C05 F 55 161 79 75 R 0 28 56 
C06 F 52 158 53 72 R 5 29 56 
C07 M 59 173 82 74 R 10 27 56 
C08 M 47 188 86 73 R 40 30 56 
C09 M 72 161 92 83 R 2 27 56 
C10 F 62 173 54 80 R 14 27 56 
C11 F 54 173 95 78 R 0 29 56 
C12 M 65 170 70 73 R 0 28 56 
C13 M 45 179 80 77 R 0 28 56 
C14 M 49 185 73 77 R 14 28 56 
C16 F 35 161 66 70 R 14 29 56 
C17 F 46 170 72 94 R 6 28 56 
C18 M 66 172 146 79 R 3 28 56 
C21 F 59 176 86 79 R 5 29 56 
C23 F 44 173 79 96 R 5 30 55 
C24 M 45 193 85 105 R 14 29 55 
C25 F 50 161 113 71 R 0 29 56 
C26 M 65 161 81 85 R 5 27 56 
C27 F 64 157 60 73 R 0 28 56 
C28 M 57 175 60 85 R 0 30 56 
C29 M 58 161 71 75 R 0 28 56 
C30 F 52 163 75 75 R 0 27 56 
C31 F 53 161 80   L 5 28 56 
C32 F 44 168 74 85 R 5 30 56 




Table 4.4: Cohort demographics 
 Cerebellar ataxia (n=27, 10F) Healthy Control (n=27, 16F) p 
Age (years) 55 [51, 63] 54 [47, 62] 0.63 
Height (cm) 171 [161, 181] 170 [161, 175] 0.38 
Mass (kg) 73 [62, 86] 79 [70, 85] 0.82 
Leg Length (cm)  80 [75, 83] 78 [74, 83] 0.40 
Diagnosis subtype 11 SCA6, 9 SPG7, AD FHx, CACNA1A ---- ---- 
Duration of diagnosis 9.6±9.6yrs ---- ---- 
Falls history 19 Non-Fallers, 8 Fallers ---- ---- 
Alcohol intake 6.6±8.4 7.4±9.6 ---- 
SARATotal (/40) 10.5 [8.0, 13.0] ---- ---- 
SARAGait&Posture (/18) 4 [3, 5] ---- ---- 
BBS (/56) 43 [39, 52] 56 [56, 56] <0.001 
MoCA (/30) 27.0 [26, 29] 28 [28, 29] <0.01 
UMN signs 9 ---- ---- 
Data reported as median [Interquartile Range]. Abbreviations: n-number participants, F-number of 
female participants, SARA-Scale for Assessment and Rating of Ataxia, BBS-Berg Balance Scale, MoCA-
Montreal Cognitive Assessment, UMN-Upper motor neuron, SCA-Spinocerebellar ataxia, SPG- Spastic 
paraplegia, AD FHx-Autosomal dominant family history, CACNA1A-Calcium Voltage-Gated Channel 
Subunit Alpha1 A missense mutation 
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Table 4.5: Disease subgroup cohort demographics 
 Healthy Control 
(n=27, 16F) 






Age (yrs) 54 [47, 62] 55 [45, 66] 55.0 [51, 63] 0.88 
Height (cm) 170 [161, 175] 170 [161, 171] 175 [161, 181] 0.48 
Mass (kg) 7 [70, 85] 62 [56, 81] 82 [69, 89] 0.34 
Leg Length (cm)  78 [74, 83] 80 [74, 90] 79 [75, 83] 0.65 
Diagnosis subtype ---- 4 SCA6, 2 SPG7, 
CACNA1A 
7 SCA6, 8 SPG7, AD 
FHx 
 
Duration of diagnosis ---- 6.8±8.2yrs 10.5±10.0yrs 0.47 
Falls history ---- 3 Fallers 5 Fallers 0.39 
Alcohol intake 7.4±9.6 8.9±8.7 5.7±8.3 0.41 
SARA (/40) ---- 4.5 [2.0, 6.0] 11.5 [10.0, 13.9] <0.001 
SARAGait&Posture (/18) ---- 1 [1, 2] 4 [4, 5] <0.001 
BBS (/56) 56 [56, 56] 55 [47, 56] 41 [37, 46] <0.001a,b,c 
MoCA (/30) 28 [28, 29] 29 [25, 30] 27 [26, 28] <0.01a,b 
Data reported as median [Interquartile Range]. Between group differences indicated by significance 
level from statistics tests conducted as discussed where posthoc test results indicates by a: healthy 
control vs mild ataxia b: healthy control vs moderate ataxia c: mild ataxia vs moderate ataxia. 
Abbreviations: n-number participants, F-number of female participants, SARA-Scale for Assessment 
and Rating of Ataxia, BBS – Berg Balance Scale, MoCA-Montreal Cognitive Assessment, UMN- Upper 
motor neuron, SCA-Spinocerebellar ataxia, SPG- Spastic paraplegia, AD FHx-Autosomal family history, 
CACNA1A -Calcium Voltage-Gated Channel Subunit Alpha1 A missense mutation 
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4.3.2. GAIT ASSESSMENT 
4.3.2.1. Validity of Data Collection 
During manual verification of each participant’s trial data for the OptoGait system, issues 
were present within some the participant trials. These issues were related to the detection 
of footfall location with invalid flight time and overlooked steps. For passes within walking 
trials where unresolvable issues were identified, the steps before/after the problem step 
were removed from analysis dependent on the location of the step within the pass in order 
to retain as much data as possible. 
For both healthy controls and CA participants, a mean 34.4±4.8 steps were captured by the 
OptoGait, while the ADPM Opal sensors algorithms detected 30.3±9.5 steps. A total of 866 
steps (404 and 462 steps in ataxia and controls respectively) were captured by both systems 
synchronously. There were also 666 stride times and 1066 stance time durations captured.  
Table 4.6 and Table 4.7 shows the results of the intercorrelation coefficient and paired T-
Test results. Values for initial contact and final contact gait events as well as step time, stride 
time and stance times estimated by the two systems showed good to excellent agreement. 
Although, there was a significant mean difference in stance time between systems, these 
differences were comparable to values identified previously (Chapter 3). 
Figure 4.3 and Figure 4.4 displays Bland-Altman plots for the correlation of differences and 
absolute differences between systems by trial, labelled by cohort membership within each 
trial completed. No clear clustering of data points is apparent for the cohorts, indicating that 
accuracy is equal for ataxic and healthy individuals.  
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Table 4.6: Study Gait Event comparison  
Initial Contact (n=36) Final Contact (n=36) 
ICC(2, 1) (95% CI) 1.000 (0.998,1.000)** 1.000 (0.996,1.000)** 
R2 1.000 1.000 
Absolute System Difference (Mean [95% LoA]) 0.06s [0.01s, 0.11s] 0.08s [0.07s, 0.09s] 
System Difference (Mean [95% LoA]) -0.06s [-0.11s, -0.01s] -0.08 [-0.09s, -0.07s] 
SEE 0.03 0.02 
p <0.001 <0.001 
Between system comparison reported for trials capture for 15 Ataxia participants and 21 healthy 
controls. Abbreviations: n-number of gait events contributing to statistical tests. ** p<0.01 
 
 
Figure 4.3: Study Gait Event comparison  
Results plotted for Initial contact and final contact gait events measured in healthy controls (blue) 
and cerebellar ataxia (red) as above. Correlation plots for OptoGait: Opal values include reference 
line x=y (--) and correlation line (..). Bland altman plots for differences and absolute differences 
between systems plotted against mean value with mean difference (---)and 95%CI (-.-) indicated.  
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Table 4.7: Study Temporal Gait Parameter Comparison 
 Step Time Stride Time Stance Time 
OptoGait Mean (SD) 0.55s (0.05) 1.10 (0.10) 0.63 (0.08) 
Opal Mean (SD) 0.55s (0.05) 1.10 (0.02) 0.66 (0.08) 
ICC(2, 1) (95% CI) 0.997 (0.993, 0.998)** 0.998 (0.997, 0.999)** 0.856 (0.592, 0.939)** 
R2 0.993 0.997 0.804 
Absolute System Difference 
(Mean [95% LoA]) 
0.02s [0.00s, 0.05s] 0.02s [0.00s, 0.04s] 0.04s [0.01s, 0.08s] 
System Difference (Mean 
[95% LoA]) 
0.00s [-0.01s, 0.01s] 0.00s [-0.01s, 0.01s] -0.02s [-0.09, 0.05] 
SEE 0.004s 0.01s 0.03s 
p 0.321 0.197 <0.001 
Between system comparison reported for trials capture for 15 Ataxia participants and 21 healthy 
controls. Abbreviations: n-number of gait events contributing to statistical tests. ** p<0.01 
 
Figure 4.4: Study Gait Parameter Comparison 
Results plotted for step time, stride time and stance time gait parameters measured in healthy 
controls (blue) and cerebellar ataxia (red) as above. Correlation plots for OptoGait: Opal values 
include reference line x=y (--) and correlation line (..). Bland altman plots for differences and absolute 
differences between systems plotted against mean value with mean difference (---) and 95%CI (-.-) 
indicated.  
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4.3.2.2. Spatiotemporal Gait Parameters 
Table 4.8 shows spatiotemporal gait characteristics measured during preferred paced 
walking. Self-paced walking gait velocity was on average lower in the patient cohort than the 
control cohort (1.13±0.25m/s vs 1.34±0.20m/s, p<0.01). While step length and stride length 
were both significantly shorter in the patient cohort than controls (62.1±9.8cm vs 
71.7±8.0cm, p<0.001; 124.5±19.7cm vs 143.5±16.0 cm, p<0.001 respectively), step width 
was significantly larger in the ataxic cohort on average (16.9±5.0cm vs 11.7±2.9cm, p<0.001). 
For the temporal parameters, no significant differences were observed. Significant step to 
step asymmetry was observed in the ataxic cohort compared with the control cohort for 
cadence (1.2 [0.5, 2.0] steps per min vs 0.5 [0.2s, 0.7] steps per min, p<0.01), stride time 
(0.01s [0.01, 0.02] vs 0.01s [0.002, 0.01], p<0.01), swing time (0.01±0.01s vs 0.00±0.00, 
p<0.01), swing phase (0.8 [0.3, 1.4]% vs 0.4 [0.2, 0.6]%, p<0.01) and single limb support (SLS) 
(0.9 [0.5, 1.4]s vs 0.5 [0.1, 0.9]s, p<0.01). Gait analysis reveals a significantly greater 
variability (coefficient of variation, %CV) in the majority of spatiotemporal gait parameters, 
in the ataxic group than in controls with the exclusion of step width variability.  
Across all the spatiotemporal gait characteristics and upper body motion measures, strong 
significant correlations with the disease severity (SARA score) were observed in very few 
variables. Those spatiotemporal variables indicating the strongest association with the SARA 
score were stride length variability, step length variability, swing time/ phase variability and 
SLS time variability.  
Correlation analysis based on speed in the ataxic cohort indicates that many spatiotemporal 
variables are associated with patient speed. For instance, cadence, stride length, step length 
as well as swing phase and SLS phase exhibit a good to an excellent positive correlation with 
gait speed. Meanwhile, the following parameters showed a good to an excellent negative 
correlation with speed: stride time, step time, stance time, DLS, stance phase, along with the 
variability of cadence, stride time, stance time, swing time, SLS, swing time phase, and SLS 
phase. Correlation analysis based on BBS scores in the ataxic cohort indicates that many 
variables are associated with an impaired balance performance related to increased risk of 
falls: speed, cadence, stride time, step time, stance time, DLS, stance phase, swing phase, 
SLS phase, DLS phase, as well as many measures of variability (cadence (%CV), swing time 
(%CV), SLS (%CV), swing phase (%CV), SLS phase (%CV)) (Table 4.8). 
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Table 4.8: Spatiotemporal Gait Parameters with mean, symmetry and variability measures.  
 
CerebellarAtaxia (n=27) HealthyControl (n=27) p 
Correlation (r) 
d SARA BBS Speed 
Spatiotemporal Measures  
Speed (m/s) 1.13 (0.25) 1.34 (0.20) <0.01 -0.451* 0.568** --- -0.06 
Cadence (steps/min) 108.7 [98.4, 117.4] 111.6 [107.0, 119.1] 0.312 -0.446* 0.532** 0.705** -0.18 
Stride Time (s) 1.10 [1.03, 1.22] 1.08 [1.01, 1.12] 0.280 0.446* -0.532** -0.709** 0.02 
Step Time (s) 0.55 [0.51, 0.61] 0.54 [0.50, 0.56] 0.312 0.435* -0.557** -0.719** 0.02 
Stride Length (cm) 124.5 (19.7) 143.5 (16.0) <0.001 -0.301 0.432* 0.909** -0.61 
Step Length (cm) 62.1 (9.8) 71.7 (8.0) <0.001 -0.299 0.425* 0.906** -0.44 
Step Width (cm) 16.9 (5.0) 11.7 (2.9) <0.001 0.364 -0.545** -0.438** 0.36 
Stance Time (s) 0.63 [0.58, 0.74] 0.60 [0.57, 0.66] 0.177 0.488** -0.667** -0.808** 0.02 
Swing Time (s) 0.47 (0.05) 0.46 (0.03) 0.828 0.152 0.013 -0.022 0.00 
SLS (s) 0.47 (0.05) 0.46 (0.03) 0.828 0.152 0.013 -0.022 0.00 
DLS (s) 0.18 [0.13, 0.21] 0.14 [0.12, 0.19] 0.169 0.452* -0.735** -0.800** 0.02 
Stance perc. (%cycle) 57.7 [56.6, 59.1] 56.5 [55.9, 58.6] 0.180 0.323 -0.617** -0.711** 0.11 
Swing perc. (%cycle) 42.3 [40.9, 43.4] 43.5 [41.4, 44.1] 0.204 -0.321 0.613** 0.710** -0.10 
SLS perc. (%cycle) 41.7 [40.8, 43.8] 43.3 [41.7, 44.1] 0.172 -0.356 0.690** 0.731** -0.09 
DLS perc. (%cycle) 16.3 [12.6, 18.4] 13.5 [11.5, 17.0] 0.192 0.336 -0.643** -0.730** 0.14 
Asymmetry Measures  
Speed (m/s) 0.01 [0.01, 0.02] 0.01 [0.003, 0.02] 0.299 -0.052 -0.117 0.152 0.01 
Cadence (steps/min) 1.2 [0.5, 2.00] 0.5 [0.2, 0.72] <0.01 -0.064 0.119 -0.030 0.13 
Stride Time (s) 0.01 [0.01, 0.02] 0.01 [0.002, 0.01] <0.01 0.034 -0.084 -0.216 0.01 
Step Time (s) 0.01 [0.001, 0.02] 0.01 [0.001, 0.01] 0.088 0.001 -0.112 -0.091 0.01 
Stride Length (cm) 1.1 [0.4, 1.60] 0.5 [0.3, 1.33] 0.268 0.418* -0.270 0.060 0.06 
Step Length (cm) 0.9 [0.7, 2.30] 0.9 [0.4, 1.49] 0.346 0.212 -0.266 -0.055 0.07 
Step Width (cm) 1.4 [0.6, 2.41] 0.8 [0.3, 1.72] 0.071 -0.298 0.201 0.049 0.05 
Stance Time (s) 0.005 [0.002, 0.01] 0.004 [0.002, 0.01] 0.250 0.056 -0.202 0.132 0.01 
Swing Time (s) 0.01 [0.01, 0.02] 0.00 [0.00, 0.01] <0.001 0.439* -0.405* -0.437** 0.01 
SLS (s) 0.01 [0.004, 0.02] 0.00 [0.001, 0.01] <0.01 0.485* -0.426* -0.342* 0.01 
DLS (s) 0.004 [0.001, 0.01] 0.005 [0.002, 0.01] 0.653 0.229 -0.284 0.050 0.00 
Stance perc. (%cycle) 0.5 [0.2, 1.3] 0.5 [0.3, 0.7] 0.413 0.068 -0.290 0.112 0.08 
Swing perc. (%cycle) 0.8 [0.3, 1.4] 0.4 [0.2, 0.6] <0.01 0.357 -0.050 -0.122 0.12 
SLS perc. (%cycle) 0.9 [0.5, 1.4] 0.5 [0.1, 0.9] <0.01 0.442* -0.446* -0.215 0.10 
DLS perc. (%cycle) 0.5 [0.2, 1.0] 0.4 [0.1, 0.8] 0.421 -0.047 -0.125 0.029 0.04 
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Variability Measures  
Speed (%CV) 5.4 [4.2, 7.7] 3.0 [2.5, 4.5] <0.001 0.472* -0.538** -0.462** 0.26 
Cadence (%CV) 3.5 [2.9, 5.9] 1.6 [1.3, 2.3] <0.001 0.385* -0.445* -0.615** 0.31 
Stride Time (%CV) 3.5 [2.9, 5.8] 1.6 [1.3, 2.3] <0.001 0.392* -0.461* -0.619** 0.31 
Step Time (%CV) 5.7 [4.3, 7.7] 2.8 [2.4, 3.7] <0.001 0.483* -0.455* -0.491** 0.34 
Stride Length (%CV) 3.7 [2.5, 6.0] 2.2 [1.9, 3.0] <0.001 0.545** -0.640** -0.415** 0.21 
Step Length (%CV) 5.6 [4.2, 8.4] 3.1 [2.7, 3.8] <0.001 0.583** -0.745** -0.488** 0.33 
Step Width (%CV) 27.8 [20.2, 38.3] 29.5 [22.9, 41.9] 0.551 0.037 0.171 0.250 -0.06 
Stance Time (%CV) 5.1 [4.0, 6.8] 3.1 [2.5, 3.5] <0.001 0.472* -0.454* -0.532** 0.29 
Swing Time (%CV) 5.9 [4.1, 8.1] 2.5 [2.3, 3.2] <0.001 0.629** -0.745** -0.620** 0.31 
SLS (%CV) 5.9 [4.1, 8.1] 2.5 [2.3, 3.2] <0.001 0.629** -0.745** -0.620** 0.31 
DLS (%CV) 14.5 [10.5, 22.4] 10.9 [8.3, 15.2] <0.05 0.102 0.128 0.145 0.29 
Stance perc. (%CV) 3.2 [2.4, 4.9] 1.9 [1.5, 2.1] <0.001 0.325 -0.315 -0.467** 0.25 
Swing perc. (%CV) 4.4 [3.2, 6.6] 2.5 [1.9, 2.9] <0.001 0.511** -0.578** -0.634** 0.26 
SLS perc. (%CV) 4.4 [3.7, 6.8] 2.9 [2.2, 3.5] <0.001 0.559** -0.616** -0.497** 0.26 
DLS perc. (%CV) 11.6 [8.6, 21.1] 9.4 [6.2, 12.3] <0.05 0.057 0.134 0.139 0.56 
Results for mean, symmetry, and variability measures of spatiotemporal gait parameters. Accompanied with results of parametric test used reported as 
mean(SD), and non-parametric test used reported as median [IQR]. Pearson’s/Spearmans correlation test used between parameters and SARA, BBS, and gait 
speed: |r|>0.6 * p<0.05, **p<0.01. |d|>0.3 indicates medium or larger effect size. Missing data: SLS asym and DLS asym (n=26). Abbreviations: n-number 
participants, r-correlation coefficient, s-seconds, cm-centimetres, %CV-coefficient of variation, SLS-single limb support, DLS-double limb support, perc.-
percentage cycle 
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4.3.2.3. Upper body Motion Gait Parameters 
Table 4.9 shows upper body motion gait characteristics measured during preferred paced 
walking. At the trunk and forehead, magnitude (Root mean square (RMS) acceleration) of 
the mediolateral (ML) axis of acceleration signals is significantly increased in CA vs healthy 
controls while those in the Vertical (V) axis are significantly reduced at the level of the trunk. 
Signal jerk is significantly increased in CA in the ML axis at the trunk and forehead and in the 
AP axis at the forehead. Values for stability, as measured by Jerk Ratio (which normalises to 
vertical (V) signal), was significantly higher in ML at all three sensor positions and in AP at 
the forehead in the CA cohort.  
The CA cohort also displayed a Root Mean Square Ratio (RMSR) that was significantly 
increased in the ML axis and reduced in vertical axis at all 3 sensor positions compared with 
the age-matched healthy cohort. AP RMSR was also significantly increased at the head. 
Attenuation (Coefficient of Attenuation, CoA) of AP components of acceleration signal 
between the pelvis and head, and trunk and head were significantly impaired in CA cohort 
compared with healthy controls. Meanwhile, attenuation of the vertical acceleration 
component was significantly higher in moving from the pelvis to shoulder and lower in 
moving from shoulder to head in the ataxic cohort than in the healthy cohort.  
Step and stride regularity (AD1, AD2) were significantly different across all three signal 
components and the resultant signal between cohorts at all three sensor positions. 
Meanwhile, step to step asymmetry of acceleration components within a stride (indicated by 
Harmonic Ratio), shows a significantly lower result for AP, ML and vertical components for 
the CA cohort at the lumbar and trunk sensors and the ML and vertical components at the 
forehead. For upper body motion metrics, harmonic ratio (lumbar and trunk in AP, lumbar, 
trunk and forehead in vertical), and autocorrelation coefficients (AD1ML lumbar, AD2V 
lumbar, trunk and forehead, AD2AP lumbar, AD2ML lumbar, AD2V forehead ) correlate most 
strongly with SARA score. 
Meanwhile, of the postural control variables tested, lumbar AP component and forehead 
vertical component Harmonic Ratio, trunk step regularity in vertical component and stride 
regularity at lumbar in AP and ML, trunk in AP and vertical and forehead in vertical, as well 
as trunk ML RMSR all showed a good to excellent strength, significant correlation with BBS 
score (Table 4.9). 
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Table 4.9: Upper body Motion Gait Parameters 





 Correlation (r)  
  p SARA BBS d 
Lumbar        
Magnitude (ms-2) AP 1.61 (0.35) 1.77 (0.38) 0.126 -0.281 0.371 -0.04 
ML 1.59 (0.38) 1.41 (0.37) 0.093 0.126 0.146 0.04 
V 2.13 (0.64) 2.33 (0.59) 0.249 -0.479* 0.409* -0.04 
R 3.55 (0.81) 3.58 (0.76) 0.865 -0.310 0.408* -0.01 
Jerk (ms-3) AP 44.58 (13.23) 45.27 (13.19) 0.853 -0.273 0.430* -0.03 
ML 54.53 (15.73) 46.20 (14.26) 0.051 0.190 0.210 0.30 
V 56.66 (20.64) 55.72 (17.22) 0.860 -0.3800 0.376 0.03 
R 39.61 (12.01) 36.11 (8.73) 0.238 -0.312 0.466* 0.15 
Harmonic Ratio AP 2.42 (0.66) 3.36 (0.81) <0.001 -0.657** 0.570** -0.15 
ML 2.05 (0.49) 2.45 (0.54) <0.01 -0.552** 0.390* -0.08 
V 2.53 (0.64) 3.65 (0.60) <0.001 -0.679** 0.517** -0.20 




0.060 -0.169 0.214 -0.02 




<0.01 0.459* -0.343 0.03 
V 0.60 (0.08) 0.65 (0.07) <0.05 -0.498** 0.212 -0.03 
Jerk Ratio (dB) AP
/V 
-0.99 (0.98) -0.89 (0.92) 0.709 0.237 -0.009 -0.01 
ML
/V 
-0.07 (1.32) -0.84 (1.15) <0.05 0.605** -0.301 0.10 




<0.001 -0.594** 0.367 -0.07 




<0.001 0.706** -0.491** 0.06 




<0.001 -0.677** 0.517** -0.08 




<0.001 -0.616** 0.640** -0.06 
Stride Regularity AP 0.71 (0.13) 0.87 (0.04) <0.001 -0.624** 0.575** -0.08 




<0.001 -0.627** 0.658** -0.07 




<0.001 -0.598** 0.608** -0.08 
R 0.66 (0.14) 0.81 (0.05) <0.001 -0.619** 0.707** -0.07 




0.733 0.144 -0.292 -0.01 
ML -0.96 (0.19) -0.93 (0.15) 0.508 0.110 0.183 -0.01 




0.540 -0.127 -0.122 0.00 




0.540 -0.032 -0.065 0.01 
Trunk        




0.934 -0.037 0.132 -0.01 
ML 1.26 (0.26) 0.97 (0.18) <0.001 0.369 -0.528** 0.09 
V 1.90 (0.53) 2.20 (0.48) <0.05 -0.450* 0.433* -0.06 
R 2.75 (0.57) 2.83 (0.63) 0.636 -0.325 0.280 -0.01 




0.197 -0.184 0.198 0.09 
ML 22.77 (7.15) 17.98 (5.96) <0.05 -0.028 0.033 0.26 
V 40.79 (11.31) 38.47 (10.37) 0.446 -0.165 0.272 0.10 
R 31.68 (9.42) 28.66 (9.57) 0.258 -0.133 0.216 0.14 
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Harmonic Ratio AP 1.82 (0.35) 2.49 (0.50) <0.001 -0.502** 0.478* -0.14 
ML 2.84 (0.63) 3.40 (0.78) <0.01 -0.292 0.110 -0.09 




<0.001 -0.660** 0.608** -0.21 




0.492 0.127 -0.052 0.00 
ML 0.48 (0.12) 0.35 (0.07) <0.001 0.475* -0.613** 0.05 




<0.001 -0.358 0.527** -0.05 






0.415 -0.125 0.009 0.02 
ML
/V 
-2.59 (1.08) -3.40 (0.85) <0.01 0.129 -0.277 0.11 
Step Regularity AP 0.51 (0.16) 0.75 (0.10) <0.001 -0.435* 0.510** -0.10 
ML -0.62 (0.15) -0.71 (0.12) <0.05 0.361 -0.032 0.04 
V 0.74 (0.16) 0.93 (0.02) <0.001 -0.628** 0.561** -0.09 
R 0.57 (0.17) 0.81 (0.06) <0.001 -0.683** 0.667** -0.10 
Stride Regularity AP 0.59 (0.17) 0.81 (0.09) <0.001 -0.429* 0.634** -0.09 




<0.05 -0.274 0.092 -0.04 
V 0.74 (0.16) 0.91 (0.03) <0.001 -0.565** 0.605** -0.08 
R 0.60 (0.16) 0.83 (0.04) <0.001 -0.581** 0.664** -0.10 




0.430 0.033 -0.246 0.00 




0.899 -0.036 0.139 -0.01 
V 1.02 (0.10) 1.02 (0.03) 0.848 -0.061 -0.219 0.00 
R 0.98 (0.19) 0.97 (0.07) 0.763 -0.222 0.115 0.00 
Forehead        




0.087 0.338 -0.162 0.03 




<0.05 0.403* -0.325 0.05 
V 1.94 (0.54) 2.11 (0.49) 0.242 -0.354 0.371 -0.03 
R 2.66 (0.54) 2.59 (0.54) 0.661 -0.036 0.150 0.01 
Jerk (ms-3) AP 20.65 (8.16) 14.01 (5.74) <0.01 0.331 -0.129 0.35 




<0.01 0.250 -0.104 0.37 
V 44.22 (12.99) 39.39 (10.35) 0.146 -0.073 0.319 0.20 
R 31.05 (8.77) 29.09 (8.19) 0.410 -0.267 0.387* 0.09 
Harmonic Ratio AP 1.46 (0.31) 1.59 (0.49) 0.263 0.024 -0.020 -0.03 
ML 2.72 (0.55) 3.17 (0.78) <0.05 -0.134 0.242 -0.08 




<0.001 -0.681** 0.622** -0.22 
RMSR AP 0.38 (0.08) 0.33 (0.08) <0.05 0.623** -0.512** 0.02 
ML 0.47 (0.13) 0.39 (0.12) <0.05 0.538** -0.543** 0.03 




<0.01 -0.437* 0.448* -0.04 
Jerk Ratio (dB) AP
/V 
-3.47 (1.52) -4.74 (1.67) <0.01 0.573** -0.525** 0.14 
ML
/V 
-3.14 (1.62) -4.35 (1.44) <0.01 0.437* -0.442* 0.14 




<0.001 -0.092 0.182 -0.06 
ML -0.63 (0.13) -0.70 (0.11) <0.05 0.182 -0.240 0.03 




<0.001 -0.677** 0.558** -0.09 
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R 0.51 (0.19) 0.71 (0.10) <0.001 -0.694** 0.747** -0.07 
Stride Regularity AP 0.51 (0.12) 0.69 (0.12) <0.001 -0.274 0.421* -0.07 
ML 0.63 (0.12) 0.70 (0.09) <0.05 -0.213 0.305 -0.03 




<0.001 -0.675** 0.621** -0.08 
R 0.54 (0.17) 0.72 (0.10) <0.001 -0.667** 0.777** -0.07 




0.808 -0.001 -0.122 0.00 




0.704 -0.034 0.059 0.01 




0.853 -0.126 -0.247 0.00 




0.823 -0.153 -0.030 0.00 
Coefficient of Attenuation (%) 
Pelvis:Head AP 34.28 (22.63) 48.14 (22.50) <0.05 -0.519** 0.474* -0.40 




0.473 -0.341 0.474* -0.08 
V 7.31 (14.11) 7.88 (10.12) 0.864 -0.389* 0.165 -0.02 
R 22.72 (14.08) 25.52 (11.79) 0.431 -0.412* 0.429* -0.11 




0.250 -0.125 0.228 -0.02 




0.061 -0.18 0.548** -0.30 
V 9.58 (8.91) 4.05 (8.43) <0.05 -0.258 0.018 0.26 




0.710 -0.07 0.410* 0.03 




<0.05 -0.422* 0.408* -0.47 




0.364 -0.384* 0.135 0.17 




<0.05 -0.173 0.125 -0.30 




0.236 -0.451* 0.266 -0.17 
Results for upper body motion variables at lumbar, trunk and forehead positions and coefficient of 
attenuation (between levels). Accompanied with results of parametric test used reported as 
mean±SD, and non-parametric test used reported as median (IQR). Pearson’s/Spearmans correlation 
test used between parameters and SARA, and BBS: |r|>0.6 * p<0.05, **p<0.01. |d|>0.3 indicates 
medium or larger effect size. Missing data: lumbar, trunk and forehead magnitude, jerk, harmonic 




4.3.3. GAIT INFLUENCES 
Further analysis was completed to examine the impact of disease severity on the gait 
pattern through participant stratification based on SARA score. The resulting Mild Ataxia 
(SARA ≤8, n=7) and Moderate Ataxia (SARA>8, n=20) were compared against the healthy 
control group. Between-group differences are displayed in Table 4.10 and Table 4.11. Many 
of the significant differences observed between CA and HC cohorts appear to be a result of a 
more severe gait phenotype in the moderate ataxia patient subgroup. However, for select 
variables such as asymmetry of cadence, step length and stride length as well as magnitude 
of ML forehead accelerations, the mild ataxia cohort appears to deviate from the typical 
course of gait impairment. 
Univariate analysis of spatiotemporal gait characteristics, adjusted for age, gender and gait 
speed as covariates, indicates group differences independent of these confounding factors. 
Many spatiotemporal variables retain significant differences between the healthy and ataxic 
cohorts. For instance, following adjustment for these factors, there remained a significant 
difference between cohorts in step/ stride length (CA vs HC: MD=-3.2cm, p<0.05, MD= -
6.2cm, p<0.05) and step width (CA vs HC: 2.95cm, p<0.01) as well as Cadence asymmetry 
(MD 0.92steps/min, p<0.001) and Stride Time asymmetry (MD=0.007s, p<0.01) (Table 4.12). 
Meanwhile, gait variability measures that retained a significant difference between cohorts, 
showed an adjusted mean increase of 1.10% to 10.47% in ataxia patients compared with 
healthy controls. Difference between disease severity subgroup analysis is also retained in a 
univariate analysis adjusted for age, sex and gait speed in with step width, cadence 
asymmetry, stride time asymmetry and a number of gait variability measures (Table 4.13). 
While with increased disease severity, step width, and gait variability measures increase, 
cadence asymmetry is significantly increased in mild and moderate ataxia groups with 
respect to healthy controls. 
In upper body motion parameters , adjusted significant differences were observed between 
ataxic and healthy control cohorts, in step to step asymmetry (harmonic ratio) at lumbar and 
trunk sensor positions in AP, ML, vertical components and at forehead in ML, vertical (range 
MD, AP: -0.67 to -0.61, ML: -0.85 to -0.35; V: -1.26 to -0.84)(Table 4.14). Adjusted values for 
magnitude and jerk of ML accelerations at the trunk (MD=0.22ms-2, p<0.01, MD = 7.98ms-2, 
p<0.001 respectively) and jerkiness of accelerations at the head, AP and ML axis also show 
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significant differences between cohorts (MD = 6.04ms-3, p<0.01; MD=8.80ms-3, p=0.01 
respectively). In addition, significant differences were observed in Jerk Ratio ML/V at the 
trunk level (MD: 0.77, p=0.02) and CoAPS in vertical axis (MD: 7.33, p=0.01). Significant 
differences were also retained between cohorts at lumbar and trunk sensor positions in AP, 
ML, vertical axes and at forehead in AP, vertical axes, in step regularity (range MD, AP: -0.18 
to -0.10, ML: 0.10 to 0.12; V: -0.12 to -0.10), and stride regularity (range MD, AP: -0.16 to -
0.09, ML: -0.09 to -0.09; V: -0.10 to -0.09)(Table 4.14). After adjusting for age, sex and speed, 
the univariate analysis also confirm many differences between analysis of disease severity 
subgroups are independent of these factors (Table 4.15). The harmonic ratio shows a 
significant reduction in more severely affected patients at the lumbar position in AP, ML, 
vertical axes, at trunk AP, ML, vertical axes and forehead vertical axis. Step regularity shows 
significant differences between disease severity subgroups: decreased at the lumbar 
position in AP, and vertical axes, trunk position in AP, vertical, R axes and forehead position 
in vertical, R axis and increased at the lumbar position in ML axis with increased disease 
severity. Meanwhile, stride regularity shows significant differences between disease severity 
subgroups: decreased at the lumbar position in AP, vertical, R axes, trunk position in AP, 
vertical, R, axes and forehead position in AP, vertical axis and increased at the lumbar 
position in ML axis with increased disease severity. Jerk at the forehead position also retains 
significant increases in AP, ML axis in the more severely affected patients.  
Between-group differences for selected variables represented by Z scores are displayed in 
Figure 4.5. These variables were significantly different between HC and CA as well as 
differentiating HC to mild ataxia or mild ataxia to moderate ataxia and were robust against 
confounding by gait speed, age, and sex.  
Partial correlation analysis of the selected variables indicated that independent of gait 
speed, step width and stride length variability both negatively correlate with trunk AP 
component stride regularity (Table 4.16). Step length variability and stride length variability 
correlate negatively with forehead resultant step regularity. Step length variability also 
correlates with lumbar resultant stride regularity and trunk harmonic ratio in AP axis.  
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Speed (m/s) 1.33 [1.23, 1.44] 1.30 [1.19, 1.51] 1.07 [0.91, 1.27] <0.001b,c 
Cadence (steps/min) 111.6 [107.0, 119.1] 112.3 [108.2, 121.8] 108.3 [97.3, 115.2] 0.164 
Stride Time (s) 1.08 [1.01, 1.12] 1.07 [0.99, 1.11] 1.11 [1.04, 1.24] 0.159 
Step Time (s) 0.54 [0.50, 0.56] 0.53 [0.49, 0.55] 0.56 [0.53, 0.62] 0.117 
Stride Length (cm) 143.5 (16.0) 137.1 (14.6) 120.0 (19.6) <0.001b 
Step Length (cm) 71.7 (8.0) 68.4 (7.3) 59.9 (9.8) <0.001b 
Step Width (cm) 11.7 (2.9) 12.6 (2.6) 18.4 (4.8) <0.001b,c 
Stance Time (s) 0.60 [0.57, 0.66] 0.58 [0.55, 0.64] 0.66 [0.61, 0.75] <0.05b,c 
Swing Time (s) 0.46 (0.03) 0.47 (0.04) 0.47 (0.06) 0.972 
SLS (s) 0.46 (0.03) 0.47 (0.04) 0.47 (0.06) 0.972 
DLS (s) 0.14 [0.12, 0.19] 0.13 [0.06, 0.16] 0.18 [0.15, 0.23] <0.05b,c 
Stance perc. (%cycle) 56.5 [55.9, 58.6] 56.6 [53.4, 57.1] 58.4 [57.1, 59.2] <0.05b,c 
Swing perc. (%cycle) 43.5 [41.4, 44.1] 43.4 [42.9, 47.8] 41.6 [40.8, 42.9] <0.05b,c 
SLS perc. (%cycle) 43.3 [41.7, 44.1] 43.8 [42.8, 46.7] 41.6 [40.6, 42.8] <0.05b,c 
DLS perc. (%cycle) 13.5 [11.5, 17.0] 12.6 [6.8, 14.2] 16.7 [13.8, 18.6] <0.05b,c 
Asymmetry Measures 
Speed (m/s) 0.01 [0.003, 0.02] 0.01 [0.01, 0.01] 0.01 [0.01, 0.02] 0.495 
Cadence (steps/min) 0.5 (0.4) 1.6 (1.4) 1.3 (0.9) <0.01b 
Stride Time (s) 0.01 [0.002, 0.01] 0.01 [0.004, 0.02] 0.01 [0.01, 0.02] <0.01b 
Step Time (s) 0.01 [0.001, 0.01] 0.01 [0.001, 0.01] 0.01 [0.002, 0.03] 0.183 
Stride Length (cm) 0.5 [0.3, 1.33] 0.2 [0.1, 1.39] 1.1 [0.6, 1.73] <0.05c 
Step Length (cm) 0.9 [0.4, 1.49] 0.8 [0.3, 3.00] 1.1 [0.7, 2.27] 0.423 
Step Width (cm) 0.8 [0.3, 1.72] 2.1 [0.9, 2.79] 1.2 [0.5, 2.08] 0.062a 
Stance Time (s) 0.004 [0.002, 0.01] 0.005 [0.001, 0.01] 0.01 [0.002, 0.01] 0.422 
Swing Time (s) 0.004 [0.002, 0.01] 0.002 [0.001, 0.01] 0.01 [0.01, 0.02] <0.001b,c 
SLS (s) 0.004 [0.001, 0.01] 0.01 [0.002, 0.01] 0.01 [0.005, 0.02] <0.01b,c 
DLS (s) 0.005 [0.002, 0.01] 0.002 [0.001, 0.01] 0.004 [0.001, 0.01] 0.331 
Stance perc. (%cycle) 0.5 [0.3, 0.7] 0.2 [0.1, 1.5] 0.5 [0.3, 1.3] 0.486 
Swing perc. (%cycle) 0.4 [0.2, 0.6] 0.3 [0.2, 0.9] 0.9 [0.5, 2.0] <0.01b 
SLS perc. (%cycle) 0.5 [0.1, 0.9] 0.6 [0.4, 1.0] 1.1 [0.6, 1.7] <0.05b 
DLS perc. (%cycle) 0.4 [0.1, 0.8] 0.5 [0.2, 0.7] 0.5 [0.1, 1.1] 0.721 
Variability Measures 
Speed Var. (%CV) 3.0 [2.5, 4.5] 4.2 [2.8, 4.8] 5.5 [4.8, 8.1] <0.001b,c 
Cadence Var. (%CV) 1.6 [1.3, 2.3] 3.3 [2.2, 3.5] 4.3 [3.2, 6.0] <0.001a,b 
Stride Time Var. (%CV) 1.6 [1.3, 2.3] 3.3 [2.2, 3.4] 4.3 [3.2, 5.8] <0.001a,b 
Step Time Var. (%CV) 2.8 [2.4, 3.7] 4.3 [3.3, 5.2] 6.3 [5.1, 8.2] <0.001a,b,c 
Stride Length Var. (%CV) 2.2 [1.9, 3.0] 2.3 [1.9, 2.6] 4.4 [3.3, 6.7] <0.001b,c 
Step Length Var. (%CV) 3.2 (0.9) 3.6 (1.0) 7.7 (3.1) <0.001b,c 
Step Width Var. (%CV) 31.2 (9.9) 33.9 (8.5) 28.1 (12.9) 0.433 
Stance Time Var. (%CV) 3.1 [2.5, 3.5] 3.7 [3.3, 4.7] 5.6 [4.4, 7.8] <0.001a,b,c 
Swing Time Var. (%CV) 2.5 [2.3, 3.2] 3.5 [3.3, 4.1] 6.6 [4.8, 8.7] <0.001a,b,c 
SLS Var. (%CV) 2.5 [2.3, 3.2] 3.5 [3.3, 4.1] 6.6 [4.8, 8.7] <0.001a,b,c 
DLS Var. (%CV) 10.9 [8.3, 15.2] 13.1 [10.1, 40.8] 14.5 [10.8, 21.0] 0.108 
Stance perc. Var. (%CV) 1.9 [1.5, 2.1] 2.2 [1.9, 8.1] 3.2 [2.9, 4.8] <0.001a,b 
Swing perc. Var. (%CV) 2.5 [1.9, 2.9] 2.7 [2.3, 3.7] 5.0 [3.9, 6.6] <0.001b,c 
SLS perc. Var. (%CV) 2.9 [2.2, 3.5] 2.6 [2.4, 4.3] 5.2 [4.2, 7.9] <0.001b,c 
DLS perc. Var. (%CV) 9.4 [6.2, 12.3] 12.4 [8.4, 29.2] 11.3 [8.7, 20.2] 0.066b 
CA group separated in mild (SARA ≤8) and moderate ataxia (SARA>8) normally distributed data 
reported as mean (SD), non-normally distributed data reported as median [IQR]. Results of one-way 
ANOVA tests and Kruskal Wallis tests with significant post hoc test results indicated a: healthy control 
vs mild ataxia b: healthy control vs moderate ataxia c: mild ataxia vs moderate ataxia. Missing data: 
SLS asym. and DLS asym. (n=26)   
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Table 4.11: Disease severity subgroups - Upper body motion Gait Parameters 
 








Lumbar      
Magnitude (ms-2) AP 1.77 (0.38) 1.79 (0.30) 1.55 (0.35) 0.107 
ML 1.41 (0.37) 1.47 (0.27) 1.63 (0.40) 0.153 
V 2.33 (0.59) 2.47 (0.81) 2.01 (0.54) 0.121 
R 3.58 (0.76) 3.83 (0.90) 3.45 (0.78) 0.547 
Jerk (ms-3) AP 45.27 (13.19) 49.71 (13.87) 42.79 (12.87) 0.484 
ML 46.20 (14.26) 47.23 (10.40) 57.09 (16.68) 0.050b 
V 55.72 (17.22) 65.25 (23.59) 53.65 (19.25) 0.378 
R 36.11 (8.73) 43.08 (16.31) 38.40 (10.36) 0.303 
Harmonic Ratio AP 3.36 (0.81) 3.24 (0.54) 2.14 (0.43) <0.001b,c 
ML 2.45 (0.54) 2.50 (0.35) 1.89 (0.44) <0.001b,c 
V 3.65 (0.60) 3.17 (0.30) 2.31 (0.58) <0.001a,b,c 
RMSR AP 0.52 [0.43, 0.56] 0.49 [0.48, 0.51] 0.46 [0.43, 0.47] 0.065b,c 
ML 0.39 (0.06) 0.39 (0.06) 0.48 (0.08) <0.001b,c 
V 0.65 (0.07) 0.64 (0.08) 0.58 (0.07) <0.05b 
Jerk Ratio (dB) AP/V -0.89 (0.92) -1.13 (0.93) -0.94 (1.02) 0.842 
ML/V -0.84 (1.15) -1.29 (0.98) 0.35 (1.16) <0.001 
Step Regularity 
 
AP 0.85 (0.06) 0.81 (0.10) 0.65 (0.13) <0.001b,c 
ML -0.65 (0.16) -0.67 (0.14) -0.39 (0.13) <0.001b,c 
V 0.88 (0.05) 0.83 (0.10) 0.63 (0.16) <0.001b,c 
R 0.74 (0.12) 0.73 (0.09) 0.55 (0.15) <0.001b,c 
Stride Regularity 
 
AP 0.88 [0.84, 0.90] 0.87 [0.79, 0.89] 0.70 [0.58, 0.76] <0.001b,c 
ML 0.72 (0.15) 0.69 (0.16) 0.46 (0.14) <0.001b,c 
V 0.88 (0.05) 0.84 (0.10) 0.64 (0.14) <0.001b,c 
R 0.81 (0.05) 0.79 (0.08) 0.61 (0.12) <0.001b,c 
Symmetry. AP 1.01 (0.20) 0.98 (0.03) 0.99 (0.14) 0.868 
ML -0.93 (0.15) -0.99 (0.08) -0.95 (0.22) 0.661 
V 1.02 (0.15) 1.01 (0.04) 1.02 (0.13) 0.962 
R 0.95 [0.82, 0.98] 0.95 [0.91, 1.00] 0.98 [0.80, 1.02] 0.820 
Trunk      
Magnitude (ms-2) AP 1.15 (0.43) 1.13 (0.44) 1.09 (0.22) 0.846 
ML 0.97 (0.18) 1.07 (0.28) 1.33 (0.22) <0.001b 
V 2.20 (0.48) 2.22 (0.65) 1.79 (0.45) <0.05b 
R 2.76 [2.48, 3.28] 2.63 [2.27, 4.11] 2.73 [2.41, 3.07] 0.784 
Jerk (ms-3) AP 29.98 (18.40) 35.14 (23.71) 31.62 (10.51) 0.766 
ML 17.98 (5.96) 22.57 (8.13) 22.84 (7.01) <0.05b 
V 38.47 (10.37) 41.72 (10.76) 40.47 (11.75) 0.725 
R 28.66 (9.57) 32.62 (10.64) 31.35 (9.24) 0.508 
Harmonic Ratio AP 2.49 (0.50) 2.20 (0.35) 1.68 (0.25) <0.001b,c 
ML 3.53 [2.73, 3.89] 3.14 [2.68, 3.58] 2.49 [2.25, 3.25] <0.05b 
V 4.47 (0.92) 4.07 (1.52) 2.57 (0.51) <0.001b 
RMSR AP 0.40 (0.07) 0.38 (0.06) 0.41 (0.05) 0.585 
ML 0.35 (0.07) 0.38 (0.11) 0.51 (0.11) <0.001b,c 
V 0.80 [0.75, 0.83] 0.77 [0.68, 0.83] 0.66 [0.60, 0.73] <0.001b,c 
Jerk Ratio (dB) AP/V -1.40 (1.15) -1.39 (1.70) -1.16 (0.84) 0.761 
ML/V -3.40 (0.85) -2.80 (0.82) -2.52 (1.17) <0.05b 
Step Regularity 
 
AP 0.75 (0.10) 0.65 (0.14) 0.46 (0.13) <0.001b,c 
ML -0.71 (0.12) -0.67 (0.09) -0.60 (0.16) <0.05b 
V 0.93 [0.91, 0.95] 0.94 [0.85, 0.96] 0.70 [0.61, 0.81] <0.001b,c 
R 0.81 (0.06) 0.74 (0.11) 0.52 (0.16) <0.001 
Stride Regularity 
 
AP 0.84 [0.75, 0.87] 0.80 [0.52, 0.85] 0.54 [0.44, 0.65] <0.001b,c 
ML 0.71 (0.11) 0.65 (0.08) 0.60 (0.16) <0.05b 
V 0.91 (0.03) 0.88 (0.08) 0.69 (0.15) <0.001b,c 
R 0.83 (0.04) 0.72 (0.11) 0.56 (0.15) <0.001b,c 
|162 
Symmetry. AP 0.95 [0.90, 0.97] 0.92 [0.83, 0.98] 0.89 [0.76, 1.07] 0.733 
ML -1.03 (0.14) -1.08 (0.18) -1.04 (0.10) 0.683 
V 1.02 (0.03) 1.02 (0.02) 1.02 (0.12) 0.981 
R 0.97 (0.07) 1.04 (0.06) 0.96 (0.22) 0.443 
Forehead      
Magnitude (ms-2) AP 0.86 (0.33) 0.79 (0.29) 1.07 (0.28) <0.05 
ML 1.00 (0.37) 0.88 (0.34) 1.37 (0.32) <0.001b,c 
V 2.11 (0.49) 2.19 (0.63) 1.85 (0.49) 0.168 
R 2.59 (0.54) 2.63 (0.61) 2.67 (0.53) 0.897 
Jerk (ms-3) AP 14.01 (5.74) 14.56 (7.21) 22.78 (7.50) <0.001b 
ML 15.11 (6.36) 16.01 (7.52) 25.17 (9.76) <0.001b 
V 39.39 (10.35) 43.81 (11.94) 44.36 (13.63) 0.350 
R 29.09 (8.19) 33.88 (10.65) 30.06 (8.09) 0.426 
Harmonic Ratio AP 1.59 (0.49) 1.39 (0.35) 1.49 (0.30) 0.452 
ML 3.17 (0.78) 2.71 (0.66) 2.72 (0.53) 0.066 
V 3.92 [3.24, 4.30] 3.41 [2.92, 4.09] 2.10 [1.94, 2.49] <0.001 
RMSR AP 0.33 (0.08) 0.30 (0.09) 0.40 (0.06) <0.01 
ML 0.39 (0.12) 0.33 (0.10) 0.52 (0.10) <0.001 
V 0.81 (0.09) 0.83 (0.11) 0.69 (0.11) <0.001 
Jerk Ratio (dB) AP/V -4.74 (1.67) -5.10 (1.42) -2.90 (1.10) <0.001 
ML/V -4.35 (1.44) -4.61 (1.37) -2.63 (1.38) <0.001 
Step Regularity 
 
AP 0.58 (0.18) 0.48 (0.19) 0.39 (0.15) <0.01 
ML -0.70 (0.11) -0.62 (0.13) -0.64 (0.13) 0.124 
V 0.90 (0.05) 0.87 (0.10) 0.64 (0.16) <0.001 
R 0.71 (0.10) 0.71 (0.13) 0.45 (0.15) <0.001 
Stride Regularity 
 
AP 0.69 (0.12) 0.55 (0.16) 0.50 (0.11) <0.001 
ML 0.70 (0.09) 0.61 (0.13) 0.63 (0.12) 0.076 
V 0.90 (0.05) 0.87 (0.09) 0.64 (0.15) <0.001 
R 0.72 (0.10) 0.72 (0.13) 0.48 (0.14) <0.001 
Symmetry AP 0.84 (0.19) 0.93 (0.22) 0.83 (0.28) 0.605 
ML -1.01 [-1.08, -0.94] -1.02 [-1.08, -0.96] -1.00 [-1.03, -0.95] 0.834 
V 1.01 [0.99, 1.03] 1.02 [0.96, 1.02] 1.00 [0.92, 1.06] 0.979 
R 0.99 [0.92, 1.06] 0.99 [0.95, 1.01] 0.99 [0.81, 1.12] 0.957 
Coefficient of Attenuation (%)    
Pelvis:Head AP 48.14 (22.50) 53.49 (20.20) 27.56 (19.72) <0.01 
ML 20.00 (40.67) 40.07 (17.90) 7.99 (33.42) 0.129 
V 7.88 (10.12) 10.32 (5.19) 6.25 (16.11) 0.745 
R 25.52 (11.79) 30.64 (6.91) 19.94 (15.01) 0.123 
Pelvis:Shoulder AP 40.38 [13.59, 51.01] 46.50 [18.35, 54.32] 31.78 [11.93, 39.33] 0.197 
ML 25.38 (23.38) 25.52 (17.70) 10.80 (27.32) 0.114 
V 4.05 (8.43) 9.22 (5.73) 9.70 (9.91) 0.077 
R 21.48 [12.61, 28.14] 24.35 [13.17, 32.87] 20.46 [13.20, 28.62] 0.747 
Shoulder:Head AP 22.27 [0.73, 37.60] 27.66 [-4.55, 36.62] 1.64 [-13.65, 13.79] <0.01 
ML 2.21 [-23.89, 14.42] 22.80 [3.83, 37.62] -4.37 [-12.21, 11.00] 0.070 
V 3.89 (6.61) 0.93 (6.30) -4.08 (13.27) <0.05 
R 6.88 (10.27) 9.18 (7.90) 0.41 (12.30) 0.076 
CA group separated in mild (SARA ≤8) and moderate ataxia (SARA>8) normally distributed data 
reported as mean (SD), non-normally distributed data reported as median[IQR]. Results of one-way 
ANOVA tests and Kruskal Wallis tests with significant post hoc test results indicated a: healthy control 
vs mild ataxia b: healthy control vs moderate ataxia c: mild ataxia vs moderate ataxia. Missing data: 
lumbar, trunk and forehead magnitude, jerk, harmonic ratio, RMSR and jerk ratio (HC n=25); step 
regularity, stride regularity, autosymmetry (HC n=23)  
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Table 4.12: Univariate analysis adjusted for age, sex, gait speed – Spatiotemporal Parameters 
 Cerebellar ataxia (n=27) Healthy Control (n=27) p 
Spatiotemporal Measures    
Speed (m/s) ---- ---- ---- 
Cadence (steps/min) 112.7 (1.4) 106.8 (1.4) <0.01 
Stride Time (s) 1.08 (0.02) 1.14 (0.02) <0.05 
Step Time (s) 0.54 (0.01) 0.57 (0.01) <0.05 
Stride Length (cm) 130.9 (1.6) 137.1 (1.6) <0.05 
Step Length (cm) 65.3 (0.8) 68.5 (0.8) <0.05 
Step Width (cm) 15.7 (0.7) 12.8 (0.7) <0.01 
Stance Time (s) 0.62 (0.02) 0.68 (0.02) <0.05 
Swing Time (s) 0.47 (0.01) 0.47 (0.01) 0.97 
SLS (s) 0.47 (0.01) 0.47 (0.01) 0.97 
DLS (s) 0.15 (0.03) 0.21 (0.03) 0.11 
Stance perc. (%cycle) 56.8 (0.6) 58.51 (0.64) 0.08 
Swing perc. (%cycle) 43.4 (0.6) 41.44 (0.64) <0.05 
SLS perc. (%cycle) 43.4 (0.7) 41.36 (0.67) <0.05 
DLS perc. (%cycle) 13.3 (1.3) 17.16 (1.30) 0.06 
Asymmetry    
Speed (m/s) 0.023 (0.005) 0.010 (0.005) 0.10 
Cadence (steps/min) 1.41 (0.16) 0.48 (0.16) <0.001 
Stride Time (s) 0.013 (0.002) 0.006 (0.002) <0.01 
Step Time (s) 0.015 (0.003) 0.006 (0.003) <0.05 
Stride Length (cm) 2.08 (0.58) 0.80 (0.58) 0.15 
Step Length (cm) 1.53 (0.23) 1.08 (0.23) 0.20 
Step Width (cm) 1.79 (0.28) 1.03 (0.28) 0.07 
Stance Time (s) 0.009 (0.002) 0.006 (0.002) 0.47 
Swing Time (s) 0.013 (0.003) 0.008 (0.003) 0.19 
SLS (s) 0.011 (0.002) 0.007 (0.002) 0.13 
DLS (s) 0.005 (0.002) 0.007 (0.00) 0.29 
Stance perc. (%cycle) 1.09 (0.23) 0.51 (0.23) 0.10 
Swing perc. (%cycle) 1.19 (0.23) 0.55 (0.23) 0.07 
SLS perc. (%cycle) 1.09 (0.19) 0.78 (0.19) 0.28 
DLS perc. (%cycle) 0.66 (0.13) 0.57 (0.13) 0.63 
Variability Measures    
Speed (%CV) 5.5 (0.4) 3.79 (0.4) <0.01 
Cadence (%CV) 4.0 (0.3) 2.09 (0.3) <0.001 
Stride Time (%CV) 3.9 (0.3) 2.12 (0.3) <0.001 
Step Time (%CV) 6.5 (0.6) 3.24 (0.6) <0.001 
Stride Length (%CV) 4.1 (0.4) 2.75 (0.4) <0.05 
Step Length (%CV) 6.0 (0.4) 3.88 (0.4) <0.01 
Step Width (%CV) 31.5 (2.2) 29.28 (2.2) 0.51 
Stance Time (%CV) 5.6 (0.4) 3.49 (0.4) <0.001 
Swing Time (%CV) 5.6 (0.9) 4.48 (0.9) 0.44 
SLS (%CV) 5.6 (0.9) 4.48 (0.9) 0.44 
DLS (%CV) 21.0 (2.2) 10.52 (2.2) <0.01 
Stance perc. (%CV) 4.7 (0.6) 1.76 (0.6) <0.01 
Swing perc. (%CV) 4.7 (1.0) 4.02 (1.0) 0.65 
SLS perc. (%CV) 5.4 (1.4) 4.88 (1.4) 0.79 
DLS perc. (%CV) 60.0 (24.2) 0.69 (24.2) 0.11 
Data are adjusted mean ± SEM. Abbreviation: SLS – single limb support, DLS – double limb support, 
%CV – coefficient of variation. Univariate analysis for group differences. Missing data: SLS asym. and 
DLS asym. (n=26)  
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Speed (m/s) ---- ---- ---- ---- 
Cadence (steps/min) 106.4 (1.4) 109.5 (2.6) 114.4 (1.8) <0.01b 
Stride Time (s) 1.15 (0.02) 1.12 (0.04) 1.05 (0.02) <0.05b 
Step Time (s) 0.58 (0.01) 0.56 (0.02) 0.53 (0.01) <0.05b 
Stride Length (cm) 137.4 (1.6) 134.0 (2.9) 129.3 (2.0) <0.05b 
Step Length (cm) 68.7 (0.8) 66.9 (1.5) 64.4 (1.0) <0.05b 
Step Width (cm) 12.5 (0.7) 13.7 (1.3) 16.8 (0.9) <0.01b 
Stance Time (s) 0.68 (0.02) 0.65 (0.04) 0.60 (0.03) 0.06 
Swing Time (s) 0.47 (0.01) 0.47 (0.02) 0.46 (0.01) 0.93 
SLS (s) 0.47 (0.01) 0.47 (0.02) 0.46 (0.01) 0.93 
DLS (s) 0.22 (0.03) 0.18 (0.05) 0.14 (0.03) 0.23 
Stance perc. (%cycle) 58.6 (0.7) 57.4 (1.2) 56.4 (0.8) 0.17 
Swing perc. (%cycle) 41.4 (0.7) 43.0 (1.2) 43.6 (0.8) 0.13 
SLS perc. (%cycle) 41.3 (0.7) 42.8 (1.3) 43.8 (0.9) 0.11 
DLS perc. (%cycle) 17.3 (1.3) 14.3 (2.5) 12.8 (1.7) 0.15 
Asymmetry Measures 
Speed (m/s) 0.008 (0.005) 0.007 (0.010) 0.032 (0.007) <0.05b 
Cadence (steps/min) 0.50 (0.16) 1.53 (0.30) 1.35 (0.21) <0.05a,b 
Stride Time (s) 0.006 (0.002) 0.014 (0.003) 0.013 (0.002) 0.08a 
Step Time (s) 0.005 (0.003) 0.006 (0.005) 0.020 (0.003) <0.01b 
Stride Length (cm) 0.54 (0.57) -0.02 (1.05) 3.17 (0.72) <0.05b 
Step Length (cm) 1.07 (0.23) 1.42 (0.43) 1.58 (0.30) 0.68 
Step Width (cm) 1.04 (0.29) 1.88 (0.53) 1.75 (0.36) 0.50 
Stance Time (s) 0.006 (0.002) 0.007 (0.004) 0.010 (0.003) 1.00 
Swing Time (s) 0.007 (0.003) 0.007 (0.005) 0.017 (0.003) 0.18 
SLS (s) 0.006 (0.002) 0.006 (0.004) 0.014 (0.003) 0.09 
DLS (s) 0.007 (0.002) 0.005 (0.003) 0.005 (0.002) 1.00 
Stance perc. (%cycle) 0.54 (0.24) 1.37 (0.43) 0.94 (0.29) 1.00 
Swing perc. (%cycle) 0.47 (0.23) 0.53 (0.42) 1.53 (0.29) <0.05b 
SLS perc. (%cycle) 0.75 (0.20) 0.87 (0.36) 1.21 (0.26) 0.60 
DLS perc. (%cycle) 0.57 (0.13) 0.68 (0.24) 0.65 (0.17) 1.00 
Variability Measures 
Speed Var. (%CV) 3.7 (0.4) 4.5 (0.7) 6.0 (0.5) <0.01b 
Cadence Var. (%CV) 2.1 (0.3) 4.0 (0.5) 4.0 (0.4) <0.01a,b 
Stride Time Var. (%CV) 2.1 (0.3) 3.8 (0.5) 4.0 (0.3) <0.001a,b 
Step Time Var. (%CV) 3.1 (0.6) 5.4 (1.0) 7.1 (0.7) <0.001b 
Stride Length Var. (%CV) 2.6 (0.4) 2.5 (0.7) 5.0 (0.5) <0.01b,c 
Step Length Var. (%CV) 3.6 (0.4) 4.0 (0.8) 7.0 (0.5) <0.001b,c 
Step Width Var. (%CV) 29.3 (2.3) 31.7 (4.2) 31.4 (2.9) 1.00 
Stance Time Var. (%CV) 3.4 (0.4) 4.9 (0.7) 5.9 (0.5) <0.01b 
Swing Time Var. (%CV) 4.4 (1.0) 5.3 (1.8) 5.7 (1.2) 1.00 
SLS Var. (%CV) 4.4 (1.0) 5.3 (1.8) 5.7 (1.2) 1.00 
DLS Var. (%CV) 10.3 (2.2) 19.2 (4.2) 21.9 (2.9) <0.05b 
Stance perc. Var. (%CV) 1.9 (0.6) 5.6 (1.1) 4.2 (0.8) 0.11a 
Swing perc. Var. (%CV) 4.1 (1.0) 5.0 (1.8) 4.5 (1.2) 1.00 
SLS perc. Var. (%CV) 4.8 (1.5) 5.0 (2.7) 5.7 (1.9) 1.00 
DLS perc. Var. (%CV) -7.6 (24.1) -7.5 (44.6) 94.7 (30.7) 0.06 
Data are adjusted mean ± SEM. Abbreviation: SLS – single limb support, DLS – double limb support. 
Univariate analysis for differences between disease severity subgroup analysis with post hoc tests a: 
healthy control vs mild ataxia b: healthy control vs moderate ataxia c: mild ataxia vs moderate ataxia. 
Missing data: SLS asym. and DLS asym. (n=26)   
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Table 4.14: Univariate analysis adjusting for age, sex, gait speed – Upper body Motion Gait 
Parameters 
 Cerebellar ataxia (n=27) Healthy Control (n=27) p 
Lumbar     
Magnitude (ms-2) AP 1.73 (0.06) 1.65 (0.06) 0.42 
ML 1.65 (0.00) 1.34 (0.07) <0.01 
V 2.35 (0.07) 2.09 (0.00) <0.05 
R 3.81 (0.11) 3.29 (0.11) <0.01 
Jerk (ms-3) AP 48.45 (2.22) 41.09 (2.32) <0.05 
ML 56.90 (2.85) 43.64 (2.98) <0.01 
V 62.55 (2.94) 49.36 (3.07) <0.01 
R 42.83 (1.71) 32.63 (1.78) <0.001 
Harmonic Ratio AP 2.55 (0.15) 3.22 (0.15) <0.01 
ML 2.07 (0.10) 2.42 (0.11) <0.05 
V 2.66 (0.12) 3.50 (0.13) <0.001 
RMSR AP 0.46 (0.01) 0.51 (0.01) <0.05 
ML 0.44 (0.01) 0.41 (0.01) 0.18 
V 0.61 (0.01) 0.63 (0.01) 0.36 
Jerk Ratio (dB) AP/V -1.07 (0.19) -0.80 (0.21) 0.40 
ML/V -0.37 (0.22) -0.51 (0.24) 0.69 
Step Regularity 
 
AP 0.72 (0.02) 0.82 (0.02) <0.01 
ML -0.51 (0.03) -0.60 (0.03) <0.05 
V 0.73 (0.02) 0.83 (0.02) <0.01 
R 0.64 (0.03) 0.70 (0.03) 0.12 
Stride Regularity 
 
AP 0.75 (0.02) 0.83 (0.01) <0.01 
ML 0.57 (0.03) 0.66 (0.03) <0.05 
V 0.73 (0.02) 0.83 (0.02) <0.01 
R 0.69 (0.02) 0.70 (0.02) <0.01 
Symmetry. AP 0.90 (0.03) 1.02 (0.04) 0.40 
ML -0.93 (0.03) -0.95 (0.04) 0.71 
V 1.01 (0.03) 1.03 (0.03) 0.52 
R 0.95 (0.04) 0.91 (0.04) 0.54 
Trunk     
Magnitude (ms-2) AP 1.15 (0.07) 1.09 (0.72) 0.55 
ML 1.23 (0.04) 1.01 (0.05) <0.01 
V 2.08 (0.06) 2.01 (0.06) 0.39 
R 2.91 (0.09) 2.66 (0.10) 0.07 
Jerk (ms-3) AP 35.69 (3.27) 26.57 (3.41) 0.08 
ML 24.31 (1.23) 16.33 (1.29) <0.001 
V 43.59 (1.90) 35.46 (1.99) <0.01 
R 34.05 (1.73) 26.10 (1.81) <0.01 
Harmonic Ratio AP 1.85 (0.09) 2.45 (0.09) <0.001 
ML 2.70 (0.14) 3.56 (0.14) <0.001 
V 3.08 (0.21) 4.34 (0.22) <0.001 
RMSR AP 0.40 (0.01) 0.40 (0.01) 0.69 
ML 0.44 (0.01) 0.40 (0.01) 0.09 
V 0.71 (0.01) 0.75 (0.02) 0.07 
Jerk Ratio (dB) AP/V -1.16 (0.23) -1.47 (0.25) 0.40 
ML/V -2.61 (0.21) -3.38 (0.21) <0.05 
Step Regularity 
 
AP 0.54 (0.02) 0.72 (0.03) <0.001 
ML -0.61 (0.03) -0.73 (0.03) <0.05 
V 0.78 (0.02) 0.89 (0.02) <0.01 
R 0.61 (0.02) 0.76 (0.03) <0.001 
Stride Regularity 
 
AP 0.62 (0.03) 0.78 (0.03) <0.001 
ML 0.61 (0.03) 0.70 (0.03) <0.05 
V 0.78 (0.02) 0.87 (0.02) <0.01 
R 0.64 (0.02) 0.79 (0.02) <0.001 
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Symmetry. AP 0.95 (0.07) 0.96 (0.07) 0.92 
ML -1.03 (0.03) -1.06 (0.03) 0.49 
V 1.01 (0.01) 1.04 (0.02) 0.29 
R 0.98 (0.03) 0.97 (0.03) 0.87 
Forehead     
Magnitude (ms-2) AP 0.97 (0.05) 0.89 (0.05) 0.24 
ML 1.19 (0.06) 1.06 (0.07) 0.20 
V 2.10 (0.07) 1.93 (0.07) 0.09 
R 2.76 (0.07) 2.48 (0.07) <0.05 
Jerk (ms-3) AP 20.36 (1.18) 14.32 (1.23) <0.01 
ML 23.33 (1.53) 14.53 (1.60) <0.001 
V 47.69 (1.86) 35.63 (1.94) <0.001 
R 33.64 (1.32) 26.29 (1.38) <0.001 
Harmonic Ratio AP 1.44 (0.08) 1.61 (0.09) 0.20 
ML 2.62 (0.14) 3.28 (0.14) <0.01 
V 2.71 (0.16) 3.80 (0.17) <0.001 
RMSR AP 0.35 (0.01) 0.36 (0.01) 0.93 
ML 0.43 (0.02) 0.44 (0.02) 0.82 
V 0.76 (0.02) 0.77 (0.02) 0.69 
Jerk Ratio (dB) AP/V -3.98 (0.23) -4.18 (0.24) 0.57 
ML/V -3.44 (0.28) -4.02 (0.30) 0.19 
Step Regularity 
 
AP 0.43 (0.03) 0.57 (0.03) <0.01 
ML -0.62 (0.03) -0.72 (0.03) <0.05 
V 0.74 (0.02) 0.86 (0.02) <0.001 
R 0.57 (0.03) 0.65 (0.03) <0.05 
Stride Regularity 
 
AP 0.53 (0.02) 0.68 (0.02) <0.001 
ML 0.63 (0.02) 0.70 (0.02) 0.06 
V 0.74 (0.02) 0.85 (0.02) <0.01 
R 0.60 (0.02) 0.65 (0.02) 0.10 
Symmetry. AP 0.87 (0.05) 0.82 (0.05) 0.52 
ML -1.00 (0.02) -1.05 (0.02) 0.13 
V 1.00 (0.02) 1.02 (0.02) 0.60 
R 0.98 (0.04) 1.02 (0.05) 0.59 
Coefficient of Attenuation (%)    
Pelvis:Head AP 40.12 (3.22) 42.30 (3.22) 0.66 
ML 25.37 (6.45) 10.94 (6.45) 0.14 
V 8.81 (2.52) 6.38 (2.52) 0.53 
R 26.17 (2.09) 22.07 (2.09) 0.20 
Pelvis:Shoulder AP 30.96 (4.95) 29.61 (4.95) 0.86 
ML 22.22 (4.30) 17.77 (4.30) 0.50 
V 10.48 (1.81) 3.15 (1.81) <0.01 
R 22.77 (2.24) 17.30 (2.24) 0.12 
Shoulder:Head AP 11.47 (4.53) 15.43 (4.53) 0.56 
ML 3.31 (5.00) -7.52 (5.00) 0.16 
V -2.07 (2.03) 3.18 (2.03) 0.09 
R 4.34 (1.99) 5.23 (1.99) 0.77 
Univariate analysis for group differences in upper body motion gait parameters at lumbar, trunk and 
forehead levels and coefficient of analysis between levels. Data are adjusted mean ± SEM. 
Abbreviation: AP – anteriorposterior, ML – mediolateral, V – vertical, R – resultant, RMSR – root 
mean square ratio, Missing data: lumbar, trunk and forehead magnitude, jerk, harmonic ratio, RMSR 
and jerk ratio (HC n=25); step regularity, stride regularity, autosymmetry (HC n=23) 
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Table 4.15: Univariate disease severity analysis adjusting for age, sex, gait speed – Upper body 
Motion Gait Parameters 
 








Lumbar      
Magnitude (ms-2) AP 1.64 (0.06) 1.64 (0.11) 1.77 (0.08) 0.50 
ML 1.30 (0.07) 1.35 (0.13) 1.81 (0.09) <0.001b,c 
V 2.08 (0.08) 2.25 (0.14) 2.40 (0.10) 0.07 
R 3.25 (0.11) 3.51 (0.19) 3.97 (0.13) <0.01b 
Jerk (ms-3) AP 40.63 (2.37) 45.03 (4.21) 50.22 (2.90) 0.07 
ML 41.77 (2.76) 43.13 (4.91) 64.05 (3.37) <0.001b,c 
V 48.80 (3.14) 58.39 (5.57) 64.71 (3.83) <0.05b 
R 32.16 (1.81) 39.36 (3.21) 44.63 (2.21) <0.001b 
Harmonic Ratio AP 3.31 (0.15) 3.18 (0.26) 2.23 (0.18) <0.001b,c 
ML 2.48 (0.10) 2.49 (0.18) 1.86 (0.12) <0.01b,c 
V 3.56 (0.12) 3.08 (0.22) 2.45 (0.15) <0.001b 
RMSR AP 0.51 (0.01) 0.48 (0.03) 0.45 (0.02) <0.05b 
ML 0.40 (0.01) 0.40 (0.03) 0.46 (0.02) 0.1 
V 0.63 (0.01) 0.63 (0.02) 0.60 (0.02) 0.51 
Jerk Ratio (dB) AP/V -0.80 (0.21) -1.05 (0.38) -1.07 (0.26) 0.7 
ML/V -0.60 (0.24) -1.01 (0.42) -0.04 (0.29) 0.2 
Step Regularity 
 
AP 0.83 (0.02) 0.79 (0.04) 0.69 (0.03) <0.01b 
ML -0.62 (0.03) -0.63 (0.05) -0.44 (0.04) <0.01b,c 
V 0.84 (0.02) 0.80 (0.04) 0.69 (0.03) <0.01b 
R 0.71 (0.03) 0.70 (0.05) 0.60 (0.03) 0.1 
Stride Regularity 
 
AP 0.11 (0.02) 0.80 (0.03) 0.72 (0.02) <0.001b 
ML 0.67 (0.03) 0.63 (0.05) 0.53 (0.03) <0.05b 
V 0.10 (0.02) 0.80 (0.03) 0.70 (0.02) <0.001b 
R 0.78 (0.02) 0.76 (0.03) 0.66 (0.02) <0.01b 
Symmetry. AP 1.03 (0.04) 0.99 (0.06) 0.97 (0.04) 0.67 
ML -0.97 (0.04) -1.02 (0.06) -0.89 (0.04) 0.25 
V 1.04 (0.03) 1.02 (0.05) 1.00 (0.04) 0.79 
R 0.91 (0.05) 0.92 (0.08) 0.97 (0.05) 0.73 
Trunk      
Magnitude (ms-2) AP 1.08 (0.07) 1.06 (0.13) 1.20 (0.09) 0.60 
ML 0.99 (0.05) 1.09 (0.08) 1.31 (0.06) <0.01b 
V 2.00 (0.06) 2.05 (0.11) 2.09 (0.07) 0.66 
R 2.64 (0.10) 2.76 (0.17) 2.99 (0.12) 0.12 
Jerk (ms-3) AP 25.95 (3.49) 31.11 (6.20) 38.07 (4.27) 0.15 
ML 15.80 (1.27) 20.43 (2.26) 26.32 (1.55) <0.001b 
V 34.71 (1.98) 38.07 (3.51) 46.45 (2.42) <0.01b 
R 25.48 (1.81) 29.48 (3.22) 36.42 (2.21) <0.01b 
Harmonic Ratio AP 2.51 (0.09) 2.23 (0.15) 1.65 (0.10) <0.001b,c 
ML 3.64 (0.14) 3.32 (0.24) 2.38 (0.17) <0.001b,c 
V 4.48 (0.20) 4.10 (0.36) 2.55 (0.24) <0.001b,c 
RMSR AP 0.40 (0.01) 0.38 (0.03) 0.40 (0.02) 0.69 
ML 0.40 (0.01) 0.42 (0.03) 0.44 (0.02) 0.2 
V 0.76 (0.02) 0.73 (0.03) 0.70 (0.02) 0.12 
Jerk Ratio (dB) AP/V -1.51 (0.25) -1.49 (0.45) -0.99 (0.31) 0.48 
ML/V -3.41 (0.22) -2.81 (0.39) -2.51 (0.27) 0.05 
Step Regularity 
 
AP 0.73 (0.02) 0.62 (0.04) 0.50 (0.03) <0.001b 
ML -0.74 (0.03) -0.70 (0.05) -0.56 (0.04) <0.01b 
V 0.90 (0.02) 0.87 (0.04) 0.73 (0.02) <0.001b,c 
R 0.78 (0.03) 0.71 (0.04) 0.56 (0.03) <0.001b,c 
Stride Regularity 
 
AP 0.79 (0.03) 0.70 (0.05) 0.57 (0.03) <0.001b 
ML 0.71 (0.03) 0.66 (0.05) 0.59 (0.03) 0.06 
V 0.88 (0.02) 0.84 (0.03) 0.75 (0.02) <0.01b 
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R 0.80 (0.02) 0.69 (0.04) 0.62 (0.03) <0.001a,b 
Symmetry. AP 0.95 (0.07) 0.91 (0.13) 0.96 (0.09) 0.95 
ML -1.07 (0.03) -1.11 (0.05) -0.98 (0.03) 0.09 
V 1.04 (0.02) 1.04 (0.03) 0.99 (0.02) 0.22 
R 0.98 (0.03) 1.05 (0.06) 0.94 (0.04) 0.37 
Forehead      
Magnitude (ms-2) AP 0.87 (0.05) 0.83 (0.08) 1.05 (0.06) 0.08 
 ML 1.03 (0.06) 0.94 (0.11) 1.32 (0.08) <0.05b,c 
 V 1.92 (0.07) 2.03 (0.13) 2.14 (0.09) 0.19 
 R 2.45 (0.07) 2.54 (0.12) 2.88 (0.09) <0.01b 
Jerk (ms-3) AP 13.56 (1.15) 14.76 (2.04) 23.26 (1.40) <0.001b,c 
 ML 13.40 (1.44) 14.99 (2.55) 27.66 (1.75) <0.001b,c 
 V 34.51 (1.84) 39.43 (3.26) 51.99 (2.24) <0.001b,c 
 R 25.95 (1.41) 31.12 (2.50) 34.95 (1.72) <0.01b 
Harmonic Ratio AP 1.61 (0.09) 1.42 (0.16) 1.45 (0.11) 0.44 
 ML 3.32 (0.14) 2.89 (0.26) 2.48 (0.18) <0.01b 
 V 3.90 (0.16) 3.41 (0.29) 2.35 (0.20) <0.001b,c 
RMSR AP 0.35 (0.01) 0.33 (0.03) 0.37 (0.02) 0.58 
 ML 0.43 (0.02) 0.38 (0.04) 0.46 (0.02) 0.27 
 V 0.78 (0.02) 0.79 (0.03) 0.75 (0.02) 0.59 
Jerk Ratio (dB) AP/V -4.25 (0.24) -4.48 (0.42) -3.72 (0.29) 0.33 
 ML/V -4.14 (0.30) -4.30 (0.52) -3.00 (0.36) 0.07 
Step Regularity AP 0.57 (0.03) 0.46 (0.06) 0.42 (0.04) <0.05b 
 ML -0.72 (0.03) -0.64 (0.05) -0.61 (0.03) 0.06 
 V 0.87 (0.02) 0.83 (0.04) 0.69 (0.03) <0.001b,c 
 R 0.66 (0.03) 0.67 (0.05) 0.51 (0.03) <0.01b,c 
Stride Regularity AP 0.68 (0.03) 0.54 (0.04) 0.52 (0.03) <0.001a,b 
 ML 0.70 (0.03) 0.61 (0.04) 0.64 (0.03) 0.16 
 V 0.86 (0.02) 0.83 (0.04) 0.70 (0.02) <0.001b,c 
 R 0.67 (0.02) 0.67 (0.04) 0.56 (0.03) <0.05b 
Symmetry. AP 0.83 (0.05) 0.91 (0.09) 0.85 (0.06) 0.73 
 ML -1.06 (0.03) -1.05 (0.04) -0.97 (0.03) 0.11 
 V 1.02 (0.02) 1.01 (0.04) 1.00 (0.03) 0.82 
 R 1.02 (0.05) 1.01 (0.08) 0.97 (0.06) 0.8 
Coefficient of Attenuation     
Pelvis:Head AP 42.88 (3.29) 44.87 (6.07) 37.68 (4.17) 0.59 
 ML 11.25 (6.63) 27.91 (12.25) 24.06 (8.43) 0.34 
 V 6.38 (2.60) 8.85 (4.80) 8.79 (3.30) 0.82 
 R 22.01 (2.15) 25.73 (3.98) 26.40 (2.74) 0.44 
Pelvis:Shoulder AP 30.08 (5.08) 34.74 (9.39) 29.01 (6.46) 0.88 
 ML 17.12 (4.40) 16.92 (8.12) 24.96 (5.59) 0.59 
 V 2.84 (1.85) 7.92 (3.41) 11.80 (2.35) <0.05b 
 R 5.48 (2.04) 6.45 (3.76) 3.25 (2.58) 0.77 
Shoulder:Head AP 15.76 (4.65) 14.19 (8.60) 10.06 (5.91) 0.79 
 ML -6.22 (5.05) 13.95 (9.33) -2.17 (6.42) 0.15 
 V 3.50 (2.07) 0.56 (3.83) -3.42 (2.63) 0.18 
 R 5.48 (2.03) 6.45 (3.76) 3.25 (2.58) 0.77 
Data are adjusted mean ± SEM. Abbreviation: AP – anteriorposterior, ML – mediolateral, V – vertical, 
R – resultant, RMSR – root mean square ratio. Univariate analysis for differences between disease 
subgroups with post hoc tests for upper body motion gait parameters at lumbar, trunk and forehead 
levels and coefficient of analysis between levels a: healthy control vs mild ataxia b: healthy control vs 
moderate ataxia c: mild ataxia vs moderate ataxia. Missing data: lumbar, trunk and forehead 
magnitude, jerk, harmonic ratio, RMSR and jerk ratio (HC n=25); step regularity, stride regularity, 




Figure 4.5: Key results presented as Z Scores  
Z scores computed for between-group differences and group differences adjusted for sex, age and 
gait speed for spatiotemporal gait characteristics and upper body Motion Gait Parameters. 
Abbreviations: HR Harmonic Ratio, AD1 Step regularity, AD2 Stride Regularity, AP anteroposterior, 
ML mediolateral, V vertical, R resultant. 
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Table 4.16: Between parameter correlations upper body motion vs spatiotemporal gait parameters 
 





















Harmonic Ratio AP -0.396* 0.218 0.146 -0.329 0.034 -0.012 -0.010 -0.433* -0.447* -0.042  
ML 0.052 0.049 0.051 -0.321 -0.041 -0.055 -0.081 -0.361 -0.431* -0.125  
V -0.420* 0.006 -0.093 -0.260 -0.152 -0.207 -0.199 -0.320 -0.447* -0.245 
Step Regularity AP -0.405* 0.202 0.071 -0.308 -0.083 -0.141 -0.050 -0.324 -0.266 -0.132  
ML 0.047 -0.209 -0.142 0.151 -0.067 -0.009 -0.038 0.277 0.285 -0.038  
V -0.212 0.080 0.015 -0.224 -0.170 -0.241 -0.260 -0.215 -0.380 -0.178 
Stride Regularity AP -0.492* 0.066 -0.104 -0.366 -0.095 -0.171 -0.124 -0.474* -0.460* -0.281 
ML -0.149 0.060 -0.029 -0.210 0.010 -0.054 -0.031 -0.397* -0.356 -0.075 
V -0.291 -0.018 -0.093 -0.219 -0.168 -0.259 -0.325 -0.309 -0.433* -0.240 





Harmonic Ratio AP -0.367 -0.065 -0.092 -0.435* -0.247 -0.242 -0.227 -0.463* -0.560** -0.322  
ML 0.119 -0.035 -0.003 -0.126 0.188 0.171 0.009 -0.190 -0.199 0.069  
V -0.156 -0.137 -0.104 -0.382 -0.266 -0.299 -0.338 -0.416* -0.411* -0.314 
Step Regularity AP -0.385 -0.061 -0.159 -0.220 -0.105 -0.132 -0.026 -0.318 -0.376 -0.117  
ML -0.187 0.028 -0.040 -0.148 -0.155 -0.251 -0.292 -0.269 -0.429* -0.176  
V -0.124 -0.187 -0.277 -0.280 -0.110 -0.168 -0.160 -0.430* -0.476* -0.303 
Stride Regularity AP -0.568** -0.111 -0.281 -0.312 -0.122 -0.170 -0.081 -0.513** -0.449* -0.250 
ML -0.347 -0.029 -0.155 -0.144 -0.155 -0.263 -0.277 -0.320 -0.417* -0.240 







Smoothness AP 0.404* -0.230 -0.096 0.104 -0.067 0.034 0.034 0.257 0.261 -0.014  
ML 0.263 -0.385 -0.298 0.168 -0.130 -0.073 -0.064 0.240 0.162 -0.082 
Harmonic Ratio V -0.395* 0.198 0.155 -0.351 -0.051 -0.088 -0.186 -0.427* -0.469* -0.179 
Step Regularity V -0.214 0.303 0.211 -0.142 -0.018 -0.077 -0.112 -0.148 -0.271 -0.083  
R -0.376 0.100 0.013 -0.444* -0.021 -0.074 -0.193 -0.529** -0.552** -0.305 
Stride Regularity AP -0.162 -0.236 -0.303 -0.205 -0.250 -0.237 -0.117 -0.240 -0.106 -0.328 
V -0.350 0.138 0.006 -0.206 -0.038 -0.115 -0.147 -0.281 -0.432* -0.176 
Correlation matrix for spatiotemporal gait characteristics compared with upper body motion variables. * p<0.05, ** p<0.01, Orange highlight = r>0.5 or r<-
0.5. Abbreviations: AP-anteroposterior, ML-mediolateral, V-vertical, R-resultant 
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4.4. DISCUSSION 
This observational study examines the gait characteristics exhibited by individuals with CA 
as well as healthy controls. Spatiotemporal and upper-body motion characteristics of gait 
(as validated in Chapter 3) were measured synchronously. We also examined their 
association with established measures of disease severity (Scale for Assessment and Rating 
of Ataxia, SARA) and falls risk (Berg Balance Scale, BBS). 
4.4.1. PARTICIPANT CHARACTERISTICS 
The cohorts were matched for age, and no significant differences were observed in body 
structure characteristics (height, mass, leg length). Upon clinical assessment, UMN signs 
such as spasticity were common among the ataxic participants, but no participants showed 
signs of cognitive impairment. Patient SARA scores reflect a relatively mild phenotype in 
this cohort with all patients capable of independent gait but some reliant on walking aids in 
daily life. SARAgait&posture score indicates that the participants within the CA cohort all 
exhibited some gait and posture related signs and the moderate ataxia subgroup had worse 
gait and posture subscores than the mild ataxia severity subgroup. Meanwhile, BBS scores 
indicate that the patient cohort has a low risk of falls, with the moderate disease severity 
subgroup at a greater risk of falls than the mild disease severity subgroup. 
4.4.2. GAIT ASSESSMENT  
Gait analysis included assessment of spatiotemporal gait parameters from a photoelectric 
system and evaluation of upper body motion parameters using IMUs during the straight-
line, steady-state phase of walking trials. 
4.4.2.1. Validity of Data Collection 
Validation of system synchronisation was completed to explore the influence of older age 
and disease severity on system accuracy. The detection of initial contact and final contacts 
associated with heel strike and toe-off gait events was associated with a high discriminant 
and concurrent validity. There was a high correlation in all measures (ICC(2, 1) (95% CI)) and 
small absolute System Difference and System Difference). Here we verified that gait events 
are detected by the OptoGait and ADPM Opal sensors  at an accuracy of <0.1s (Table 4.6, 
Figure 4.3). This is in the order of previous results (Chapter 3) where the OptoGait and 
ADPM Opal sensors were compared to the Vicon 3D Motion Capture system. 
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High agreement was also observed between systems in step time, stride time or stance 
time. The OptoGait system was configured in reference to manufacturers 
recommendations (3 LED in/out). A recent publication has indicated that LED thresholds do 
not need to be as stringent as these recommendations (Healy et al., 2019), however, gait 
events detected here were within acceptable ranges and showed good precision between 
systems. Upon examination of the relationship between system differences and measured 
values for gait events and gait parameters for healthy and ataxic participants (Figure 4.3, 
Figure 4.4), data points did not appear to cluster by cohort. This indicates that the accuracy 
of gait event detection and gait parameter calculation was not confounded by diagnosis of 
ataxia. 
4.4.2.2. Spatiotemporal Gait Parameters 
Overall, the preferred paced walking of the patient cohort appears to be a lower velocity 
than the preferred paced walking of the control cohort. Similar to previous findings, 
(Chapter 2), the ataxic cohort exhibit a shorter step and stride length compared with 
controls. Step width was larger in ataxic participants on average, reflecting the hallmark 
characteristic of ataxia (Stolze et al., 2002). In humans, an individual’s step width is selected 
in order to minimise the metabolic cost of walking (Donelan et al., 2001). In people with PD, 
step width is increased in challenging walking tasks incorporating different surfaces 
(Caetano et al., 2009).Therefore, in Ataxia, the increase in step width reflects the 
participant’s preference to expand their base of support due to gait instability. Temporal 
parameters were not significantly affected between cohorts in our study in unadjusted 
statistical analysis. Gait variability, relates to the accuracy of foot placement during walking. 
Here, in the ataxic group, average variability (%CV) is higher in the majority of gait 
parameters compared with the controls, which corroborates findings across the published 
literature (Ebersbach et al., 1999, Gouelle et al., 2013, Ienaga et al., 2006, Palliyath et al., 
1998, Schmitz-Hübsch et al., 2016, Schniepp et al., 2014, Serrao et al., 2012). An increased 
asymmetry was also observed in cadence, stride time, swing time and SLS time as well as 
swing phase perc. and SLS phase perc. in the CA cohort. This may reflect asymmetrical 
weakness and spasticity, which commonly affects people with CA. 
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4.4.2.3. Upper body Motion Gait Parameters 
Meanwhile, as postural motion data and spatiotemporal gait parameters have been 
acquired in synchronisation it is possible to explore specific biomechanical interactions in 
CA. Here in an ataxic cohort, we have observed significantly lower vertical RMS acceleration 
signal at the trunk and  increased ML RMS acceleration signal at the trunk and forehead. 
These changes reflect a reduced intensity of trunk rotation and increased intensity of 
flexion/extension motion during walking gait. Fazio et al. (2013) described a lower RMS 
resultant acceleration at the lower back in 24 ataxia patients compared with 24 healthy 
controls. Shirai et al. (2015) meanwhile, observed significantly increased ML and reduced 
vertical and AP RMS acceleration at the lower back and upper back in 25 patients with 
spinocerebellar degeneration compared with 25 healthy controls. Hickey et al. (2016) also 
identified that increased ML accelerations in the upper body during gait correlated with 
disease severity in individuals with mild to moderate ataxia. 
Changes in harmonic ratio indicate that people with ataxia exhibited greater step to step 
asymmetry and reduced rhythmicity of AP, ML and vertical acceleration components at the 
lumbar and trunk sensors and the ML and vertical components at the forehead. This implies 
that ataxic individuals display lower stability of the upper body segment during walking 
compared with healthy controls. This corroborates recent findings during lab-based, 
supervised free and real-life walking in ataxia using a single waist-worn sensor (Ilg et al., 
2019). 
Autocorrelation analysis indicates that step and stride regularity were significantly impaired 
in ataxia across all three signal components and the resultant signal at all three sensor 
positions compared with controls. Here, our ataxia cohort compared with healthy 
individuals also displayed a significantly increased body sway (RMSR) in ML axis and 
reduced in vertical component at all 3 sensor positions and increased body sway in AP axis 
at the head. Matsushima et al. (2015) reported that in gait tests with a waist-worn triaxial 
accelerometer, people with CA exhibit lower step regularity in AP and vertical axis as well as 
increased body sway (RMSR in ML axis).  
Attenuation of upper body oscillations during walking gait is vital to ensure an efficient 
locomotion (Mazza et al., 2008). Our results indicate that people with ataxia display less 
effective attenuation of AP accelerations pelvis to trunk and trunk to head causing 
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increased lateral bending of the trunk during walking gait. Further, while ML accelerations 
are consistently increased throughout the upper body in ataxia relating to uncontrolled 
trunk flexion, vertical direction accelerations appear to display an impaired coupling of the 
trunk segments resulting in increased rotation of the upper trunk but not the pelvis or 
forehead. This builds on the work from Conte et al. (2014) who recognised, in motion 
capture studies, that people with ataxia, during walking is characterised by increased 
forward flexing, lateral bending and rotation. 
In our cohort of people with CA, jerk signal was significantly increased in the ML axis at the 
trunk and forehead and in the AP axis at the forehead. Although vertical jerk is inherently 
associated with gait speed, the slower ataxic cohort did not exhibit significant differences at 
any level of the lower back. Further, using Jerk Ratio as a speed-independent measure of 
stability, the CA cohort was significantly higher in ML/V ratio at all three sensor positions 
and in AP/V ratio at the forehead. Again this reflects impaired control of postural gait 
changes in this cohort. Fazio et al. (2013) described lower RMS jerk values in ataxia patients 
at the thoracic level therefore, these differing results may indicate there may be differences 
between study participants and gait tests. 
4.4.3. GAIT INFLUENCES 
In the present study, a number of gait metrics show good correlations with the SARA as a 
measure of disease severity. Meanwhile, in subgroup analysis, in terms of the 
spatiotemporal gait parameters, the mild ataxia group, appears to form an intermediate 
phenotype, characterised by a reduction in stride length, step length, and increase in step 
width compared with healthy controls. For speed and many asymmetry measures, the mild 
ataxia group remains in line with control cohort results while differentiating from the 
moderate ataxia group. A number of temporal gait variability measures display a significant 
difference between disease severity subgroups and healthy controls. This indicates that 
increased gait variability may be an early gait change in CA that is further worsened with 
disease severity. These variables retained significant differences when adjusted for age, sex 
and gait speed in univariate analysis.  
For the upper body motion measures extracted from the acceleration signals, the Mild 
Ataxia cohort also appears to form a phenotype intermediate to the Healthy and Moderate 
Ataxia cohorts particularly in the HRV measured at Lumbar position. Therefore, changes to 
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rhythmicity of gait may represent an early indicator of ataxia.  However, the Moderate 
Ataxia group differentiates from the Mild Ataxia and Healthy cohorts in many other 
variables, independent of gait speed. In particular, HRAP at lumbar and trunk, HRML lumbar 
and trunk, HRV at lumbar, trunk and forehead; AD1 and AD2 lumbar in AP, ML, vertical and 
R, trunk in AP, vertical and R, and forehead in vertical and resultant components. Therefore, 
increased severity of ataxia is associated with an exacerbation of rhythmicity and regularity. 
Since these variables are able to distinguish between mild and moderate ataxia 
independent of changes in gait speed, they may show promise as robust biomarkers of 
disease progression in future work.  
4.4.4. CLINICAL CONTEXT OF FINDINGS 
Here we hypothesised that disease-related differences (disease severity and genetic 
diagnoses) in upper-body motion during gait would complement spatiotemporal gait 
parameters. 
Analysis of trunk stability in walking gait has proven to be an interesting area of research in 
PD and Multiple Sclerosis but is not yet established in CA research and clinical practice. 
Spatiotemporal gait changes in individuals with CA are a form of compensation for trunk 
instability (Bunn et al., 2013), therefore assessing the two aspects of gait in synchronisation 
is highly advantageous to the research community.  
Our results also indicate the advantage of performing instrumented gait analysis over un-
instrumented alternatives such as the timed-up and go or six-minute walk test. These 
alternative walking tasks can obtain information regarding gait speed and exercise capacity 
which can indicate a disability. However, they do not have the temporal resolution to 
characterise gait changes on a stride by stride basis. This limits their use as an objective 
biomarker for disease severity. 
To the best of our knowledge, very little investigation of head motion during walking gait in 
CA has previously been reported. In this cohort, jerkiness, rhythmicity and regularity of the 
head motion, correlate well with clinical measures, differentiate healthy controls from 
people with ataxia and mild severity ataxia from moderately severe ataxia. The differential 
findings from the trunk and head measurements indicates a potential uncoupling of the 
neck and shoulders in people with CA.Therefore, there may be additional value in including 
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these measures in the gait assessment protocol and this should be considered when 
designing future studies.  
Since we have not formally assessed neurological impairments through neuroimaging 
techniques such as MRI or CT, it is not possible to draw direct correlation between gait 
impairments and physical abnormalities in the brain. However, previous studies have 
identified atrophy and lesions in the brains of individuals with ataxia and compared gait 
characteristics in different neurological conditions. For instance, since the lateral 
cerebellum receives visual input to plan stepping during walking, lesions in this region lead 
to foot placement issues (Cerminara et al., 2005, Walker HK, 1990). While we have 
observed this phenomenon in our spatiotemporal gait parameters such as gait variability, 
the upper body motion parameters add detail about the impact of stepping on postural 
control during gait. Here, in people with cerebellar ataxia, gait instability was objectively 
measured as uncontrolled forward flexing, and lateral bending as well as increased gait 
variability. This may be a result of a un/conscious compensation for loss of coordination 
during walking or part of the clinical manifestation of ataxia. Differentiating between 
compensatory responses and pathological gait changes is essential to the development of 
gait as a biomarker for disease severity and balance performance. While for some variables, 
the mild ataxia cohort values are in line with the healthy control group for other results, the 
mild ataxia group show an intermediate phenotype with respect to the control and 
moderate ataxia group. Variables that distinguish early ataxia from healthy controls, as well 
as those distinguishing mild from moderate ataxia, have potential as biomarkers of disease 
progression. Our findings were further explored by univariate analysis including age, sex 
and gait speed as covariates. Many variables retained significant differences between 
cohorts and disease severity subgroups demonstrating that these findings are independent 
of age, sex and gait speed. This is particularly important as many gait variables exhibit 
considerable interdependency especially with gait speed (Hebenstreit et al., 2015). 
In ataxia, reduced intersegmental coordination, instability of walking and increased 
frequency of falls are common especially during slow-paced walking (Schniepp et al., 2016). 
The Berg Balance scale (BBS) was developed as a marker of falls risk and balance 
performance. Here, many variables correlate with a reduced BBS score: speed, cadence, 
step width and gait variability measures are especially correlated with the BBS score as well 
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as asymmetry, and regularity of upper body motion. To enable efficient walking gait, a level 
of variability is necessary to be able to adapt to a changing environment. This gait variability 
is consistent amongst young and older adults (Herssens et al., 2018) but increased 
variability can be a measure of gait instability and related to an increased risk of falls 
(Hausdorff et al., 2001b). Meanwhile, a systematic review of falls in PD indicates that non-
fallers display a lower ML and V motion at head and pelvis (Creaby and Cole, 2018). 
Meanwhile, the literature also indicates that AP gait stability also correlates with a history 
of falls (Chini et al., 2016). Previous studies have shown that harmonic ratios of the head 
are associated with fall risk (Menz et al., 2003) in healthy individuals. Although many of the 
cohort differences correlate with BBS scores, we were not able to corroborate this in the 
present ataxia cohort since a detailed falls assessment was not undertaken. 
In the present study, people with ataxia walked significantly slower than healthy controls 
and many spatiotemporal and variability gait parameters correlated with gait speed similar 
to previous studies (Wuehr et al., 2013). Our findings from linear regression analyses 
incorporating gait speed as a confounding variable, indicate that the ataxic gait pattern is 
not just a result of the change in gait speed. Therefore, our findings suggest the additional 
value of implementing an instrumented gait test rather than clinical rating scales and un-
instrumented alternatives where only gait speed and exercise capacity are measured 
objectively.  
Meanwhile, partial correlation analysis indicates that independent of gait speed, step 
width, step length variability and stride length variability show negative correlations with 
postural control variables. These results suggest that asymmetry of truncal lateral bending, 
the stride regularity of truncal lateral bending and lumbar motion, and step regularity of 
overall forehead motion are associated with increased spatiotemporal gait impairment. 
Looking forward to longitudinal assessment many gait characteristics and quality 
parameters are able to characterise disease severity in the patient cohort and distinguish 
mild ataxia from healthy controls. For instance, speed, step width, variability, attenuation, 
postural symmetry, and regularity measures show differences between disease severity 
subgroups and many correlate with BBS score. Therefore, these parameter(s) have the 
potential to detect subtle gait changes as a result of disease progression over time. 
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4.4.5. LIMITATIONS 
Some data within trials were excluded due to technical difficulties with data capture and/ 
or analysis software and as such the results reported here reflect fewer steps within trials 
than were originally captured. Despite completing visual checks at the time of assessment 
and taking precautions to ensure data validity, some issues with the technique persisted, 
particularly for the OptoGait. For instance, occasional steps were identified as having an 
invalid flight time and other steps were overlooked by the built-in algorithm. As much data 
was retained as possible by removing sections or passes of walking trials where issues were 
identified so that outcomes were provided for every participant.  
It should also be noted that despite clear instructions to wear flat-soled outdoor shoes, 
differences in participant’s footwear will inherently influence gait (Franklin et al., 2015). In 
addition, since our ataxic participants needed to be comfortable completing walking tests 
unaided, our findings are only generalisable to a relatively mild phenotype. Meanwhile, 
small differences in the walkway length (<1m) may have occurred with repeated 
assessment sessions and changing venues although an effort was made to keep the system 
as similar as possible. 
A previous sample size estimate based on the previous literature suggested that the cohort 
of 27 people with ataxia and 27 healthy control participants recruited in this study would be 
sufficient for the spatiotemporal characteristics. As a consensus gait pattern has not been 
established for the upper body motion characteristics a sample size calculation for these 
was not possible. However, effect size estimation based on the results of this study, 
indicate that a larger cohort is still needed to confirm these findings and we may not have 
reached significance. Therefore, these findings should be considered preliminary and 
warranting further study in a larger cohort.  
It is also possible that individual characteristics such as disease features, and sex disparity 
have influenced the ability to observe between-cohort differences. The inclusion/exclusion 
criteria restricted recruitment to individuals that were capable of walking unaided for the 
purpose of the testing. Although some participants did report use of walking aids in their 
daily life, the recruited cohort of people with ataxia inherently exhibit a mild phenotype. 
This will limit the generalisability of these results to the wider ataxia population. 
Differences in gait due to sex have been previously explored in healthy individuals (Mazzà 
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et al., 2008). While, there is no conclusive indication of sex influencing ataxia onset and 
symptoms, it is important to recognise that in the present study, recruitment was not 
controlled on the basis of sex resulting in 37.0% and 59.3% females in CA and HC cohorts 
respectively. Therefore, some differences between cohorts may exist due to the disparate 
male: female ratio and should be considered in future work. However, univariate analysis 
with age, sex and gait speed as covariate factors was completed in an attempt to control for 
these confounding variables and our key findings are reported independent of these 
factors. 
In addition, due to the limited number of participants recruited, subgroup analyses to 
investigate the influence of disease diagnosis was not completed at this time. The most 
prevalent genetic diagnoses recruited were spinocerebellar ataxia 6 (SCA6) which is 
considered a “pure” cerebellar ataxia, and spastic paraplegia 7 (SPG7) which is primarily 
characterised by weakness and spasticity but is associated with ataxia. Due to the clinical 
differences between the syndromes, it is possible that there are underlying differences in 
the pathology which could impact the gait pattern. This limitation will be investigated 
further in the future. 
As established in Chapter 3, the OptoGait and ADPM Opal sensors systems have a limit to 
their precision and accuracy. Although the agreement between the two systems was less 
than in the validation study, values for gait event detection and gait parameter calculation 
correlate well and are within reasonable ranges. Our measurement of step width in 
particular should also be interpreted with care since validation study indicated that a 
systematic bias (±3.76cm, 95%LoA) is present in the estimation. Previous findings have 
indicated that slow walking can interfere with the accuracy of gait event detection using 
inertial sensors (Feng et al., 2017). Although this was not explicitly explored here, despite 
the slow walking speed exhibit by people with CA and healthy control participants, our 
validity findings are comparable to others (Pacini Panebianco et al., 2018). In addition, 
Bland-Altman plots did not indicate that ataxia cohort membership leads to inaccurate gait 
event detection and gait parameter calculation compared with healthy controls. Gait speed 
has a large influence on many gait parameters. Although our additional analysis allows us to 
explore group differences while using gait speed as a covariate, further work may explore 
the influence of speed changes on the gait pattern further.  
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In addition, a large number of gait variables were explored in this study. This was intended 
to avoid restricting the hypotheses to variables that have already been reported and allow 
a holistic view of the gait pattern to be assembled. However, as already discussed many 
aspects of the gait pattern are fundamentally interrelated and associated with gait speed in 
particular. Therefore, it is important to subsume variables where possible and to be 
informed by the clinical features of a movement disorder. This will be considered going 
forward in the selection of gait variables for longitudinal assessment in a subset of 
participant and for future clinical use. For instance, while gait speed has been selected for 
further consideration, cadence and step/ stride time have not due to their 
interdependency. In addition, while overall trunk motion can be reflected in the resultant 
values for gait measures, the clinical value of individual components will also be considered 
in future work. Partial correlation analysis also indicated that step variability, stride 
variability and step width show interdependence with postural asymmetry, stride regularity 
and step regularity. Therefore, further work is required to explore if these spatiotemporal 
gait parameters are interchangeable with postural control variables and which variables are 
most relevant to patient stratification in ataxia. Further work is also required to explore 
these variables with respect to a detailed falls assessment. 
4.5. CONCLUSION 
Here ataxic gait is characterised by excessive sagittal, lateral and vertical oscillations as well 
as insufficient coordination between the upper and lower body segments. Speed, step 
width, gait variability as well as step to step asymmetry, step regularity and stride regularity 
all show promise as biomarkers of gait ataxia. In individuals with CA, spatiotemporal gait 
changes such as increased step width and gait asymmetry appear to be a form of 
compensation for lateral instability. This indicates the advantage of assessing the two 
aspects of gait in synchronisation. 
Since some spatiotemporal gait variables may be interchangeable for postural control 
variables, further work in a larger cohort is required to validate the ability of these variables 
to classify ataxic gait through multivariate regression analysis. Patients with a pre-
symptomatic/mild ataxia phenotype can be differentiated from more severely affected 
patients and healthy controls using gait as a biomarker. Further work is required to examine 
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longitudinal gait changes in ataxia over time and to expand examination of differences 
between disease diagnoses and falls history. 
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Chapter 5. GAIT ANALYSIS FOR THE LONGITUDINAL ASSESSMENT OF 
HEREDITARY CEREBELLAR ATAXIA  
5.1. INTRODUCTION 
Presently, in the clinical care of people with cerebellar ataxia (CA), clinicians rely on clinical 
assessment tools to measure an individual’s disease severity and disease progression. In CA, 
slowly progressing neurodegeneration causes damage to the cerebellum and worsening 
incoordination and balance performance. The rate of progression can vary between 
individuals and specific ataxia diagnoses (Schmitz-Hübsch et al., 2016). This limited ability of 
current rating scales to monitor symptom changes over short-term periods indicates their 
unsuitability to measure the effect of interventions and treatment. 
Very few longitudinal studies have explored objectively measured gait changes over time in 
adult ataxia and have so far provided inconsistent results (Milne et al., 2018). For instance, 
in a cohort of 18 individuals with degenerative and static cerebellar damages, although 
stance time percentage and step width correlated with International Cerebellar Ataxia 
Rating Scale (ICARS) scores, no significant changes were observed over a 12 month period 
(Morton et al., 2010). In a 4-year follow-up study meanwhile, gait decline was quantified as 
reduced step length and hip, knee, and ankle joint RoM and increased trunk rotation range 
of motion (RoM) as well as stride length and step length variability (Serrao et al., 2017a). A 
study of postural stability during gait and standing indicated that autocorrelation and Root 
Mean Square Ratio may also have potential in the longitudinal assessment of cerebellar 
disease (Matsushima et al., 2015). Previous studies in Friedrich’s Ataxia, indicated that gait 
velocity and double limb support percentage as well as swing/stance percentage gait cycle 
and knee range of movement are particularly promising in measuring disease progression 
(Vasco et al., 2016, Zesiewicz et al., 2017). Since gait velocity has been proposed as a 6th 
vital sign (Fritz and Lusardi, 2009), it follows that gait impairment over time may manifest 
as reduced gait speed.  
Reliable normative values for spatiotemporal parameters and upper body motion are 
needed and establishing the degree of change in gait parameters that reflect genuine 
disease progression is vital to distinguish the pattern of gait disturbances for different 
movement disorders (Hollman et al., 2011). Therefore, gait analysis techniques potentially 
provide a measure that can be monitored over time better than current clinical methods.  
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We have previously established gait pattern in CA during the systematic review (Chapter 2) 
and baseline assessment (Chapter 4) and the gait analysis system accuracy through the 
study of gait event detection in healthy individuals (Chapter 3) and people with CA (Chapter 
4). In this previous work, people with CA walk with reduced gait speed, increased step 
width and increased gait variability while postural symmetry and regularity are also 
impaired. Since these measures show sensitivity to disease severity and correlate with 
clinical measures of balance impairment, here we explore these variables in the context of 
a longitudinal study. 
5.1.1. AIMS AND HYPOTHESIS 
This study aimed to identify spatiotemporal and upper-body gait characteristics capable of 
objectively quantifying gait changes over 12 months period in people with CA and examine 
whether this relates to disease progression. A second follow-up visits was intended to be 
completed at 24 months to examine a longer disease course.  
In our previous study (Chapter 4) many gait measures were sensitive to disease severity, 
therefore these variables may also show promise in measurement of disease progression. 
We hypothesise that spatiotemporal and upper body motion characteristics may be able to 
recognize disease progression in an ataxic cohort.  
5.2. METHODS 
5.2.1. STUDY INFORMATION 
This longitudinal study of gait characteristics in cerebellar ataxia is incorporated by “Gait 
Analysis in Cerebellar Ataxia and Hereditary Spastic Paraparesis”, which is sponsored by the 
Sheffield Children’s Hospital. This project aims to detect subtle gait characteristics of ataxia. 
This study was conducted, according to the Declaration of Helsinki, and received ethical 
approval by the North West - Liverpool East Research Ethics Committee (REC: 
16/NW/0343). Local approvals were obtained from the Sheffield Children’s Hospital as 
study sponsor and the Sheffield Teaching Hospitals Trust as the site of data collection 
(SCH2048 and STH19282). All testing took place at the Clinical Research Facility at the 
Northern General Hospital, Sheffield. All participants signed an informed consent form. 
|188 
5.2.2. PARTICIPANTS 
Ataxic participants enrolled in the Clinic-based gait analysis study (Chapter 4) were invited 
to attend follow-up assessments (1) 12-18 months after their baseline assessment and (2) a 
further 12-18 months after their 12 month follow-up if this occurred within the data 
collection period. If they were no longer able to complete the gait analysis tasks unaided, 
they did not complete in any further assessments. Follow-up assessments visits took place 
between November 2017 and December 2018. Therefore, some participants did not reach 
their follow-up assessment date within this time period. Details of participant attrition rate 
provided in section 5.3.1. 
5.2.3. PROTOCOL 
Follow-up assessments took place at 12-18 months later and at 24-28 months following 
baseline assessment. Participants underwent the same protocol as at baseline in order to 
be consistent in our gait assessment methods. Usual clinical care was not examined within 
this study and no change was made during the follow-up period to care received. A 
structured medical interview and clinical examination completed (Appendix 14) with recent 
falls history, and upper motor neuron signs of lower limb spasticity (clonus, spastic limbs, 
and hyperreflexia) were noted. Validated rating scales were also completed: Montreal 
Cognitive Assessment (MoCA, Nasreddine et al., 2005), Berg Balance Scale (BBS, Berg et al., 
1995), and the Scale for Assessment of Ataxia (SARA, Schmitz-Hübsch et al., 2006). The 
SARAGait&Posture subscore was calculated (Lawerman et al., 2017). For individual changes in 
the SARA score, a minimal detectable change (MDC) considered as <3.5 (Schmitz-Hübsch et 
al., 2010).  
Participants performed a short gait task, at a self-selected speed. The OptoGait 
photoelectric 5m gait analysis system with Boosted transmission bar was implemented 
(Microgate Corporation, Bolzano, Italy) while wearing five ADPM Opal triaxial inertial 
sensors (APDMInc, Portland, OR, USA) (see Section 4.2.4 for further information on 
equipment used). 
5.2.4. EQUIPMENT 
As discussed in Chapter 4, gait analysis was performed on participants using two gait 
analysis systems: the OptoGait LED array system (Microgate Corporation, Bolzano, Italy) 
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and the ADPM Opal system of triaxial inertial sensors (APDMInc, Portland, OR, USA). 
Equipment was set up in the same synchronised way as at baseline assessment (Chapter 4). 
All data gathered for the purposes of the study was backed up to an encrypted external 
hard drive and stored in a locked cupboard within the Sheffield Institute for Translational 
Neuroscience, the University of Sheffield alongside completed study report forms. Signed 
consent forms were stored within the site file in the possession of Dr McNeill and lists of 
recruited participants maintained regularly. 
5.2.5. DATA ANALYSIS 
5.2.5.1. Spatiotemporal Gait Parameters 
The gait events that were automatically detected by the OptoGait system were verified 
visually and trial results exported to Microsoft Excel. Only footfalls where both heel strike 
and toe-off were considered to begin within the system were included to ensure accurate 
detection of initial and final contact events for calculation of gait parameters.  
Spatiotemporal gait parameters selected in Chapter 4 and therefore used here include 
measurement of speed (m/s), step width (cm), cadence asymmetry (steps/min), stride time 
asymmetry (s) and variability of a number of these measures (%CV). For further explanation 
of gait parameters, see Figure 1.1.  
The within-person variability of spatiotemporal gait parameters was considered through 
the calculation of the coefficient of variation (CV, expressed as a percentage) (Equation 
5.1). 
Meanwhile, computing left-right asymmetry (Equation 5.2) from absolute difference of 
mean gait measures recorded for left and right feet enables an appreciation of step to step 
differences (Godfrey et al., 2015). 
5.2.5.2. Upper body Motion Gait Parameters 
As described previously, motion inertial data was analysed using MATLAB (Mathworks Inc., 
Natick, MA, USA) through custom computational programmes (Section 4.2.5.2). Trial data 
were segmented into single passes and gait events detected from the left and right ankle 
angular velocity signal following the method used by Salarian et al (2004).  
Equation 5.2: 𝐴𝑠𝑦𝑚𝑚𝑒𝑡𝑟𝑦 = [𝑚𝑒𝑎𝑛𝐿𝑒𝑓𝑡 − 𝑚𝑒𝑎𝑛𝑅𝑖𝑔ℎ𝑡] 
Equation 5.1: Coefficient of Variation (%) = S mean⁄ ×  100 
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A number of upper body motion variables were selected on the basis of univariate analysis 
of baseline gait results incorporating age, sex and baseline analysis as covariate factors 
(Chapter 4). Computational analysis of acceleration signals included: Root Mean Square 
(RMS) of accelerations (at each of the three levels) (Helbostad and Moe-Nilssen, 2003), 
Harmonic Ratio (Latt et al., 2008), RMS Jerk (also at the three levels, (Brodie et al., 2014, 
Fazio et al., 2013)). Auto-correlation coefficients for step and stride durations were 
computed for each pass for each walking trial (Moe-Nilssen and Helbostad, 2004). Details of 
the analysis of motion at the head, trunk and pelvis levels can be found in Table 4.1.  
Descriptive analysis of upper-body gait parameters was then completed per participant in 
MATLAB prior to export in preparation for cohort statistical analysis.  
5.2.6. STATISTICAL ANALYSIS 
Descriptive analysis (average and standard deviation) was completed for demographic 
characteristics. Participant level summary of gait measures were assembled into a single 
data table for cohort level statistical analysis (SPSS Statistics (version 23, IBM)).  
To appreciate changes in gait measures at 12 month follow-up, descriptive analysis was also 
completed for spatiotemporal gait characteristics and upper body measures to compare 
between study visits for the ataxia cohort. Normality of the datasets was tested using 
Shapiro Wilks tests, then between-visit differences assessed through paired t-tests and 
Wilcoxon non-parametric paired samples test. A significance level assumed at p value<0.05. 
The effect size was calculated based on the results of paired samples test as Cohen’s d 
(Equation 5.3) where paired difference calculated as baseline – 12month result. The 
threshold thresholds of 0.1, 0.3, and 0.5 were recommended by Field (2018) for small, 
medium, and large effect sizes, respectively. 
Paired samples correlation coefficients are also reported to indicate agreement between 
partcipants. To explore how disease severity correlates with gait change over 12month 
period, paired samples correlation tests were completed for change in SARA and change in 
gait measures. For parameters that achieved a large effect size, individual results were 
plotted against SARA score at each timepoint.  
Equation 5.3: Effect Size = Paired mean difference SD paired differences⁄  
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Due to the small number of participants that completed 24 month follow-up, no formal 
analyses were completed. As an exploratory examination of the trends, the results for 
parameters that achieved a large effect size were plotted to appreciate any intra-individual 
differences. 
5.3. RESULTS 
5.3.1. PARTICIPANT RETENTION 
Of the 27 ataxic participants recruited to the study at baseline, 16 completed their 12-
month follow-up within the data collection period at 12.8±1.8months after baseline. Two 
participants were not able to complete gait tasks unaided due to disease progression, 1 
participant was not well enough to attend so withdrew from further participation. Three 
participants chose not to return for follow-up assessment (n=3). For 5 participants recruited 
to the study, due to the timing of their baseline assessments, their 12-month follow-up visit 
was not due until following the end of the data collection period. 
A subgroup of 5 participants also completed their 24month follow-up at 12.1±0.2months 
after their 12-month visit. No other participants reached their follow-up assessment date 
within the data collection period.   
5.3.2. PARTICIPANT CHARACTERISTICS 
The participant demographics for the individuals who completed at 12 month and 24month 
follow-ups are detailed in Table 5.1. 
16 participants (7 female) completed 12-month follow-up assessments. 5 Participants also 
completed a 24month follow-up assessment (approx. 12 months following 2nd visit). No 
significant difference was observed in SARA, MoCA and BBS between visits 1 to 2 and visits 
1 to 3. For individuals, change in SARA score greater than the MDC <3.5 did not occur in any 
of the individuals that completed 12 month or 24-month follow-up. Therefore, for the 
cohort on the whole, the disease status was stable within this time period and no disease 
progression occurred.  
The 5 participants who were able to complete 24 month follow-up displayed a less severely 
affected subgroup of the cohort assessed at 12 month follow-up as indicate by a lower 
average SARA score and SARAGait&Posture subscore as well as better balance performance 
(higher BBS score). 
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P01 F 52 161 54 78 R 0 SCA6 N 6 N 14.5 6  29 53 11.5 3 30 40        
P03 M 54 174 70 77 R 5 SPG7 Y 21 N 14 4 26 43 11.5 3 29 46        
P04 M 51 162 82 78 L 0   • Y   N 10 3  27 41 8.5 3 29 51        
P06 M 53 187 81 90 R 6 SPG7 N 3 N 6 1 25 56 6 1 26 54 9 2 27 48 
P07 F 55 160 56 74 R 5 SCA6 N 21 Y 2 1 30 56 0 0 29 56 0 0 30 55 
P08 M 52 180 90 83 R 2 ADFHx Y 42 Y 13 5 26 31 14 6 27 28        
P10 M 52 175 91 73 R 23 SPG7 Y 16 N 8.5 4 30 39 12 4 28 46 9.5 2 28 44 
P11 F 61 171 60 80 R 3 SCA6 N 4 Y 2.5 1 29 56 2.5 1 29 56 3 1 30 56 
P13 M 65 186 105 87 L 30 SCA6 N 10 N 10 5 25 42 8 5 27 45 9 2 28 40 
P14 F 57 161 41 84 R 0 SCA6 N 6 N 18 5 27 29 18 7 26 26        
P16 F 66 171 62 92 R 5 SPG7 N 0 N 4.5 2 24 44 2 2 24 44        
P17 M 65 181 63 75 L 5   • N 10 N 10.5 4 28 51 9 4 29 48        
P18 M 37 175 73 73 R 0   • N   N 11 3 25 41 12 3 23 40        
P20 M 53 175 73 83 R 0 SPG7 Y 7 Y 8.5 5 26 39 9 4 26 35        
P21 F 19 161 62 67 R 5 SCA6 N 0.5 N 11.5 4 28 47 8 3 27 45        
P22 F 63 131 68 79 L 5 SCA6 N 1.5 N 11.5 4 26 52 9 3 27 48        
Values for demographics characteristics and clinical rating scales as measured at baseline, 12 months & 24months. Abbreviations: M-Male, F-Female, cm-
centimetre, SARA-Scale for Assessment and Rating of Ataxia, BBS-Berg Balance Scale, MoCA-Montreal Cognition Assessment
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Table 5.2: Descriptive summary of participants that completed follow-up 
a) Baseline (n=16, 7F) 12 month Follow-up (n=16, 7F) p 
Age (years) 53.44 (11.71)   
Height (cm) 169.41 (13.62)   
Mass (kg) 70.64 (16.14) 71.03 (16.59) 0.60 
Leg Length (cm) to floor 90.25 (5.54)   
Diagnosis subtype 7 SCA6, 5 SPG7, AD FHx  
Duration of diagnosis 10.57 (11.39)   
Time to follow-up 12.8±1.8months  
Falls history 12 Non-Fallers, 4 Fallers  
Alcohol intake 5.88 (8.47)   
SARA (/40) 9.75 (4.36) 8.81 (4.61) 0.06 
SARAGait&Posture (/18) 3.56 (1.59) 3.25 (1.81) 0.26 
BBS (/56) 45.0 (8.51) 44.25 (8.84) 0.40 
MoCA (/30) 26.94 (1.88) 27.25 (1.95) 0.57 
UMN signs Present in 4 patients  
b) Baseline (n=5, 2F) 24 month Follow-up (n=5, 2F) p 
Age (years) 57.20 (5.59)   
Height (cm) 175.80 (11.21)  
Mass (kg) 78.58 (20.69) 77.10 (19.57) 0.21 
Leg Length (cm) to floor 90.6 (5.86)  
Diagnosis subtype 3 SCA6, 2 SPG7  
Duration of diagnosis 10.80 (7.73)  
Time to follow-up 12.1±0.2months  
Falls history 3 Non-Fallers, 2 Fallers  
Alcohol intake 13.40 (12.26)   
SARA (/40) 5.80 (3.55) 6.10 (4.34) 0.75 
SARAGait&Posture (/18) 2.4 (1.95) 2.4 (1.82) 1.00 
BBS (/56) 49.80 (8.56) 48.60 (6.91) 0.41 
MoCA (/30) 27.80 (2.59) 28.60 (1.34) 0.60 
UMN signs Present in 4 patients  
 
a) 12 month follow-up and b) 24 month follow-up. Data reported as mean (SD). Statistical test: 
paired sampled T-Test. Abbreviations: n-number of patients, SARA- Scale for Assessment and Rating 




5.3.3. GAIT ASSESSMENT 
5.3.3.1. Baseline vs 12 months 
Table 5.3 contains the results of gait assessment at baseline and 12 month follow-up with 
effect size and significance level from paired statistical-tests. 
At 12 month follow-up, of the spatiotemporal gait parameters selected from baseline study, 
CA patients exhibit a significant increase in step width (mean difference (MD) =1.00cm, 
p=0.04, effect size (d)=-0.57). For the upper body motion gait characteristics selected based 
on baseline findings, lumbar HRML (MD=-0.2, p<0.01, d=0.86), and ML stride regularity 
(MD=-0.1, p=0.04, d=-0.38) as well as forehead HRV (MD=-0.41, p=0.05, d=-0.36) and 
resultant step regularity (MD=-0.06, p=0.02, d=0.67) display significant differences and 
medium to large effect sizes compared with baseline. Insufficient adjacent steps were 
computed for 1 participant at 12-month followup to be able to compute upper body 
motion parameters. In addition, Stride time asymmetry, lumbar anteroposterior (AP) stride 
regularity and Trunk AP harmonic ratio show medium to large effect sizes. Therefore, this 
study may be underpowered to detect changes in these variables within 12 months. 
Paired samples correlations indicate a measurement consistency across the cohort in many 
variables between baseline and 12-month follow-up. Notably, step width, lumbar HRML and 
forehead AD1R change significantly over time and have strong paired correlations with a 
good effect size (Figure 5.1). 
No decline in SARA score occurred over the 12-month period, a significant correlation was 
only observed between intra-individual change in trunk HRML and SARA score but none of 
the other measures examined (Table 5.3, Figure 5.2). Since no significant change occurred 
in this measure over time this does not reflect any clinically relevant change over time. 
There does not appear to be much consistency in the responsiveness of the gait measures 
to the SARA on an individual level and how these changed between visits.  
5.3.3.2. Baseline vs 24months 
For the 5 participants that completed 24month follow-up, gait parameters with medium to 
large effect sizes at 12 months were examined visually (Figure 5.3). These individuals reflect 
a less severely disabled ataxia cohort and no consistent changes appear to be present in 
these variables at 12 months and 24 month follow-up. It is not possible to determine 
whether a decline of gait occurs in this small cohort.  Since there is also no change in 
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disease severity or balance performance occurs, any trend observed in this subgroup may 
be a natural fluctuation and not a genuine progression of gait impairment.  
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Speed (m/s) 1.18 (0.18) 1.16 (0.24) 0.50 0.17 0.80*** 0.01 
Step Width (cm) 15.86 (4.71) 16.86 (5.28) <0.05 -0.57 0.94*** -0.04 
Asymmetry Measures 
Cadence (Steps per 
min) 
1.32 [0.55, 1.99] 0.76 [0.36, 1.23] 0.23 -0.21 0.23 -0.30 
Stride Time (s) 0.013 (0.009) 0.009 (0.005) 0.12 0.41 0.00 -0.34 
Variability Measures 
Speed (%CV) 5.27 [4.21, 6.54] 4.89 [3.31, 7.13] 0.64 -0.08 0.53* -0.09 
Cadence (%CV) 3.49 [2.95, 5.81] 3.22 [2.67, 5.34] 0.72 -0.06 0.11 -0.09 
Stride Time (%CV) 3.46 [2.97, 5.66] 3.18 [2.66, 5.33] 0.64 -0.08 0.18 -0.13 
Step Time (%CV) 5.69 [4.20, 7.44] 5.90 [3.69, 7.50] 0.84 -0.04 0.10 0.01 
Stride Length (%CV) 3.42 [2.53, 4.47] 4.72 [2.88, 6.24] 0.43 -0.17 0.64** -0.16 
Step Length (%CV) 5.07 [4.14, 7.91] 6.94 [4.65, 9.09] 0.28 -0.16 0.64** 0.03 
Stance Time (%CV) 4.79 [4.05, 6.76] 5.19 [3.13, 6.68] 0.54 -0.11 0.26 -0.05 
Lumbar 
Harmonic Ratio AP 2.48 (0.53) 2.29 (0.75) 0.11 0.44 0.58* 0.42 
ML 2.02 (0.44) 1.82 (0.42) <0.01 0.86 0.60* 0.30 
V 2.65 [2.07, 3.17] 2.12 [1.80, 2.68] 0.17 -0.25 0.69** 0.30 
Step Regularity AP 0.70 (0.16) 0.69 (0.12) 0.86 -0.05 0.72** 0.29 
ML -0.47 (0.17) -0.41 (0.14) 0.45 -0.20 0.56* -0.25 
V 0.70 (0.18) 0.66 (0.15) 0.67 0.11 0.59* 0.09 
Stride Regularity AP 0.74 (0.11) 0.70 (0.13) 0.17 0.37 0.76*** 0.11 
ML 0.52 [0.43, 0.65] 0.42 [0.38, 0.51] <0.05 -0.38 0.60* -0.05 
V 0.70 (0.16) 0.67 (0.17) 0.69 0.10 0.69** -0.17 
R 0.69 (0.12) 0.64 (0.13) 0.27 0.30 0.63* -0.18 
Trunk 
Harmonic Ratio AP 1.75 (0.25) 1.54 (0.25) 0.06 0.54 0.49 0.11 
ML 2.46 [2.19, 3.39] 2.63 [2.04, 3.20] 1.00 0.00 0.79*** 0.53* 
V 2.79 (0.64) 2.55 (0.77) 0.35 0.25 0.55* 0.45 
Step Regularity AP 0.48 (0.13) 0.44 (0.14) 0.39 0.23 0.58* 0.29 
V 0.74 (0.17) 0.73 (0.15) 0.90 0.03 0.75** -0.04 
R 0.60 (0.15) 0.55 (0.17) 0.51 0.18 0.45 0.11 
Stride Regularity AP 0.59 (0.12) 0.57 (0.16) 0.82 0.06 0.61* 0.08 
V 0.76 (0.14) 0.72 (0.15) 0.29 0.28 0.78*** -0.05 
R 0.65 (0.13) 0.61 (0.15) 0.51 0.18 0.59* -0.03 
Forehead 
Jerk (ms-3) AP 21.71 (8.25) 32.23 (10.67) 0.72 -0.10 0.83*** 0.05 
ML 25.30 (9.47) 22.74 (5.58) 0.97 -0.01 0.87*** -0.34 
Harmonic Ratio V 2.51 [2.06, 3.19] 2.10 [1.81, 2.53] <0.05 -0.36 0.63* 0.48 
Step Regularity V 0.71 (0.17) 0.67 (0.16) 0.34 0.26 0.87*** 0.27 
R 0.55 (0.18) 0.46 (0.17) <0.05 0.67 0.85*** 0.12 
Stride Regularity AP 0.50 (0.10) 0.48 (0.18) 0.70 0.10 0.68** -0.15 
V 0.72 (0.16) 0.68 (0.16) 0.16 0.38 0.86*** 0.06 
Results displayed as mean (SD) or median [IQR]. Also shown: effect size calculation; paired samples 
correlation coefficient; the correlation between change (Δ) in each gait variable and change (Δ) in 
disease severity (SARA score) at 12month follow-up. *p<0.05, **p<0.01, *** p<0.001. Missing data: 
Lumbar, Trunk and Forehead parameters – 12 month follow-up (n=15)
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Figure 5.1: Follow-up results of selected variables. 
Results for healthy controls at baseline and cerebellar ataxia at baseline, and 12 months follow-up 
with lines between individual CA participant results. Significant change indicated: * p<0.05, ** 
p<0.01 Missing data: Upper body motion parameters - visit 2 (n=15). 
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Figure 5.2: Results for selected gait variables plotted against SARA score 
Indicates the change over time and the relationship between disease severity (SARA /40) and gait 
abnormality. Black circles: baseline measure compared with baseline SARA score, Grey circles: 12 
month gait measure compared with 12 month SARA score, ---- individual change in gait measure 
and SARA score. Missing data: Upper body motion parameters - visit 2 (n=15).  
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Figure 5.3: Results for participants that completed 24month follow-up for selected variables. 
Results for cerebellar ataxia at baseline, 12 months and 24months follow-up with lines between 
individual CA participant results. Missing data: Upper body motion parameters - visit 2 (n=4). 
|200 
5.4. DISCUSSION 
5.4.1. PARTICIPANT CHARACTERISTICS 
Follow-up was completed in 16 participants, 12 months after their baseline assessment.  
Diagnosis duration and age are comparable to those who only completed baseline 
assessment (Chapter 4). No significant difference was observed between baseline and 
either 12month follow-up in disease severity and none of the participants exhibited a 
change greater than the minimal detectable change (SARA score, <3.5pts). Individual 
changes in balance performance  were also not within a clinically relevant range (BBS 
<8pts). For the subgroup of 5 participants who also complete 24months within the data 
collection period, no longitudinal change in disease severity or balance performance 
occurred. While the subgroup of participants that completed 12-month follow-up are 
similar to those recruited to the study population at baseline in terms of disease severity 
and frequency of ataxia subtypes, the 5 participants who completed 24-month follow-up 
exhibited a more mild phenotype than the cohorts at previous timepoints. 
5.4.2. GAIT ASSESSMENT 
In the present cohort, after 12 months, a significantly increased step width, reduced 
rhythmicity (HRML at pelvis and HRV forehead), and reduced regularity (resultant forehead 
step regularity and ML component of lumbar stride regularity) were detected with good 
statistical power. These measures showed a strong significant paired correlation over time. 
However, none of the participant showed a deterioration in disease severity, balance 
performance or gait speed in this time period. No significant correlations were observed 
between change in SARA score and these gait measures. Also, in the small subgroup of 
participants that completed the 24month follow-up, no clear trends are apparent in these 
selected gait measures.  
The change in these measures was also small, for instance, the increased step width, was 
approximately 1cm over 12 months. Although this could be considered to reflect a 
compensation mechanism for impaired balance (Serrao et al., 2012), since this change is 
within the limit of agreement for the OptoGait system (Table 3.11), it is not likely to be a 
genuine change. As this adjustment of step width over time was only slight, it may not 
provide considerable additional gait control later in the disease process. A previous study of 
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gait in ataxia over a 4-year period did not identify any significant progression in step width 
over time (Serrao et al., 2017a). 
None of the spatiotemporal gait variability or asymmetry variables investigated showed 
significant change over time in the present study. Left step length variability has previously 
been identified as increasing over time in a cohort of patients with ataxic gait (Serrao et al., 
2017a). 
At the lower back and forehead, harmonic ratio (ML and V axis respectively) was able to 
distinguish between gait assessment visits. Recent studies have explored the harmonic ratio 
as a marker of disease severity in CA (Caliandro et al., 2019, Ilg et al., 2019). Meanwhile, the 
changes in the ML component of stride regularity at the lower back, and resultant step 
regularity at the forehead are also significantly different over time. Previous studies have 
indicated the potential of step and stride regularity as a measure of postural control 
(Matsushima et al., 2015). Shirai et al. (2019) also recently reported that over a 1.5yr 
period, Spinocerebellar Degeneration (SCD) is associated with impaired ML amplitude of 
accelerations which complements our findings. Previous studies have indicated that lateral 
balance and adjustment of step width reflects instability more than step length (Collins and 
Kuo, 2013). Therefore, this alteration in the ML asymmetry over time may complement 
these findings.  
However, since these selected measures do not exhibit consistent deterioration in the same 
direction or trunk segment which would indicate a specific change in gait pattern and gait 
strategy over time. This infers that, the participants in this study may not exhibit a genuine 
worsening of postural control within 12months. These variables that have been identified 
may be able to detect subtle gait changes that are not evident when using clinical rating 
scales and un-instrumented walk tests but also could be a result of random fluctuations. 
Since the SARA scores did not show significant progress in the present cohort either and the 
effect size was small for these variables in the present study, it is likely that there were too 
few heterogeneous patients in this study to corroborate this finding. The intra-individual 
change in SARA was small in this time frame so although for many gait measures, a worse 
result is clearly associated with a worse SARA score, the correlation between changes in 
gait measures and changes in SARA scores was inconsistent. With a longer follow-up where 
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genuine change in function is detected it will be possible to better stratify rate of disease 
progression in CA depending on the extent to which an individual’s gait pattern changes.  
Our estimate of the statistical power of these acceleration variables in objectively 
measuring gait impairment over time indicates that each of these variables had a medium 
to large effect size. Although this could indicate that a sufficient number of individuals 
participated in the follow-up to detect impairment in this cohort, due to the heterogeneity 
of the cohort and lack of consistency between the gait domains, this may also give weight 
to the conclusion that these changes in the gait pattern are not specific to disease 
progression in ataxia. This may also be related to the small sample size and short follow-up 
duration. 
5.4.3. LIMITATIONS 
The main restraint within this study is the limited number of participants that completed 
follow-up. Firstly, of the 27 participants that took part in the baseline study, only 16 were 
able to be included in the follow-up assessment. Of those that did not complete follow-up 
(n=11), the reasons included: disease progression so that gait tasks could not be completed 
unaided, illness and disinterest in returning. The remaining participants were not 
approached for follow-up as the data collection period was closed prior to scheduling. 
Further, only 5 participants completed follow-up assessment at 24 months as the remaining 
participants had not reached the appropriate timepoint within the data collection period. 
Therefore, few conclusions can be drawn from this additional time point.  Further, as the 5 
participants that completed follow-up at 24months had a mean SARA score that was 
approx. 4 points lower than the 12 month follow-up cohort. Therefore, this subset 
represents a milder phenotype than those that completed the 12-month follow-up only.  
In addition it is important to consider that this cohort included individuals with different 
types of cerebellar ataxia, (SCA6, SPG7, AD FHx and other forms of ataxia) and there may be 
some heterogeneity in their disease course depending on the genotypes (Marsden and 
Harris, 2011). Whilst SCA6 and SPG7 are both associated with slowly progressing ataxia, 
other features of the disease such as spasticity and weakness contrast and may influence 
the gait pattern differently over time and with treatment (Ashizawa et al., 2013, Jacobi et 
al., 2012). Therefore, further work is required to confirm whether longitudinal gait changes 
are subtype specific. 
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Sex disparity was not controlled in the invitation to follow-up or explored in analysis. 
However, the cohorts retained an approximate female: male ratio between baseline (10/27 
female, 37.0%), 12 month follow-up (7/16 female, 43.8%) and 24month follow-up (2/5 
female, 40.0%) and was comparable to the sex split in previous literature (44.12% female, 
Table 2.1). However, in light of the aforementioned differences between sexes in gait 
characteristics and considering that hereditary ataxias are not more prevalent in a specific 
sex, future study should endeavour to control for this within recruitment strategies. 
In this study, individual participant’s usual care was not altered and not detailed 
extensively. In this disease cohort, symptoms such as spasticity and vertigo are treated 
through medication and many people undergo physiotherapy and undertake regular 
exercise. It is therefore possible that changes to their usual care implemented by their 
treating physician could impact a participant’s gait performance within a 12-month period. 
However, since no disease modifying therapy exists for ataxia, this impact was likely 
minimal. 
Limitations of the gait analysis systems selected also contributed to these results. For 
instance, for 1 participant algorithms were unable to accurately identify every gait event in 
the walking bout so the walking bout was too short to provide multiple adjacent strides. 
The algorithms were then unable to compute the upper body motion parameters reliably 
and so their upper body characteristics were excluded from follow-up analysis but 
spatiotemporal measures included. Therefore, further disease specific adaptation of the 
algorithms may be necessary to ensure data is not lost.  
It is also important to consider that by pre-selecting variables on the basis of baseline 
disease severity and ability to differentiate CA from HC, some features of the gait pattern 
may have been missed. It is possible that there may be gait measures that are sensitive to 
disease progression despite not meeting the criteria implemented here. Therefore, further 
appraisal of gait changes with disease progression is needed to confirm the potential of gait 
measures as a biomarker.  
5.5. CONCLUSION 
There is a considerable interest in the use of postural control as a biomarker for monitoring 
of CA. Here we report, the results of a longitudinal assessment of gait in a cohort of adults 
with CA gait. Our findings indicate that although accelerometery measures reflecting 
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rhythmicity and regularity of gait display statistically significant changes at 12month follow-
up, as no disease progression occurred during this time period, these may not be 
generalisable to the wider population. The small degree of change within short follow-up 
period for a heterogeneous cohort indicate that the trend of gait decline in CA may not 
reflect a genuine functional change.  
Further study in people with homogenous ataxia phenotype over a longer follow-up period, 
is necessary to further explore the gait changes that were detected here as the present 
study may be underpowered to detect change in these measures. Future studies should 
explore postural changes during gait in a larger cohort as it may be possible to identify 
further measures of gait progression and to validate those recognised here as biomarkers 
of disease progression. 
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Chapter 6. GENERAL DISCUSSION 
6.1. REVIEW OF AIMS & OBJECTIVES AND PRINCIPAL FINDINGS 
Chapter 2: Aimed to completion of a systematic review to summarise and meta-analyse the 
reported gait characteristics of cerebellar ataxia (CA). Critical appraisal and quality 
assessment was planned to summarise previously reported results. The gait characteristics 
differentiating between CA and controls were identified. An estimation of the objective gait 
pattern in CA was completed and sample size estimation completed. 
Following our searches and subsequent scrutiny of the literature from the last 20 years, 
twenty-six studies were identified that considered spatiotemporal gait characteristics in 
individuals with cerebellar ataxia (CA), as measured by instrumented analysis techniques 
during preferred paced steady-state walking.  
During preferred paced walking, there is strong evidence that CA patients display the 
following gait differences against healthy controls: 
• reduced walking speed and cadence 
• reduced step length, stride length, and swing phase 
• increased base width, stride time, step time, stance phase and double limb support 
phase 
• increased variability of step length, stride length, and stride time. 
The gait parameters that were greatest affected in CA were speed, double limb support 
phase duration (%cycle) and stride time variability followed by step length variability and 
step length. 
Unfortunately, due to limitations of the dataset, it is not possible to formally explore the 
influence of distinct confounding influences such as ataxia diagnosis type separately from 
equipment used, the correlations between upper body and spatiotemporal gait 
parameters, or the effect of changing velocity or disease progression on gait characteristics. 
Sample size estimation indicated that between 2-47 individuals can be recommended for 
studies of gait in CA. However, since estimating sample size from meta-analyses results can 
lead to an overestimation of statistical power, a more conservative estimation should be 
considered for most gait parameters evaluated. 
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Chapter 3: An in-house validation was planned to compare the proposed gait analysis 
equipment (Microgait OptoGait photoelectric walkway and APDM Opal inertial sensors) 
against the gold-standard of gait analysis (Vicon 3D motion capture). This intended to 
ensure the accurate measurement of spatiotemporal parameters and confirm the 
synchronisation of data capture.  
A group of healthy control participants were recruited to the study and completed 
preferred speed walking trials. The Vicon 3D motion capture system was the reference 
device/gold standard. This experiment lead to the development of algorithms to process 
the OptoGait output.  
Examination of the agreement and consistency of the three system measurements and 
algorithm identified that statistically differences are present for gait event detection by the 
OptoGait system and ADPM Opal sensors, these are small and agreement was good. There 
was a larger but still not substantially higher systematic bias for the detection of final 
contact than initial contact timing. There was a minimal impact of this on the calculations if 
step and stride duration but stance and swing durations correlated more weakly for the 
OptoGait system and APDM Opal sensors but systematic differences were small. The step 
and stride length estimation by the OptoGait system showed excellent correlations and 
negligible systematic bias. However, step width estimation by the Optogait system was 
associated with a systematic bias between systems and a generally poor level of 
agreement. This is likely due to the differing parameters definitions between the systems. 
Also, the participant gait speed was not correlated with the accuracy of the gait analysis 
systems. However, being a healthy control cohort, the range of gait speeds captured were 
not reflective of potential pathological cohorts.  
Taken together, thresholds for valid measurements can be inferred from limits of 
agreement in preparation for interpretation of clinical gait assessments (Table 3.11). 
Chapter 4: An observational gait analysis study was completed to assess the gait 
characteristics of people with CA (n=27) compared with a healthy age-matched control 
population (n=27). The association between upper-body motion and spatiotemporal gait 
parameters as well as the influence of disease severity and walking speed were explored.  
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Spatiotemporal gait parameters and upper-body motion characteristics were measured 
concurrently and additional validation in a CA cohort completed. This indicated that in a 
pathological cohort, during longer walking trials, a similar level of agreement and precision 
are possible to that estimated in a young healthy cohort (Chapter 3).  
Here ataxic gait pattern is characterised by an attempt to compensate for excessive sagittal, 
lateral and vertical oscillations despite insufficient coordination between the upper and 
lower body segments. Speed, step width, gait variability as well as step to step asymmetry, 
step regularity and stride regularity are able to differentiate between disease severity 
subgroups independent of changes in gait speed. Therefore, these variables show promise 
as biomarkers for severity of gait ataxia. This corroborates findings from Chapter 2, while 
also quantifying ataxic gait in terms of measures of trunk motion. 
Comparison of gait characteristics against clinical measures of disease severity (Scale for 
Assessment and Rating of Ataxia (SARA) and balance performance (Berg Balance Scale, BBS) 
was completed. Indeed, objectively measured gait changes in CA, differentiate patients 
with a pre-symptomatic/mild CA phenotype from more severely affected patients and 
healthy controls independent of age, sex and gait speed. This indicates their potential as 
gait biomarkers for disease severity.  
Since in people with CA, spatiotemporal gait changes may be a form of compensation for 
loss of balance, assessing the two aspects of gait in synchronisation is highly advantageous. 
In addition, since step variability, stride variability and step width negatively correlate with 
postural asymmetry, stride regularity and step regularity, further work could explore 
whether spatiotemporal gait parameters are interchangeable with upper body motion 
variables in the monitoring of CA. Further work is also required to examine differences 
between disease diagnoses and falls history. 
Chapter 5: Follow up assessments of gait in the study population was planned to be 
completed after a 12 month and after 24-month interval. While the majority of the study 
cohort completed 12 month follow-up, many were did not complete either 12 month or 24 
month follow-up visits as: they were no longer able to complete the gait tasks due to 
disease progression; they were recruited towards the end of the data collection period so 
were not due to complete their follow-up visit in time; they chose not to take part for other 
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reasons. Therefore, the 24 month follow-up can only give an estimation of the trends 
within the small cohort. 
In order to reduce the number of variables, a 37 gait measures were selected to be 
implemented that had shown sensitivity to disease severity in baseline assessments. 
Following clinical assessment of disease severity, balance performance, gait tasks were 
completed in the same way as at baseline to objectively measure whether the gait pattern 
changes over time in CA and how. This would provide evidence for the use of the 
instrumented gait tasks to detection of disease progression. I hypothesised that 
spatiotemporal and upper body motion characteristics may be able to recognize disease 
progression in an ataxic cohort.  
Over a 12 month period, people with CA did not show significant progression in disease 
severity or balance performance. In preferred speed self-paced walking gait tests, the 
cohort, exhibited an increased step width and reduced rhythmicity and regularity. However, 
the small cohort of participants had a heterogeneous disease pathology, the follow-up 
period short and changes detected were within the previously established limit of 
agreement for the gait analysis systems. Therefore, it is likely that these changes do not 
reflect a genuine change of function. Due to small numbers of participants that completed 
the 24month follow-up, these findings could not be analysed formally at a longer follow-up 
period in this study. A longer follow-up period of assessment in a larger more 
homogeneous cohort is required to detect true disease progression in people with CA.  
6.2. UNDERLYING GAIT CHANGES 
Here I examined the spatiotemporal and upper body motion characteristics that 
characterise CA and how these are changed with disease severity. I also assessed whether 
the gait pattern in cerebellar ataxia changes over 12-month follow-up and if instrumented 
gait tests can objectively measure these changes. Taken together, the ataxic walking gait 
pattern corroborates the characteristics reported in the literature: slow and highly variable 
footfall with a wide base of support that is also associated with uncontrolled regularity of 
lateral motion and reduced rhythmicity of trunk rotation as well as more jerky head motion. 
Here I recognise that despite a relatively mild severity of ataxia present in the recruited 
cohort, it is possible to distinguish between healthy controls, very mild ataxia, and more 
moderate ataxia. Due to the nature of the walking tasks, it was not possible to explore gait 
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in people who require a walking aid at all times. Therefore, these results are limited to 
people with a lower level of disability. 
Further, stratifying patients on the basis of their disease severity enabled the identification 
of gait changes that occur in mild/presymptomatic ataxia compared with a more severe 
ataxia phenotype. The mild ataxia cohort also exhibits an intermediate gait phenotype 
compared with the other cohorts, which is characterised particularly by temporal 
variability, and rhythmicity of pelvis rotation. These gait changes that distinguish mild ataxic 
gait from healthy controls may have diagnostic benefit. In the more moderately affected 
ataxia cohort, these features are exacerbated, and other aspects of the gait pattern are 
additionally impacted. 
Since no disease progression was observed in the people recruited to this study, although 
changes were identified in selected variables, these are not likely to reflect genuine disease 
progression. The variables that exhibit an ability to differentiate CA and healthy controls 
and disease severity subgroups and were also able to characterise 12-month follow-up in 
ataxia were gait speed, step width, asymmetry, variability, postural symmetry, and 
regularity measures. 
6.3. NOVEL FINDINGS 
These features of ataxic gait require instrumented gait analysis tests in order to be 
objectively measured. Current non-instrumented clinical assessments of gait changes 
require a subjective rating and previous experience to rate ataxic gait severity. The key 
outcomes of existing performance tests such as the timed up and go and six-minute walk 
test include submaximal exercise capacity and gait speed. Reduced gait speed is a common 
feature of gait impairment and loss of balance confidence (Fritz and Lusardi, 2009). 
Therefore, while poor performances on these tests can be indicative of gait disability, they 
cannot determine specific gait pattern deficiencies. Here we provide a thorough description 
of gait impairment in cerebellar ataxia that cannot be discerned from non-instrumented 
tests. Our findings also provide evidence of speed-independent gait impairment in 
cerebellar ataxia. 
This offers the potential to use gait variables as quantitative biomarkers for disease severity 
and disease progression. This in turn opens the possibility of using gait measures including 
upper body motion as outcomes in clinical trials in cerebellar ataxia to establish treatment 
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effects. Further detailed studies are required to fully characterise the gait phenotype in 
relation to clinical and molecular features of cerebellar ataxia such as genetic and neuro-
imaging findings in preparation for this purpose. 
In terms of instrumentation, the OptoGait is not widely used in clinical settings. However, it 
enables a portable method of detection spatiotemporal gait characteristics so can be 
implemented in a wide range of settings. The system is quick to set up and provides 
feedback reports for participants. It is also possible to synchronise recordings between 
systems through an external trigger signal. Here, I have validated the OptoGait system in a 
healthy control cohort and an ataxia cohort within clinical and laboratory settings. 
Although, previous studies have explored the different settings for the LED filter thresholds 
(Healy et al,. 2019), the use of the perpendicular bar to assess step width has rarely been 
reported in the literature to my knowledge. Therefore, our estimation of the agreement 
between the OptoGait and reference system for step width indicates that further work is 
required to improve the accuracy and precision of this measurement.   
6.4. STRENGTHS AND LIMITATIONS 
The strengths and limitations of this work have been discussed in the previous chapters. To 
summarise however, there are factors to consider when interpreting these findings. 
By examining the existing literature in a systematic review and meta-analysis it was possible 
to create a thorough summary of the previous understanding while fully assessing the 
methodological quality of all included studies. It provided an estimation of the usual 
recruitment targets and by pooling data it was possible to better calculate the statistical 
power possible in a large CA cohort. Although this may have led to an under-estimation of 
the number of participants required for a single study, it was clear that there is consistency 
between studies despite within-study variability and heterogeneous cohorts.  
Throughout this work, healthy individuals have been used as control participants. Our 
findings therefore indicate there may be a diagnostic value of gait analysis. While this was 
intended to reduce the impact of possible comorbidities on measurements, further work 
differentiating ataxia from other disease cohorts is also necessary to establish a disease-
specific gait signature. In preparation for this work, validation calculations for the OptoGait 
system and APDM Opal sensors were completed in data from the young healthy, older 
healthy and cerebellar ataxia cohorts in laboratory and clinical settings. Further validation 
 |213
of step width measurements is recommended since there were short comings to the 
approach taken here. Namely the use of two marker set placement meant that the lateral 
markers were inconsistent between participants and not able to be included in the model 
of the foot placement.  This led to an inherently different strategy for determining step 
width than the OptoGait system implements. The incorporation of force platforms in future 
validation studies would also improve the reliability of foot placement estimations. 
The main restraint within this study is the limited number of participants that were 
recruited at baseline and those completed follow-up. Of the 27 participants that took part 
in the baseline study, only 16 were able to be included in the 12-month follow-up 
assessment and only 5 participants that completed follow-up at 24months. The main 
reason for these missing assessments was data collection period was closing prior to 
scheduling of visits. As indicated in results of the systematic review, these recruitment 
numbers are similar to those recruited in the previous literature. Also since sample size 
estimation based on the meta-analysis results indicate that between 2-14 participants is 
necessary to achieve statistical power. However, effect size was calculated for each of the 
statistical tests completed to indicate the probability that sufficient statistical power was 
achieved for each comparison.   
Further, the recruited cohort of people with CA included individuals with different types of 
cerebellar ataxia, (SCA6, SPG7, AD FHx and others), there may be heterogeneity in their 
clinical characteristics, and disease progression. This was not accounted for in either the 
baseline or follow-up analyses reported here, but further work is underway to explore this. 
The difference between SCA6 and SPG7 for instance will confirm whether these gait 
contributions are related to ataxia or confounded by spasticity which is common in SPG7. 
As discussed, an individual participant’s usual care was not altered as part of this study. 
Therefore, changes to usual care may have occurred during the study period. Since no 
disease modifying therapy is available in this disease cohort, symptomatic treatment is 
often implemented. Spasticity is treated through used of muscle relaxants and to combat 
weakness many patients undertake regular physiotherapy and exercise. Therefore, it is 
possible that changes to a participant’s usual care could impact gait performance within a 
12-month period. As this was not explored in detail in this study, this potential confounding 
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factor will be considered in design of future protocols and careful interpretation of these 
findings should occur in light of this. 
In systematic review of the previous literature and these primary studies, the use of walking 
aids was not considered. Given the nature of the walking tests, participants with a low 
disease burden and disability are commonly recruited to such studies. However, since use 
of walking aids is a common aspect of daily life for many people with CA, it is important to 
consider how this can affect walking gait, and balance performance. As a result, our 
findings cannot be generalised to people with more severe ataxia or to walking while using 
a walking aid. 
In this study, recruitment was not controlled on the basis of sex. Although there is no 
conclusive indication of sex influencing ataxia onset and symptoms since mechanics is 
impacted by body structure, this may have influenced the between-cohort differences. This 
should be considered in future work through matching specific controls to specific patient 
participants. However, to account for this, supplementary analysis where age, sex and gait 
speed were included as covariate factors was completed in and our key findings are 
reported independent of these factors. 
Walking gait characteristics reliant of gait speed. From a technical point of view, slow 
walking can interfere with the accuracy of gait event detection using inertial sensors (Feng 
et al., 2017). Since the CA cohort, adopt a slower preferred walking pace, it was important 
to verify the validity of gait event detection in HC and CA between the OptoGait system and 
APDM Opals sensors. Bland-Altman plots did not indicate that ataxia cohort membership 
leads to inaccurate gait event detection and gait parameter calculation compared with age-
matched healthy controls. Gait strategies during different walking speeds was not explicitly 
explored here. Instead the difference in gait speed between HC and CA was accounted for 
in univariate analyses and the correlation between speed and gait measures reported. 
Further work may explore the influence of speed changes on the gait pattern as the study 
protocol included fast and slow speed self-paced walking trials. From the literature, it is 
expected that an individuals’ preferred walking pace reflects their most comfortable and 
energy efficient gait strategy, while slow and fast paced walking provide a challenging task 
that requires an altered gait strategy. 
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Similarly, as walking gait parameters are inherently interdependent, it is essential to 
subsume gait measures where possible. For the systematic review of the literature, gait 
measures assessed were dependent on the data provided in the articles. However, an effort 
was made to calculate supplementary metrics where necessary to reduce the number of 
measures overall and increase the amount of data included in each meta-analysis. For 
instance, where gait cycle and phase duration were reported such as single support time, 
the percentage of each phase with respect to the gait cycle was calculated. Therefore these 
results could be combined to provided a larger dataset for meta-analysis. For the clinical 
studies, in order to appreciate the full gait pattern, additional gait measures were reported. 
However, informed by the results of baseline assessments and the knowledge of the 
interrelated gait parameters a short-list of 37 gait measures was selected for appraisal of 
the longitudinal gait changes in CA. In a larger cohort, multi linear regression analysis would 
be a better approach to outline the essential gait measures to be included in a model gait in 
CA. 
For the clinical studies, despite completing visual checks at the time of assessment and 
taking precautions to ensure data validity, some issues with the technique persisted, 
particularly for the OptoGait. Issues with the detection of the gait events by the OptoGait 
occasionally occurred. For instance, occasional steps were identified as having an invalid 
flight time and other steps were overlooked by the built-in algorithm. This was considered 
to be related to differences in footwear and gait speed. Issues with synchronisation of the 
systems were also occurred which may pose an issue if data is to be segmented by gait 
events detected by another system. However, testing was quick to complete, lasting a 
maximum of 1.5 hours for patient participants, which indicating a low fatigue burden.   
6.5. RECOMMENDATIONS FOR FUTURE WORK 
While the studies discussed in this thesis largely conclude the planned activity for the 
clinical study “Gait Analysis in Cerebellar Ataxia and Hereditary Spastic Paraparesis”, there 
are a number of recommendations for future developments of the work that will enable 
the findings to be widely taken up into clinical practice.  
6.5.1. CLINICAL GAIT ANALYSIS FOR RESEARCH 
Despite the advantages of implementing the OptoGait system into a clinical study, in order 
to be used more reliably further validation is necessary. Most importantly, the inaccuracy of 
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step width estimation has been discussed in previous sections. Since different estimation 
methods employed between the OptoGait system and the Vicon 3D motion capture system 
future studies should be wary of this measurement until further validation is completed. 
Researchers should consider whether incorporation of an offset is necessary to correct the 
systematic bias detected here. 
Further, position of step detection and labelling of left/right footfalls, can occasionally be 
incorrectly identified by the built-in algorithm, therefore it is important to minimise issues 
wherever possible through proper configuration and by monitoring recurring problems. 
Although visual checks at the time of data collection is recommended, since people with 
pathological gait may be prone to fatigue, repeating of trials, is not always possible. A semi-
automated method of assessing validity of the data capture has been established to ensure 
correct labelling of data and to remove data that is incorrectly captured. Use of this system 
all restricted the walkway length to the length of the bars and the amount of support that 
could be provided to participants. A longer walkway enables participants to achieve a true 
steady state walking pace in the centre portion of a walking bout. Here, to avoid 
confounding results with the influence of acceleration/deceleration periods of gait, the 
steps outside of the system were not considered. However, this restricts the assessment 
space to 4 m x 1 m and therefore the number of gait events captured within this is limited. 
For this study, the OptoGait system was used to compute the temporal and spatial features 
of gait. However, since the temporal gait parameters can be accurately obtained from 
acceleration and angular velocity signals, these measures were arguably redundant. 
Therefore, with the development of reliable approaches to measure spatial gait 
parameters, future studies could implement just IMU and avoid the need for an external 
gait analysis system. This exclusive use inertial sensors would provide additional flexibility 
to protocols. 
Meanwhile, our findings indicate the importance of control of the upper trunk and 
forehead in control of gait in CA. Therefore, a holistic view of the gait pattern through 
spatiotemporal and acceleration variables are useful, the addition of the trunk and or 
forehead sensor to protocols should be considered in future studies in CA. In addition, 
there appears to be overlap in the information provided by spatiotemporal gait variables 
and postural control parameters. Therefore, with additional research in a larger cohort, 
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multivariate regression analysis can be completed to identify the variables best able to 
classify CA and distinguish from other neurological gait disorders. 
6.5.2. CEREBELLAR ATAXIA SUBTYPE STRATIFICATION 
Although, genetic forms of ataxia are associated with heterogeneity of symptoms, here 
many CA subtypes were assumed to be homogeneous in the interest of exploring the 
influence of symptom severity and progression. Of the participants recruited to the clinical 
studies, while some participants had previously received a diagnosis of a “pure” cerebellar 
ataxia (e.g. SCA6), others exhibited a more complex gait impairment with spasticity and 
weakness involved (e.g. SPG7). Combining these cohorts may mask the differences that are 
inherent to the clinical features, (Coarelli et al., 2019). Therefore, further work is underway 
to explore the differences between these specific genotypes. In future, recruitment of a 
larger cohort of each will be necessary to confirm the diagnostic value of instrumented gait 
tests in this situation. To assist with this effort, the inclusion of genetic testing and magnetic 
resonance imaging (MRI) would allow a better stratification of ataxia subtypes by allowing 
accurate genotyping and assessment of neurological degeneration.   
6.5.3. LONGITUDINAL GAIT CHANGES 
As discussed previously, in the present cohort, no disease progression appears to have 
occurred within the study period. Since progression of CA, changes over a longer period 
than 12months, to assess whether ataxic gait pattern reflects longitudinal disease 
progression, further characterisation in a larger, better-defined cohort and in comparison, 
to other disease groups over a longer follow-up interval is required.  
Since no disease progression occurred in this time point, it is not possible to determine 
whether the pre-selected variables implemented here would be sensitive to disease 
progression. As these were selected on the basis of baseline disease severity and ability to 
differentiate CA from HC, some features of the gait pattern may have been missed due tp 
the criteria implemented. Further work is needed to assess the gait changes in a hypothesis 
free manner and to develop a model of gait in CA. This will help establish gait measures as 
biomarkers for disease progression in addition to stratifying for disease severity.  
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6.5.4. MACHINE LEARNING 
Through the use of machine learning techniques, it may be possible to identify gait 
parameters and patterns that might be most effective at distinguishing between healthy 
controls and individuals with ataxia. Machine learning algorithms group data points based 
upon statistical similarity rather than testing pre-specified hypotheses. These techniques 
can involve a phase of training based on previous datasets before testing new datasets to 
find and recognise patterns.  
In this way, the classification of participants by analysing gait data using machine learning 
techniques could improve generalisability to a wider population and identification of 
patterns unique to specific disease groups. It is important to balance sensitivity and 
specificity in order to appropriately diagnose ataxic gait without falsely classifying healthy 
gait as a disease.  
Automated pattern recognition systems such as an artificial neural network (ANN) and 
support vector machine (SVM) methods have previously been implemented to classify 
neurological gait disorders using data from the GaitRite pressure-sensitive carpet (Pradhan 
et al., 2015). Researchers successfully classified spatiotemporal gait patterns of phobic 
postural vertigo, CA, progressive supranuclear palsy (PSP), bilateral vestibulopathy (BVP), 
and healthy participants with high sensitivity. This study also indicated the relevance of the 
difference between gait patterns when selecting a machine learning method since high 
false-negative rates were present for BVP and PSP depending on the method used. 
Using the full gait signals to classify gait rather than predetermined variables, may permit 
finer resolution of gait abnormalities and reveal novel biomarkers of disease progression. 
However, it is vital to establish the essential gait and postural information required to 
distinguish healthy from ataxic gait and between movement. For instance, if classification 
can be made based on a single sensor-based approach to gait analysis, then it may be 
quicker and easier to capture and process gait data while being minimally intrusive to 
participant gait. In addition, these requirements could be improved by identifying gait tasks 
most likely to distinguish the gait of healthy individuals and different disease subgroups 
such as fast-paced walking, tandem walking, simulated activity tasks or dual-task gait 
conditions. These gait tasks have not been explored in this thesis but can add value to 
studies of gait in neurodegenerative gait disorders.  
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6.5.5. REAL WORLD GAIT ANALYSIS IN HEREDITARY CEREBELLAR ATAXIA 
Observation and test conditions can influence the behaviour being measured 
(McCambridge et al., 2014). This is in part due to the considerable differences in observed 
gait in a clinical or laboratory setting and that seen in daily life (Storm et al., 2016). Indeed, 
inconsistencies between average daily gait speed and average in-laboratory gait speed have 
been identified (Takayanagi et al., 2019). 
Further, even in healthy individuals, the physical activity level is sensitive to changing 
abilities. For instance, older adults demonstrate a decreased energy expenditure and 
physical activity (Meijer et al., 2001), and display a tendency to spend a higher proportion 
of daily life in lower intensity activities than younger healthy controls (Copeland and Esliger, 
2009).  
Recent studies have shown the importance of capturing real-life physical activity in 
pathological cohorts. Remote monitoring of physical activity has been shown to be feasible 
in many neurological conditions including ataxia and offer the ability to quantify walking 
gait and falls in daily life (Block et al., 2016, Ilg et al., 2018). However, a single study has 
explored physical activity in individuals with CA (Subramony et al., 2012). This study 
reported that during home-based gait monitoring in Spinocerebellar Ataxia (SCA) physical 
activity correlated with disease duration and participant’s functional stage. More recently, 
gait has been measured during “supervised free walking” and “real-life walking” conditions 
in ataxia where stride time variability and harmonic ratio AP distinguished subgroups during 
lab-based walking (Ilg et al., 2019). 
In future, we hope to corroborate these findings in our cohort of participants. Therefore, a 
subset of participants (n=11) within the present observational study of gait in CA (Chapter 
4, Chapter 5), completed week-long physical activity monitoring using the Dynaport 
Movemonitor (MM+, McRoberts, The Hague, The Netherlands) in a subset of participants in 
addition to their within-clinic gait analysis tests. These participants wore the Dynaport 
MM+ using an elastic belt alongside the ADPM Opal sensors during clinic-based gait analysis 
to enable validation of gait event detection. Then by wearing the sensor over a seven-day 
period, data on the participants' gait and movement in the home environment to will 
provide a measure of their gait in a “natural” setting. 
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As well as using the proprietary processing platform (MyMcRoberts) to generate physical 
activity monitoring reports relating to physical activity type, raw triaxial accelerometry data 
will be processed to compute spatiotemporal and upper body motion gait characteristics 
over the seven-day period. This will use similar processing methods to that described in 
Chapter 4 and Chapter 5. Since participants were asked to complete the physical activity 
diary, a validation of the activity types completed during this time, and the length of time 
each activity was performed for can be provided. This will enable us to determine which 
laboratory gait parameters correlate best with real-life activity levels and assess gait 
characteristics during free walking periods for comparison against those captured during 
laboratory testing. 
6.5.6. ACCEPTABILITY STUDY 
At present, there are no guidelines regarding the use of gait analysis in the diagnosis of CA 
or diagnostic values and thus, they have not been implemented into clinical practice. For 
gait analysis to be truly feasible in a clinical setting it should provide real-time clinical 
feedback and provide a tangible improvement on the current gait assessment methods. 
Equipment with real clinical potential will need to be simple to use, provide easy to 
interpret results, relatively cheap, and appropriate to the setting in which assessment will 
occur. To encourage healthcare providers to invest and make them part of standard 
practice, it is also essential that their use in a clinical setting is tolerated well by patients 
and clinicians.  
Therefore, in future, a mixed methods patient and clinician centred acceptability study 
should be completed to enable feedback to be gathered about how well this equipment 
would be accepted in a clinical setting and at home for monitoring of real-life gait. A small 
number of studies have been completed in individuals with Multiple Sclerosis (Newland et 
al., 2016), Parkinson’s disease (Cancela et al., 2014) and stroke survivors (Taylor-Piliae et al., 
2016) to explore the acceptability of using in-home and wearable sensor technology for fall 
risk detection and continuous remote monitoring of symptoms.  
Since gait has real potential as a novel biomarker, a similar acceptability study for 
assessment of gait in a clinical or real-life setting would support our findings and emphasise 
the benefit that gait analysis could provide to patient care and clinical assessment. In this 
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way, health trusts and services can potentially be encouraged to invest in the equipment 
and resources required to incorporate gait assessment techniques into clinical practice. 
6.6. OVERALL CONCLUSION 
Instrumented gait analysis tests have the potential to identify and diagnose cases of 
movement disorders by capturing subtle characteristics more accurately than present 
methods. Motion analysis techniques have been shown to be comparable to the current 
gold standard of movement assessment in Parkinson’s Disease: the UPDRS ptIII (Parisi et al., 
2015). An early attempt by Ferrarin et al. (2005) in the context of CA, demonstrated 
moderate to good correlations between the results of kinematic analysis and the equivalent 
ICARS items. 
Our systematic review of the literature and our validation and longitudinal gait analysis 
study, indicate the diagnostic ability to differentiate HC from in CA. This project has also 
identified gait variables that correlate well with SARA and BBS scores at baseline in CA and 
discriminate ataxic gait pattern from Healthy gait and between CA subgroups stratified for 
disease severity. No disease progression occurred over a 12 month period in the CA cohort 
therefore, although some variables exhibit significant changes over time this may not 
reflect a genuine functional change. Further work is required in order to establish whether 
the objective measurement of the CA gait pattern can provide a novel biomarker for 
disease progression. Since gait analysis variables appear to be superior to present methods 
of examination in the monitoring of gait changes over time, our findings contribute to the 
body of literature suggesting the value of gait measures in clinical practice and research 
(Gordt et al., 2018).  
In future, as well as confirming our findings in larger cohorts, continuing real-life 
monitoring, examination of the gait patterns specific to different movement disorders and 
ataxia subtype is essential. This will enable the future use of gait measures as endpoints in 
clinical trials, and objective methods of monitoring disease progression. 
Routine gait analysis in the UK, is restricted to expensive 3D motion capture techniques. 
The uptake of more portable gait analysis systems such as wearable sensors might provide 
valuable data to clinicians regarding patient physical activity and gait impairment. Since this 
vital information can be captured in a more realistic setting than a clinical gait analysis lab, 
this has potential to be more clinically relevant and widespread than motion capture. This 
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could enable the accurate characterisation of gait, and measurement of falls occurrence, 
physical activity, and real-world gait impairment. There is potential to save time and money 
for the NHS and patients by reducing the amount of time spent in clinic. For instance, in 
future, clinician’s may be able to refer patients to physical activity monitoring or gait 
analysis tests prior to a care review in order to discuss recent gait impairment and 
treatment effects more reliably than is possible with current subjective methods. Taken 
further, clinicians could review a patient’s progress to avoid unnecessary clinic visits in 
stable patients and prompt further clinic visits for individuals most in need. 
These results indicate that gait measures are able to differentiate between healthy controls 
and disease severity subgroups in CA. Although further work is needed to clarify whether 
the gait changes occur in CA in line with disease severity, instrumented gait tests have 
potential in the monitoring of disease progression in CA. This will make it possible to 
accurately monitor intervention effects, and produce evidence for rehabilitation and 
treatment options that are available to patients and clinicians. 
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Chapter 2 (Systematic Review) supplementary material 
Appendix 1: Literature Search Strategies. 
 
The strategy comprised of three key levels of search terms and was adapted for each of the 
databases searched. 
  
Psycinfo via OvidSP: Medline via OvidSP: 
1. cerebellar ataxia.ti,ab.  
2. gait Ataxia.ti,ab.  
3. exp ataxia/  
4. 1 or 2 or 3  
5. (measur* or assess*).ti,ab. 
6. (evaluat* or examin*).ti,ab. 
7. (analysis or analyse or analyze).ti,ab. 
8. Biomechanic.ti,ab.  
9. exp biomechanics/  
10. kinematic.ti,ab.  
11. instrumented.ti,ab.  
12. gait analysis.ti,ab.  
13. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 
14. exp Walking/  
15. (walk or walks).ti,ab. 
16. gait.ti,ab.  
17. exp Gait/  
18. exp Locomotion/  
19. locomotion.ti,ab.  
20. 14 or 15 or 16 or 17 or 18 or 19  
21. 4 and 13 and 20 
1. cerebellar ataxia.ti,ab.  
2. exp Cerebellar Ataxia/  
3. gait Ataxia.ti,ab.  
4. exp Gait Ataxia/  
5. 1 or 2 or 3 or 4  
6. (measur* or assess* or analysis or analyse or 
analyze).ti,ab. 
7. (evaluat* or examin*).ti,ab. 
8. Biomechanic.ti,ab.  
9. kinematic.ti,ab.  
10. instrumented.ti,ab.  
11. gait analysis.ti,ab.  
12. 6 or 7 or 8 or 9 or 10 or 11 
13. exp Walking/  
14. (walk or walks).ti,ab. 
15. gait.ti,ab.  
16. exp Gait/  
17. exp Locomotion/  
18. locomotion.ti,ab.  
19. 13 or 14 or 15 or 16 or 17 or 18 
20. 5 and 12 and 19 
PubMed: 
(((((((((Walking[Title/Abstract]) OR walk[Title/Abstract]) OR walks[Title/Abstract]) OR gait[Title/Abstract]) 
OR Locomotor[Title/Abstract]) OR Locomotion[Title/Abstract]))  
AND (((((((((measur* [Title/Abstract]) or evaluat*[Title/Abstract]) or examin*[Title/Abstract]) OR assess* 
[Title/Abstract]) OR analysis[Title/Abstract]) OR analyse[Title/Abstract]) OR 
analyze[Title/Abstract]) OR Biomechanic[Title/Abstract]) OR kinematic[Title/Abstract]) OR 
instrumented[Title/Abstract]) OR gait analysis[Title/Abstract]))  
AND ((((cerebellar ataxia[Title/Abstract]) OR cerebellar/ataxic[Title/Abstract]) OR 
ataxia/cerebellar[Title/Abstract]) OR gait ataxia[Title/Abstract]) 
IEEExplore (metadata only): 
(Walking OR walk OR walks OR gait OR Locomotor OR Locomotion) 
AND (Measur* OR assess* OR analysis or evaluat* or examin*OR analyze OR analyse OR 
Biomechanic OR kinematic OR instrumented OR gait analysis) 
AND (cerebellar ataxia OR gait ataxia) 
Web of Science Core Collections: 
TS=(Measur* OR assess* OR analysis OR analyze OR analyse or evaluat* or examin*  OR 
Biomechanic OR kinematic OR instrumented OR gait analysis) 
AND TS=(Walking OR walk OR walks OR gait OR Locomotor OR Locomotion) 
AND TS=(cerebellar ataxia OR gait ataxia) 
Scopus: 
(TITLE-ABS-KEY ( walking  OR  walk  OR  walks  OR  gait  OR  locomotor  OR  locomotion )   
AND TITLE-ABS-KEY ( measur*  OR  assess*  or evaluat* or examin*  OR  analysis  OR  analyze  OR  
analyse  OR  biomechanic  OR  kinematic  OR  instrumented  OR  gait  analysis )   
AND TITLE-ABS-KEY ( cerebellar  ataxia  OR  gait  ataxia ) ) 
Cochrane trials database: 
(Walking or walk or walks or gait or Locomotor or Locomotion):ti,ab  
AND (Measur* or assess* or evaluat* or examin* or analysis or analyze or analyse or Biomechanic or 
kinematic or instrumented or gait analysis):ti,ab 
AND (cerebellar ataxia or gait ataxia):ti,ab 
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Appendix 2: Inclusion & Exclusion Criteria for Article Screening. 
 
To be applied to screening of Title, Abstract and Full Texts. 
  
 Inclusion Criteria Exclusion Criteria 
Participants/ 
Population: 
Adult (Age 18yrs Or 
Older), Diagnosis of 
Cerebellar Ataxia, 
Human 
Animal, Robot, Amputee, 
Inpatient, Freezing of 
Gait, Heart, Blood, 
Cardiac Related Study, 
Women or Men Only 
Intervention(s), 
Exposure(s): 
Assessed During Walking 
on a Treadmill or 
Overground but are not 
required to undergo any 
type of intervention 
Gait Assessed Via 
Observation or Rating 
Scale or Single Muscle 




Control population (no 






Study Types: All designs.  Not English, review, 
earlier than 1996 
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Appendix 3: Quality Assessment Scale. 
 
Adapted from NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional 
Studies (QATOCCS). 
 
When assessing an article, for each question 
give rating of: Yes (Y); No (N); cannot 
determine (CD); not applicable (NA); not 
reported (NR). Then at the reviewer’s 
discretion a rating of “Good”, “Fair” or 
“Poor” should then be assigned to judge 
whether the article has a low, some or high 
risk of bias respectively. 
1. Was the research question clearly stated? 
2. Were the inclusion and exclusion criteria 
clearly stated? 
3. Was the study population clearly specified and 
defined? 
4. Were the subjects in the study representative 
of the pathological population? 
5. Were all the subjects selected or recruited 
from the same or similar populations (including 
the same time period)? 
6. Did control group’s age and gender match 
those of the pathological group? 
7. Was a sample size justification via power 
analysis provided? 
8. Were the main findings of the study clearly 
described? 
9. Were the spatiotemporal gait parameters well 
defined? 
10. Were trial instructions clearly stated and 
uniformly applied to all participants? 
11. Was the walking protocol appropriate to 
measure spatiotemporal gait parameters? 
12. Were key potential confounding variables 
measured and adjusted statistically for their 
impact on the relationship between exposure(s) 
and outcome(s)? 
13. Were the outcome assessors blinded to the 
exposure status of participants? 
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Mixed CA: 19, 10F 




1 3 3D Motion Capture System; 
10m walking; barefoot; 
preferred speed. 
Stance, swing time, DLS%, 
speed, step length, step width + 
kinematic joint features 
ITL G 
Chini et al.  
(2016) 
Mixed CA: 16, 5F 
Control: 16, 5F 
ICARS: 22.5±12.6 
No. Falls (1yr): 
3.0±6.1 
Local stability 
with STPs and 
falls history 
1 3 Inertial sensor; 20m 
walkway; 16 passes; 
preferred (CA) and slow (HS) 
speed; barefoot. 
Cadence, DLS%, Speed, 
Stance%, Stride Length, Stride 
Time, Swing% 
ITL G 
Conte et al.  
(2014) 
Mixed CA: 16, 5F 








1 3 3D Motion Capture System; 
8m walkway; barefoot; 
comfortable and slow (HS) 
speed. 
Cadence, DLS%, Speed, 
Stance%, Step Length, Step 




et al. (1999) 
Mixed CA: 20, 7F 
Control: 30, 3F 





1 3 Pulley system via optical 
recording device; 10m 
walking; 10 passes; normal, 
slow, fast, very slow, very 
fast speed. 
Cadence, DLS%, Speed, Step 





FRDA: 14 adults, 
9F (of 31 total) 








1 3 Pressure Sensitive Mat; 
comfortable speed; bare-
foot; 488, 610 or 732 cm 
mat with 2m run-up and 2m 
exit; min. 3 trials. (data 
taken from assessments at 
SLS Time, Speed, Stance Time, 
Step Length, Step Time, Stride 
Length, Stride Time, Swing Time 
FR F 
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6month intervals over 2 year 
follow-up period) 
Ienaga et al.  
(2006) 
All Ataxia: 18, 7F 
MSAc: 8, 3F 
SCA6: 4, 1F 
16qADCA: 6, 3F 





1 3 3D Motion Capture System + 
insole pressure sensors; 
preferred speed; 6 
consecutive steps. 
Cadence, Speed, Stance Time, 
Step Width, Stride Length, 
Swing Time 
JP F 
Ilg et al.  
(2007) 
 
Mixed CD: 13, 5F 
Control: 9, 3F 




1 3 3D Motion Capture System, 
self-selected pace; barefoot; 
8-12 gait cycles from 2-3 
trials. 
Speed, Step Length, Step 





Ilg et al.  
(2009) 
All Ataxia: 16, 8F 
CA: 10, 5F 
AA: 6, 3F 
 







1 4 3D Motion Capture System; 
self-selected pace; barefoot; 
12-15 gait cycles from 3 
trials; examination at 4 time 
points (incl. 8 weeks before 
and after training). 
Speed, Step Length, Step 
Width, Sway Path 
DE G 
Im et al. 
(2016) 
 
Mixed CA: 19, 12F 
 
ICARS: 34.2±6.8 Rehabilitation 
in CA via 12-
week training 
programme 
1 4 3D Motion Capture System; 
preferred & slow speeds; 6m 
walkway; examination 
before, and after training 
and at 3month follow-up; 
COM Displacement, COM 





Mixed CA: 19, 5F 
Control: 20, 7F 







1 3 3D Motion Capture System 
& Surface EMG; ~7m 
walkway; barefoot; 
preferred, fast (CA) & slow 
(HS) speed; min. 15 trials. 
Speed, Stance Time, Step 




et al. (2015) 
Mixed CA: 51, 27F 
Control: 56, 28F 
SARA: 8.6±3.6 
(1-16)  





with 6 month 
follow-up 
1 3 Inertial sensor; 10m 
walkway; 12 repeats; 
comfortable speed, 6 month 
follow-up 
Cadence, Speed, Step Length JP F 
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Milne et al.  
(2014) 








1 3 Pressure Sensitive Mat; 
830cm mat + 80cm run-up 
and exit; 6 trials; preferred, 
fast & slow speed 
Base of Support, Cadence, 





Mixed SCA: 23, 9F  Influence of 
cognitive load 
on gait 





Mixed CD: 10, 1F 






Analysis in CA 
1 3 3D Motion Capture System 




Cadence, Heel Off Time, Speed, 
Stance Time, Step Length, Step 
Length Asymmetry, Step Length 
CV, Step Time, Step Width, Step 
Width Asymmetry, Step Width 
CV, Stride Length, Stride Length 
Asymmetry, Stride Length CV, 
Stride Time, Stride Time CV, 
Swing Time, Toe off Time 
USA F 
Rochester 
et al. (2014) 
SCA6: 18, 13F 
Preclinical SCA6: 
6, 4F 
Control: 25, 17F 
(HS vs Clin) 
ICARS: 3 (1, 3) vs 
20.5 (13.8, 20.5)  
(HS vs Pre-Clin vs 
Clin) 
ABCS: 96±3.7 vs 
86.3±8.1 vs 
59.2±24.3  
No. Falls (3mo): 




1 3 Pressure Sensitive Mat; 7m 
mat within 12m walkway; 4 
trials; comfortable speed 
Cadence, Speed, Step Length, 
Step Length Asymmetry, Step 
Length CV, Step Time 






SCA14: 8, 3F 
Control: 9, 6F 





1 3 Pressure Sensitive Mat; 5.1m 
mat within 8m walkway; 10 
trials; comfortable, slow, 
very slow, fast, max speeds 
Base of Support, Cadence, 
Speed, Step Length CV, Stride 
Length, Stride Length CV, Stride 





Mixed CA: 48, 22F SARA: 10 (3,20) 
BBS: 4 (2,8) 
FGA: 17,(6,30) 
Gait variability 
and falls in CA 
1 3 Pressure Sensitive Mat; 6.7m 
mat with 1.5m run-up and 
1.5m exit; preferred, slow, 
fast speeds 
Base of Support, Base of 
Support CV, Cadence, DLS%, 
Speed, Stride Length, Stride 
DE G 
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Mixed CD: 32, 
13F 
Control: 34, 18F 
 Neuro 
impairments 
and base of 
support with 
free and 
paced walking  
1 3 3D Motion Capture System, 
Force plates & LED array; 
10m walkway; barefoot; 
preferred speed and paced; 
two trials in each condition 
(free vs metronome 
(120bpm)) 
Base of Support, Speed USA F 
Serrao et al. 
(2012) 
All Ataxia: 16, 8F 
SCA1/2: 8, 2F 
FRDA: 8, 6F 
Control: 15, 7/8F 






1 3 3D Motion Capture System 
& Force plates; barefoot; 
comfortable speed, 4m 
examined from 10m 
walkway; 10 gait cycles from 
5 trials 
DLS%, Stance%, Step Length, 




et al. (2015) 
FRDA: 8, 2F 
Control: 8, 2F 
BBS: P<0.05 
LOS Test: 48±1.3 
(44-56) 
Gait in FRDA 1 3 Pressure Sensitive Mat; 
comfortable & fast speed; 
7.93m mat with 1m run-up 
and >1m exit; 5 trials for 
each speed  
Cadence, DLS%, Speed, 
Stance%, Step Length, Stride 





Mixed CA: 11, 8F 
Control: 11, 8F 










1 3 Pressure Sensitive Mat & 
Pressure Sensitive Treadmill; 
6.7m mat with 1.5m run-up 
and 1.5m exit; preferred and 
max speed; 2 trials at each 
speed; five 5min trials on 
treadmill at Preferred, & 
20%, 40%, 70%, 80% of Max. 
speed 
Base of Support CV, Stride 
Length CV, Stride Time CV 
DE F 
Full details of study information including quality assessment results. Abbreviations: F-Female, SD-standard deviation, 1 - Journal Article, 2 - Conference 
Abstract; 3 - Prospective Observational, 4 - Intervention, ITL - Italy, AT - Austria, FR - France, JP - Japan, DE - Germany KR - South Korea, AU - Australia, IN – 
India, G-good, F-fair, CD-cannot determine. 
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Appendix 5: Full Quality Assessment Results 
































































































































































































































































































































































Overall Rating (Good, Fair, Poor) G G G F F F F G F G F F CD F G G G F G G F 
1. Was the research question 
clearly stated? 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
2. Were the inclusion and 
exclusion criteria clearly 
stated? 
Y Y Y Y Y Y Y Y Y Y Y Y N Y Y Y Y Y Y Y Y 
3. Was the study population 
clearly specified and 
defined? 
CD Y Y Y N Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
4. Were the subjects in the study 
representative of the 
pathological population? 
Y Y Y Y Y Y Y Y Y Y Y Y Y N Y Y Y Y Y Y Y 
5. Were all the subjects selected 
or recruited from the same 
or similar populations 
(including the same time 
period)? 
CD Y Y Y CD Y Y Y Y Y Y Y CD Y Y Y Y Y Y Y Y 
6. Did control group’s age and 
gender match those of the 
pathological group? 
Y Y Y Y N Y N/A Y N/A Y Y N/A CD Y Y Y N/A Y Y Y Y 
7. Was a sample size justification 
via power analysis provided? 
N N N N N N N N N N N N N N N N N N N N N 
8. Were the main findings of the 
study clearly described? 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
9. Were the spatiotemporal gait 
parameters well defined? 
Y Y N N Y N Y Y N Y Y Y N Y Y Y N N Y Y Y 
10. Were trial instructions 
clearly stated and uniformly 
applied to all participants? 
Y Y Y Y Y Y Y Y Y Y Y Y CD Y Y Y Y Y Y Y Y 
11. Was the walking protocol 
appropriate to measure 
spatiotemporal gait 
parameters? 
Y Y Y Y Y Y Y Y Y Y Y Y CD Y Y Y Y Y Y Y Y 
12. Were key potential 
confounding variables 
measured and adjusted 
statistically for their impact 
Y Y Y Y N Y N Y N Y N Y CD Y Y Y Y Y Y Y N 
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Appendix 6: Full Study Results.  
All data extracted from the 21 included articles. (Green= data collected within a protocol where patients and controls were matched for speed, Blue = result 
standardised/normalised to height or leg length, orange=variability measured as combined Left/Right standard deviation, yellow=results calculated from 
subgroup results following cochrane review guidelines) 



































































































































Caliandro_2016_CA 19 10 9 50.5 
           
Caliandro_2016_HC 15 8 7 54.5 
           
Chini_G_2016_CA 16 5 11 50.5 8.9 
        
14.3 6.8 
Chini_G_2016_HC 16 5 11 49.8 8.8 
          
Conte_C_2014_CA 16 5 11 51.0 10.7 165.8 8.4 69.7 7.9 
  
24.4 3.0 10.9 6.4 




Ebersbach_G_1999_CA 20 7 13 41.4 14.2 169.2 8.1 
        
Ebersbach_G_1999_HC 30 11 19 60.9 9.0 171.8 9.1 
        
Gouelle_A_2013_CA 14 9 5 20.5 1.9 166.0 8.3 
  
85.0 4.0 
    
Gouelle_A_2013_HC 123 65 58 32.3 12.8 167.9 8.3 
  
87.0 4.0 
    
Ienaga_Y_2006_CA 18 7 11 61.6 6.4 
        
45.9 44.9 
Ienaga_Y_2006_CA_ADCA 6 3 3 62.5 6.6 
        
36.8 32.0 
Ienaga_Y_2006_CA_MSAc 8 3 5 61.3 7.8 
        
27.8 24.6 
Ienaga_Y_2006_CA_SCA 4 1 3 61.0 4.2 
        
96.0 62.7 
Ienaga_Y_2006_HC 6 3 3 58.3 
           
Ilg_W_2007_CA 13 5 8 50.4 14.4 
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Ilg_W_2007_HC 9 3 6 48.1 13.8 
          
ilg_W_2009_CA 16 8 8 61.4 11.2 
        
12.9 7.8 
ilg_W_2009_CA_AA 6 3 3 56.2 12.9 
        
17.7 5.4 
ilg_W_2009_CA_CA 10 5 5 64.6 9.4 
        
10.0 7.8 
Im_S_J_2016_CA 19 12 7 53.2 13.8 
        
4.5 5.4 
Martino_G_2014_CA 19 5 14 48.5 
   
68.0 8.0 78.0 6.0 
  
11.0 7.1 
Martino_G_2014_HC 20 7 13 52.0 
   
70.0 14.0 80.0 5.0 
    
Matsushima_A_2015_CA 51 27 24 60.3 10.4 
        
8.7 6.5 
Matsushima_A_2015_HC 56 28 28 57.2 14.1 
          
Milne_S_C_2014_CA 13 1 12 32.0 12.9 173.2 7.8 70.1 18.5 
  
23.1 4.9 11.6 4.9 
Mondal_B_2015_CA 23 9 14 47.2 12.1 
          




Palliyath_S_1998_HC 10 1 9 46.0 
           
Rochester_L_2014_CA 18 13 5 61.5 8.5 165.0 8.0 78.8 12.5 
  
28.6 3.7 3.7 3.2 



















   
26.1 
   





Seidel_B_and_D_E_Krebs_2002_CA 32 13 19 45.0 13.2 
      
33.9 6.7 
  
Seidel_B_and_D_E_Krebs_2002_HC 34 18 16 46.9 15.0 
      
25.0 3.5 
  
Serrao_M_2012_CA 16 8 8 40.1 15.8 
        
132.8 113.5 
Serrao_M_2012_CA_FRDA 8 6 2 33.1 18.5 
        
121.5 82.0 
Serrao_M_2012_CA_SCA 8 2 6 47.1 9.2 
        
144.0 143.6 
Serrao_M_2012_HC 15 7 8 40.0 15.8 
          





Stephenson_J_2015_HC 8 2 6 29.6 9.1 174.0 12.5 75.2 16.9 
  
24.8 
   
Wuehr_M_2013_CA 11 8 3 47.0 9.4 176.9 6.7 
  
91.2 6.2 
    
Wuehr_M_2013_HC 11 8 3 46.1 17.8 168.8 17.8 
  
90.5 7.1 
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Chini_G_2016_HC 
  





    
Conte_C_2014_CA 0.2 0.0 52.3 4.9 13.7 3.2 16.0 8.1 0.8 0.3 8.7 6.5 63.5 3.3 3.8 1.7 0.4 0.1 




    
0.7 0.2 




    
1.0 0.1 
        
Gouelle_A_2013_CA 0.1 0.1 97.3 14.2 24.8 6.6 18.5 11.6 1.0 0.2 12.6 8.5 62.3 4.4 9.1 6.1 0.6 0.1 
Gouelle_A_2013_HC 0.1 0.0 117.3 7.0 21.5 2.0 7.5 1.8 1.3 0.1 2.9 0.8 60.6 1.0 2.6 0.5 0.7 0.1 
Ienaga_Y_2006_CA 0.2 0.0 93.6 15.3 
    
0.8 0.2 
        
Ienaga_Y_2006_CA_ADCA 0.2 0.0 89.2 8.7 
    
0.7 0.2 
        
Ienaga_Y_2006_CA_MSAc 0.2 0.0 98.8 12.7 
    
0.8 0.2 
        
Ienaga_Y_2006_CA_SCA 0.1 0.1 89.6 26.2 
    
0.6 0.3 
        
Ienaga_Y_2006_HC 0.1 0.0 113.6 4.9 
    
1.3 0.1 
        
Ilg_W_2007_CA 0.1 0.0 
      
0.8 0.2 
      
0.5 0.1 
Ilg_W_2007_HC 0.1 0.0 
      
1.2 0.1 
      
0.6 0.1 
ilg_W_2009_CA 
        
0.8 0.1 
        
ilg_W_2009_CA_AA 
        
0.7 0.1 
        
ilg_W_2009_CA_CA 
        
0.9 0.1 
        
|250 
Im_S_J_2016_CA 
                  
Martino_G_2014_CA 0.4 0.1 




    
Martino_G_2014_HC 0.3 0.0 








    
0.9 0.3 29.6 





    
1.3 0.1 9.4 
     
0.7 0.1 
Milne_S_C_2014_CA 0.1 0.1 105.6 7.6 24.7 5.8 1.4 0.8 1.2 0.2 5.2 2.1 
      
Mondal_B_2015_CA 
                  
Palliyath_S_1998_CA 0.1 0.0 102.2 15.9 
    
0.5 0.2 5.7 2.2 
    
0.3 0.1 
Palliyath_S_1998_HC 0.2 0.1 111.0 7.6 
    
0.9 0.4 3.8 4.5 
    
0.5 0.2 
Rochester_L_2014_CA 0.2 0.1 101.2 18.3 
    
1.0 0.3 
      
0.5 0.2 
Rochester_L_2014_HC 0.1 0.0 119.0 9.2 
    
1.5 0.2 
      
0.8 0.1 
Schmitz-Hübsch_T_2016_CA 0.2 0.0 111.6 9.8 25.9 4.5 
  
1.0 0.2 
        
Schmitz-Hübsch_T_2016_HC 0.1 0.0 107.1 8.3 23.5 4.0 
  
1.3 0.2 
        
Schniepp_R_2014_CA 0.1 0.1 102.0 15.0 31.0 9.0 
  
0.9 0.3 
        
Seidel_B_and_D_E_Krebs_2002_CA 0.2 0.1 
      
1.0 0.2 
        
Seidel_B_and_D_E_Krebs_2002_HC 0.2 0.0 
      
1.3 0.2 
        
Serrao_M_2012_CA 0.2 0.0 
  
13.5 0.5 9.9 1.1 1.1 0.1 4.7 0.6 67.7 2.7 5.7 0.6 0.6 0.1 
Serrao_M_2012_CA_FRDA 0.2 0.0 
  
13.3 0.5 10.6 1.1 1.1 0.1 4.3 0.5 67.9 2.3 5.4 0.6 0.6 0.0 
Serrao_M_2012_CA_SCA 0.2 0.0 
  
13.8 0.6 9.1 0.4 1.0 0.1 5.1 0.3 67.5 2.8 6.0 0.5 0.7 0.1 
Serrao_M_2012_HC 0.1 0.0 
  
7.7 0.3 4.4 0.9 1.4 0.1 3.7 0.9 60.4 2.0 2.4 0.7 0.7 0.0 
Stephenson_J_2015_CA 
  
















Wuehr_M_2013_CA 0.1 0.1 
      
1.0 0.2 
        
Wuehr_M_2013_HC 0.1 0.0 
      
1.2 0.2 








































































































































































































































































Conte_C_2014_CA 5.6 2.9 
  
5.2 2.7 
    
1.2 0.1 6.6 6.8 36.5 3.3 0.5 0.3 
Conte_C_2014_HC 4.2 2.9 
  
3.2 1.7 
    
1.4 0.2 4.0 2.1 35.1 4.1 0.5 0.1 
Ebersbach_G_1999_CA 7.7 5.5 
          
4.8 2.1 
    
Ebersbach_G_1999_HC 2.8 1.2 
          
2.3 1.2 
    
Gouelle_A_2013_CA 11.2 7.3 0.6 0.1 
  
1.2 0.3 8.7 6.0 1.3 0.2 7.0 5.0 37.2 3.6 
  
Gouelle_A_2013_HC 2.1 0.4 0.5 0.0 
  
1.4 0.1 1.7 0.4 1.0 0.1 2.0 0.5 39.4 1.0 
  
Ienaga_Y_2006_CA 11.0 6.8 
    
0.4 0.3 
          
Ienaga_Y_2006_CA_ADCA 9.7 4.7 
    
0.2 0.0 
          
Ienaga_Y_2006_CA_MSAc 7.5 3.4 
    
0.6 0.1 
          
Ienaga_Y_2006_CA_SCA 15.8 11.6 
    
0.1 0.1 
          
Ienaga_Y_2006_HC 4.0 2.7 
    
0.9 0.1 
          
Ilg_W_2007_CA 
          
1.2 0.1 
    
0.4 0.0 
Ilg_W_2007_HC 
          
1.0 0.2 
    
0.4 0.1 
ilg_W_2009_CA 
                  
ilg_W_2009_CA_AA 
                  
ilg_W_2009_CA_CA 
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Im_S_J_2016_CA 
                  
Martino_G_2014_CA 




      
Martino_G_2014_HC 




      
Matsushima_A_2015_CA 25.1 
                 
Matsushima_A_2015_HC 8.6 
                 
Milne_S_C_2014_CA 
      
1.3 0.2 




                  
Palliyath_S_1998_CA 7.2 4.3 0.6 0.1 12.5 5.1 0.6 0.1 6.1 3.4 1.2 0.2 4.3 2.7 
  
0.4 0.1 










              
Schmitz-Hübsch_T_2016_CA 
      
0.6 0.1 5.5 2.4 1.1 0.1 5.0 1.9 
    
Schmitz-Hübsch_T_2016_HC 
      
0.8 0.0 2.2 0.7 1.1 0.1 2.0 1.0 
    
Schniepp_R_2014_CA 
      
1.0 0.2 6.1 3.5 1.2 0.5 5.2 4.1 
    
Seidel_B_and_D_E_Krebs_2002_CA 
                  
Seidel_B_and_D_E_Krebs_2002_HC 
                  
Serrao_M_2012_CA 7.8 1.6 
  
13.3 2.6 
    
1.2 0.1 5.8 1.1 
    
Serrao_M_2012_CA_FRDA 7.0 1.2 
  
15.5 0.5 
    
1.2 0.1 4.9 0.3 
    
Serrao_M_2012_CA_SCA 8.7 1.7 
  
10.7 0.9 
    
1.3 0.1 6.8 0.7 
    
Serrao_M_2012_HC 3.4 0.9 
  
2.9 0.9 
    
1.0 0.0 
      
Stephenson_J_2015_CA 
      
1.0 0.3 




      
1.4 0.1 
    
2.2 0.6 39.2 1.1 
  
Wuehr_M_2013_CA 




      
Wuehr_M_2013_HC 
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Appendix 7: Correlation analysis between gait parameters and disease severity 
Results of non-parametric bivariate correlation analysis between gait parameters and disease severity where data were available. Correlation r >0.6 and r<-
0.6 = bold, significance p<0.05 = *, p<0.01=**. n= number of articles reporting feature. 
a) Results for CA cohort 
i) Correlation between demographics and gait parameters 
 Walkway length ICARS score SARA score Disease Severity Age Height Mass BMI Disease Duration 
ICARS score -0.553, n=9         
SARA score -0.671, n=5         
Disease Severity -0.404, n=13 0.725*, n=9 0.866, n=5       
Age -0.178, n=20 0.167, n=9 -0.200, n=5 0.098, n=13      
Height -0.315, n=10   0.655, n=6 -0.248, n=10     
Mass 0.049, n=8 0.500, n=3   0.310, n=8 0.179, n=7    
Leg Length 0.866, n=3   0.866, n=3 -0.500, n=3     
BMI 0.179, n=8    0.333, n=8 -0.250, n=7 0.857*, n=7   
Disease Duration -0.028, n=13 0.071, n=7 0.400, n=4 -0.261, n=10 0.022, n=13 0.257, n=6 0.214, n=7 -0.086, n=6  
Base/Step Width -0.042, n=11 -0.800, n=4 -0.500, n=3 -0.612, n=7 0.109, n=11 -0.314, n=6 0.800, n=4 0.800, n=5 0.543, n=6 
Cadence -0.150, n=10  -0.500, n=3  0.261, n=10 0.262, n=8 0.371, n=6 0.029, n=6 0.143, n=7 
DLS perc. -0.206, n=7    0.126, n=7 0.154, n=5 0.316, n=4 0.316, n=4 -0.410, n=5 
Speed 0.352, n=16 -0.500, n=5 -0.200, n=5 -0.311, n=9 -0.209, n=16 -0.183, n=9 -0.200, n=6 0.036, n=7 0.200, n=9 
Speed var. 0.258, n=4    0.400, n=4     
Step Length 0.401, n=7 0.000, n=4   -0.393, n=7 -0.500, n=3   0.400, n=4 
Step Length var. 0.507, n=6    0.086, n=6     
Step Time 0.500, n=3    -0.500, n=3 -0.500, n=3    
Stride Length 0.655, n=6   0.000, n=3 -0.657, n=6 -0.100, n=5   -0.600, n=4 
Stride Length var. 0.500, n=4    -0.632, n=4 -0.632, n=4 -0.866, n=3 -0.866, n=3  
Stride Time 0.348, n=7 0.500, n=3 -0.500, n=3 -0.393, n=6 -0.414, n=7 -0.700, n=5    
Stride Time var. 0.676, n=6    -0.486, n=6 -0.700, n=5 -0.500, n=3 -0.500, n=3 -0.500, n=3 
Swing perc.  
 





ii) Correlation between gait parameters  
Base/ Step  
Width 
Cadence DLS perc. Speed Speed var. Stance perc. Step  
Length 








Cadence 0.257, n=6 
          
DLS perc. -0.657, n=6 -0.410, n=5 
         
Speed -0.036, n=11 0.515, n=10 -0.342, n=7 






       
Stance perc. 
  
-0.600, n=4 -0.400, n=4 
       
Step Length -0.300, n=5 -0.400, n=4 -0.400, n=4 0.893**, n=7 
 
-0.400, n=4 






0.600, n=6 0.800, n=4 
      
Stride Length -0.300, n=5 0.500, n=5 -0.949, n=4 0.829*, n=6 
  
0.500, n=3 0.866, n=3 




-0.949, n=4 -0.500, n=3 -0.316, n=4 
       
Stride Time -0.200, n=6 
 
0.000, n=4 -0.108, n=7 0.866, n=3 
   




-0.400, n=4 -0.200, n=5 -0.600, n=4 0.714, n=6 0.500, n=3 
    
0.632, n=4 0.667, n=5 
Swing perc. -0.500, n=3 
 
0.200, n=4 
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b) Results for HC cohort 
i) Correlation between demographics and gait parameters  
Age Height Mass Leg Length BMI 
Height -0.250, n=7 
    
Mass -0.800, n=5 0.600, n=4 
   
Leg Length -0.500, n=3 
    
BMI 0.000, n=5 -0.400, n=4 0.400, n=4 0.500, n=3 
 
Base/ Step Width 0.071, n=8 0.800, n=4 
   
Cadence -0.190, n=8 -0.600, n=5 
  
0.500, n=3 
DLS perc. -0.154, n=5 0.000, n=3 
   
Speed -0.266, n=12 -0.257, n=6 
  
0.400, n=4 
Stance perc. 0.800, n=4 
    
Step Length -0.286, n=7 -0.500, n=3 
   
Step Length var. 0.314, n=6 
    
Step Time -0.500, n=3 




   
Stride Time 0.348, n=6 0.500, n=3 
   
Stride Time var. 0.100, n=5 0.000, n=4 
   
Swing perc. -0.500, n=3 
    
 
ii) Correlation between gait parameters  
Base/ Step  
Width 
Cadence DLS perc. Speed Speed var. Stance perc. Step Length Step Length  
var. 
Stride Length  
var. 
Stride Time 
DLS perc. -0.600, n=4 -0.866, n=3      
 
  
Speed -0.310, n=8 0.750, n=7 -0.359, n=5     
 
  
Speed var.  -0.500, n=3  0.000, n=4    
 
  
Stance perc. 0.500, n=3  -0.211, n=4 -0.800, n=4    
 
  
Step Length -0.300, n=5 0.200, n=4 0.211, n=4 0.964**, n=7 0.500, n=3   
 
  
Step Length var.  0.000, n=5 -1.000, n=2 0.500, n=5 0.800, n=4  0.500, n=3 
 
  
Stride Length var.    -0.500, n=3    
 
  
Stride Time -0.462, n=5   -0.348, n=6 0.500, n=3  -0.500, n=3 -0.500, n=3   




-0.500, n=3 -0.500, n=3 
Swing perc.  
 
0.866, n=3 0.500, n=3 
 




Appendix 8: Equipment & diagnosis subgroups analysis 
Forest plots for supplementary equipment and disease diagnosis subgroup analysis. 

















b) Disease subgroup meta-analysis. Abbreviations: CA – Cerebellar Ataxia, FRDA – 

















c) Subgroup meta-analysis for variables where diagnosis and subgroup could not be extracted from 
each other. CA – Cerebellar ataxia, 3DMC – 3D motion capture, FRDA – Friedreich's Ataxia, PSW – 
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Appendix 10: Synchronization configuration gpo files. 
Custom gpo file for Vicon Nexus to trigger OptoGait photoelectric system to begin recording 
(Microgate Inc.).  







 <StartOffset Frames="0" MicroSeconds="0"/> 
 <StopOffset Frames="0" MicroSeconds="0"/> 
 <PulseWidth Frames="0" MicroSeconds="0"/> 
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Appendix 11: Participant Information Sheets 
Participant information sheet for people with Cerebellar ataxia (v1.6 02/05/2018) and Healthy 
Controls (v1.6 02/05/2018).  










































Appendix 13: Written informed consent forms 
The written informed consent forms for people with i) Cerebellar ataxia (v1.3 23/03/2018) and ii) 
Healthy Controls (v1.2 23/03/2018).  












Appendix 14: structured medical interview proforma 
Form and checklist intended to be used at all study visits with participants to ensure all essential 






Appendix 15: Custom-made cable for synchronisation between OptoGait system and ADPM Opal 
sensors access point. 
 
A custom solution cable has been manufactured to enable a direct trigger signal to be transmitted 
between Motion Studio software and the OptoGait software. 
 
a) OptoGait end:  Green banana plug->Green socket 
Yellow/Green plug->Black socket (Earth) 
b) ADPM Opal sensors end: 6 pin digital I/O connector 
 
